US20230148463A9 - Method for producing albicanol and/or drimenol - Google Patents

Method for producing albicanol and/or drimenol Download PDF

Info

Publication number
US20230148463A9
US20230148463A9 US17/673,465 US202217673465A US2023148463A9 US 20230148463 A9 US20230148463 A9 US 20230148463A9 US 202217673465 A US202217673465 A US 202217673465A US 2023148463 A9 US2023148463 A9 US 2023148463A9
Authority
US
United States
Prior art keywords
seq
sequence
polypeptide
albicanol
sesquiterpene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US17/673,465
Other versions
US11932894B2 (en
US20220186265A1 (en
Inventor
Michel Schalk
Pauline Anziani
Christian Goerner
Daniel Solis Escalante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Firmenich SA
Original Assignee
Firmenich SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Firmenich SA filed Critical Firmenich SA
Priority to US17/673,465 priority Critical patent/US11932894B2/en
Assigned to FIRMENICH SA reassignment FIRMENICH SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANZIANI, Pauline, GOERNER, CHRISTIAN, SCHALK, MICHEL, SOLIS ESCALANTE, Daniel
Publication of US20220186265A1 publication Critical patent/US20220186265A1/en
Publication of US20230148463A9 publication Critical patent/US20230148463A9/en
Application granted granted Critical
Publication of US11932894B2 publication Critical patent/US11932894B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/03Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)

Definitions

  • biochemical methods of producing albicanol, drimenol and related compounds and derivatives which method comprises the use of novel polypeptides.
  • Terpenes are found in most organisms (microorganisms, animals and plants). These compounds are made up of five carbon units called isoprene units and are classified by the number of these units present in their structure. Thus monoterpenes, sesquiterpenes and diterpenes are terpenes containing 10, 15 and 20 carbon atoms, respectively. Sesquiterpenes, for example, are widely found in the plant kingdom. Many sesquiterpene molecules are known for their flavor and fragrance properties and their cosmetic, medicinal and antimicrobial effects. Numerous sesquiterpene hydrocarbons and sesquiterpenoids have been identified. Chemical synthesis approaches have been developed but are still complex and not always cost-effective.
  • terpene synthases There are numerous sesquiterpene synthases present in the plant kingdom, all using the same substrate (farnesyl diphosphate, FPP), but having different product profiles. Genes and cDNAs encoding sesquiterpene synthases have been cloned and the corresponding recombinant enzymes characterized.
  • sesquiterpenes for example drimenol
  • drimenol the main sources for sesquiterpenes
  • these natural sources can be low.
  • terpenes, terpene synthases and more cost-effective methods of producing sesquiterpenes such as albicanol and/or drimenol and derivatives therefrom.
  • a method for producing a drimane sesquiterpene comprising:
  • the drimane sesquiterpene comprises albicanol and/or drimenol.
  • the polypeptide having bifunctional terpene synthase activity comprises
  • the above method comprises contacting the drimane sesquiterpene with at least one enzyme to produce a drimane sesquiterpene derivative. In another embodiment, the above method comprises converting the drimane sesquiterpene to a drimane sesquiterpene derivative using chemical synthesis or biochemical synthesis.
  • the above method comprises transforming a host cell or non-human host organism with a nucleic acid encoding the above polypeptide.
  • the method further comprises culturing a non-human host organism or a host cell capable of producing FPP and transformed to express a polypeptide comprising a HAD-like hydrolase domain under conditions that allow for the production of the polypeptide, wherein the polypeptide
  • the polypeptide comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • the class I terpene synthase-like motif of the above method comprises SEQ ID NO: 54 (DD(K/Q/R)(L/I/T)(D/E)), the class II terpene synthase-like motif comprises SEQ ID NO: 57 (D(V/M/L)DTT), and the drimane sesquiterpene is albicanol.
  • polypeptide comprises
  • polypeptide comprises
  • polypeptide comprising a HAD-like hydrolase domains and having bifunctional terpene synthase activity comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5 or comprising
  • the isolated polypeptide further comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • nucleic acid molecule Provided herein is an isolated nucleic acid molecule
  • a vector comprising the above nucleic acid molecule or a nucleic acid encoding the above polypeptide.
  • the vector is an expression vector.
  • the vector is a prokaryotic vector, viral vector or a eukaryotic vector.
  • a host cell or non-human organism comprising the above nucleic acid or above vector.
  • the host cell or non-human organism is a prokaryotic cell or a eukaryotic cell or a microorganism or fungal cell.
  • the prokaryotic cell is a bacterial cell.
  • the bacterial cell is E. coli.
  • the host cell or non-human organism is a eukaryotic cell.
  • the eukaryotic cell is a yeast cell or plant cell.
  • the yeast cell is Saccharomyces cerevisiae.
  • the drimane sesquiterpene is albicanol. In another aspect, in the above use of the polypeptide, the drimane sesquiterpene is drimenol.
  • FIG. 1 Structure of drimane, (+)-albicanol and ( ⁇ )-drimenol.
  • FIG. 2 Mechanism of cyclization of farnesyl-diphosphate by a class II terpene synthase and class I terpene synthase enzymatic activity.
  • FIG. 3 GCMS analysis of the sesquiterpenes produced in-vivo by the recombinant CvTps1 enzyme in bacteria cells modified to overproduce farnesyl-diphosphate.
  • A Total ion chromatogram of an extract of E. coli cells expressing CvTps1 and the mevalonate pathway enzymes.
  • B Total ion chromatogram of an authentic standard of albicanol.
  • C Total ion chromatogram of an extract of E. coli cells expressing only the mevalonate pathway enzymes. 1, albicanol; 2, trans-farnesol (from hydrolysis of FPP by endogenous phosphatase enzymes).
  • FIG. 4 Comparison of the mass spectra of the product of CvTps1 and of an authentic standard of albicanol.
  • FIG. 5 GCMS analysis of the sesquiterpenes produced by the LoTps1 and CvTps1 recombinant protein.
  • the peak labeled ‘1’ is (+)-albicanol.
  • FIG. 6 A-C Amino acid sequences alignment of putative terpene synthases containing class I and class II motifs: CvTps1 (SEQ ID NO: 1), LoTps1 (SEQ ID NO: 5), OCH93767.1 (SEQ ID NO: 9), EMD37666.1 (SEQ ID NO: 12), EMD37666-B (SEQ ID NO: 15), XP_001217376.1 (SEQ ID NO: 17), OJJ98394.1 (SEQ ID NO: 20), GA087501.1 (SEQ ID NO: 23), XP_008034151.1 (SEQ ID NO: 26), XP_007369631.1 (SEQ ID NO: 29), ACg006372 (SEQ ID NO: 32), KIA75676.1 (SEQ ID NO: 35), XP_001820867.2 (SEQ ID NO: 38), CEN60542.1 (SEQ ID NO: 41), XP_009547469.1 (SEQ ID NO: 44), K
  • FIG. 7 GCMS chromatograms of the sesquiterpenes produced by the LoTps1, CvTps1, OCH93767.1, EMD37666.1, EMD37666-B, and XP_001217376.1, recombinant proteins.
  • the peak labeled ‘1’ is (+)-albicanol.
  • FIG. 8 GCMS chromatograms of the sesquiterpenes produced by the OJJ98394.1, GAO87501.1, XP_008034151.1, XP_007369631.1, and ACg006372 recombinant proteins.
  • the peak labeled ‘1’ is (+)-albicanol.
  • FIG. 9 GCMS chromatograms of the sesquiterpenes produced by the KIA75676.1, XP_001820867.2, CEN60542.1, XP_009547469.1, KLO09124.1 and OJI95797.1 recombinant proteins.
  • the peak labeled ‘1’ is ( ⁇ )-drimenol and the peak labeled ‘2’ is farnesol.
  • FIG. 10 GCMS chromatograms of the sesquiterpenes produced by CvTps1 and AstC expressed in E. coli cells with and without the AstI and AstK phosphatases.
  • the major peak obtained with AstC is drim-8-ene-11-ol and the major peak obtained with CvTps1 is (+)-albicanol.
  • FIG. 11 GCMS analysis of the sesquiterpenes produced in-vivo by the recombinant XP_006461126.1 enzyme in bacteria cells modified to overproduce farnesyl-diphosphate.
  • A Total ion chromatogram of an extract of E. coli cells expressing XP_006461126.1 and the mevalonate pathway enzymes.
  • B Mass spectra of peak 13.1 minutes identified as drimenol.
  • FIG. 12 GC-FID analysis of drimane sesquiterpenes produced using the modified S. cereviciae strain YST045 expressing five different synthases: XP_007369631.1 from Dichomitus squalens , XP_006461126 from Agaricus bisporus , LoTps1 from Laricifomes officinalis , EMD37666.1 from Gelatoporia subvermispora and XP_001217376.1 from Aspergillus terreus.
  • polypeptide means an amino acid sequence of consecutively polymerized amino acid residues, for instance, at least 15 residues, at least 30 residues, at least 50 residues.
  • a polypeptide comprises an amino acid sequence that is an enzyme, or a fragment, or a variant thereof.
  • protein refers to an amino acid sequence of any length wherein amino acids are linked by covalent peptide bonds, and includes oligopeptide, peptide, polypeptide and full length protein whether naturally occurring or synthetic.
  • isolated polypeptide refers to an amino acid sequence that is removed from its natural environment by any method or combination of methods known in the art and includes recombinant, biochemical and synthetic methods.
  • bifunctional terpene synthase or “polypeptide having bifunctional terpene synthase activity” relate to a polypeptide that comprises class I and class II terpene synthase domains and has bifunctional terpene synthase activity of protonation-initiated cyclization and ionization-initiated cyclization catalytic activities.
  • a bifunctional terpene synthase as described herein comprises a HAD-like hydrolase domain which is characteristic of polypeptides belonging to the Haloacid dehalogenase (HAD)-like hydrolase superfamily (Interpro protein superfamily IPR023214, www.ebi.ac.uk/interpro/entry/IPR023214; Pfam protein superfamily PF13419, pfam.xfam.org/family/PF13419).
  • HAD-like hydrolase domain is a portion of a polypeptide having amino acid sequence similarities with the members of the HAD-like hydrolase family and related function.
  • a HAD-like hydrolase domain can be identified in a polypeptide by searching for amino acid motifs or signatures characteristic of this protein family.
  • Proteins are generally composed of one or more functional regions or domains. Different combinations of domains give rise to the diverse range of proteins found in nature. The identification of domains that occur within proteins can therefore provide insights into their function.
  • a polypeptide which comprises a HAD-like hydrolase domain and/or characteristic HAD-like hydrolase motifs functions in binding and cleavage of phosphate or diphosphate groups of a ligand.
  • a bifunctional terpene synthase may also comprise one or more of conserved motifs A, B, C, and/or D as depicted in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • dimethyl methacrylate relates to a terpene having a drimane-like carbon skeleton structure as depicted in FIG. 1 .
  • class I terpene synthase relates to a terpene synthase that catalyses ionization-initiated reactions, for example, monoterpene and sesquiterpene synthases.
  • class I terpene synthase motif or “class I terpene synthase-like motif” relates to an active site of a terpene synthase that comprises the conserved DDxx(D/E) motif.
  • the aspartic acid residues of this class I motif bind, for example, a divalent metal ion (most often Mg 2+ ) involved in the binding of the diphosphate group and catalyze the ionization and cleavage of the allylic diphosphate bond of the substrate.
  • class II terpene synthase relates to a terpene synthase that catalyses protonation-initiated cyclization reactions, for example, typically involved in the biosynthesis of triterpenes and labdane diterpenes.
  • the protonation-initiated reaction may involve, for example, acidic amino acids donating a proton to the terminal double-bond.
  • class II terpene synthase motif or “class II terpene synthase-like motif” relates to an active site of a terpene synthase that comprises the conserved DxDD or DxD(T/S)T motif.
  • albicanol synthase or “polypeptide having albicanol synthase activity” or “albicanol synthase protein” relate to a polypeptide capable of catalyzing the synthesis of albicanol, in the form of any of its stereoisomers or a mixture thereof, starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP).
  • Albicanol may be the only product or may be part of a mixture of sesquiterpenes.
  • dipeptide having a drimenol synthase activity or “drimenol synthase protein” relate to a polypeptide capable of catalyzing the synthesis of drimenol, in the form of any of its stereoisomers or a mixture thereof, starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP).
  • Drimenol may be the only product or may be part of a mixture of sesquiterpenes.
  • biological function refers to the ability of the bifunctional terpene synthase to catalyze the formation of albicanol and/or drimenol or a mixture of compounds comprising albicanol and/or drimenol and one or more terpenes.
  • mixture of terpenes or “mixture of sesquiterpenes” refer to a mixture of terpenes or sesquiterpenes that comprises albicanol and/or drimenol, and may also comprise one or more additional terpenes or sesquiterpenes.
  • nucleic acid sequence refers to a sequence of nucleotides.
  • a nucleic acid sequence may be a single-stranded or double-stranded deoxyribonucleotide, or ribonucleotide of any length, and include coding and non-coding sequences of a gene, exons, introns, sense and anti-sense complimentary sequences, genomic DNA, cDNA, miRNA, siRNA, mRNA, rRNA, tRNA, recombinant nucleic acid sequences, isolated and purified naturally occurring DNA and/or RNA sequences, synthetic DNA and RNA sequences, fragments, primers and nucleic acid probes.
  • nucleic acid sequences of RNA are identical to the DNA sequences with the difference of thymine (T) being replaced by uracil (U).
  • nucleotide sequence should also be understood as comprising a polynucleotide molecule or an oligonucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid.
  • isolated nucleic acid or “isolated nucleic acid sequence” relates to a nucleic acid or nucleic acid sequence that is in an environment different from that in which the nucleic acid or nucleic acid sequence naturally occurs and can include those that are substantially free from contaminating endogenous material.
  • naturally-occurring as used herein as applied to a nucleic acid refers to a nucleic acid that is found in a cell of an organism in nature and which has not been intentionally modified by a human in the laboratory.
  • Recombinant nucleic acid sequences are nucleic acid sequences that result from the use of laboratory methods (for example, molecular cloning) to bring together genetic material from more than on source, creating or modifying a nucleic acid sequence that does not occur naturally and would not be otherwise found in biological organisms.
  • Recombinant DNA technology refers to molecular biology procedures to prepare a recombinant nucleic acid sequence as described, for instance, in Laboratory Manuals edited by Weigel and Glazebrook, 2002, Cold Spring Harbor Lab Press; and Sambrook et al, 1989, Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press.
  • gene means a DNA sequence comprising a region, which is transcribed into a RNA molecule, e.g., an mRNA in a cell, operably linked to suitable regulatory regions, e.g., a promoter.
  • a gene may thus comprise several operably linked sequences, such as a promoter, a 5′ leader sequence comprising, e.g., sequences involved in translation initiation, a coding region of cDNA or genomic DNA, introns, exons, and/or a 3′non-translated sequence comprising, e.g., transcription termination sites.
  • a “chimeric gene” refers to any gene which is not normally found in nature in a species, in particular, a gene in which one or more parts of the nucleic acid sequence are present that are not associated with each other in nature.
  • the promoter is not associated in nature with part or all of the transcribed region or with another regulatory region.
  • the term “chimeric gene” is understood to include expression constructs in which a promoter or transcription regulatory sequence is operably linked to one or more coding sequences or to an antisense, i.e., reverse complement of the sense strand, or inverted repeat sequence (sense and antisense, whereby the RNA transcript forms double stranded RNA upon transcription).
  • the term “chimeric gene” also includes genes obtained through the combination of portions of one or more coding sequences to produce a new gene.
  • a “3′ UTR” or “3′ non-translated sequence” refers to the nucleic acid sequence found downstream of the coding sequence of a gene, which comprises, for example, a transcription termination site and (in most, but not all eukaryotic mRNAs) a polyadenylation signal such as AAUAAA or variants thereof. After termination of transcription, the mRNA transcript may be cleaved downstream of the polyadenylation signal and a poly(A) tail may be added, which is involved in the transport of the mRNA to the site of translation, e.g., cytoplasm.
  • “Expression of a gene” encompasses “heterologous expression” and “over-expression” and involves transcription of the gene and translation of the mRNA into a protein. Overexpression refers to the production of the gene product as measured by levels of mRNA, polypeptide and/or enzyme activity in transgenic cells or organisms that exceeds levels of production in non-transformed cells or organisms of a similar genetic background.
  • “Expression vector” as used herein means a nucleic acid molecule engineered using molecular biology methods and recombinant DNA technology for delivery of foreign or exogenous DNA into a host cell.
  • the expression vector typically includes sequences required for proper transcription of the nucleotide sequence.
  • the coding region usually codes for a protein of interest but may also code for an RNA, e.g., an antisense RNA, siRNA and the like.
  • an “expression vector” as used herein includes any linear or circular recombinant vector including but not limited to viral vectors, bacteriophages and plasmids. The skilled person is capable of selecting a suitable vector according to the expression system.
  • the expression vector includes the nucleic acid of an embodiment herein operably linked to at least one regulatory sequence, which controls transcription, translation, initiation and termination, such as a transcriptional promoter, operator or enhancer, or an mRNA ribosomal binding site and, optionally, including at least one selection marker.
  • Nucleotide sequences are “operably linked” when the regulatory sequence functionally relates to the nucleic acid of an embodiment herein.
  • regulatory sequence refers to a nucleic acid sequence that determines expression level of the nucleic acid sequences of an embodiment herein and is capable of regulating the rate of transcription of the nucleic acid sequence operably linked to the regulatory sequence. Regulatory sequences comprise promoters, enhancers, transcription factors, promoter elements and the like.
  • Promoter refers to a nucleic acid sequence that controls the expression of a coding sequence by providing a binding site for RNA polymerase and other factors required for proper transcription including without limitation transcription factor binding sites, repressor and activator protein binding sites.
  • the meaning of the term promoter also includes the term “promoter regulatory sequence”.
  • Promoter regulatory sequences may include upstream and downstream elements that may influences transcription, RNA processing or stability of the associated coding nucleic acid sequence. Promoters include naturally-derived and synthetic sequences.
  • the coding nucleic acid sequences is usually located downstream of the promoter with respect to the direction of the transcription starting at the transcription initiation site.
  • constitutive promoter refers to an unregulated promoter that allows for continual transcription of the nucleic acid sequence it is operably linked to.
  • operably linked refers to a linkage of polynucleotide elements in a functional relationship.
  • a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or rather a transcription regulatory sequence, is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • Operably linked means that the DNA sequences being linked are typically contiguous.
  • the nucleotide sequence associated with the promoter sequence may be of homologous or heterologous origin with respect to the plant to be transformed. The sequence also may be entirely or partially synthetic.
  • nucleic acid sequence associated with the promoter sequence will be expressed or silenced in accordance with promoter properties to which it is linked after binding to the polypeptide of an embodiment herein.
  • the associated nucleic acid may code for a protein that is desired to be expressed or suppressed throughout the organism at all times or, alternatively, at a specific time or in specific tissues, cells, or cell compartment.
  • Such nucleotide sequences particularly encode proteins conferring desirable phenotypic traits to the host cells or organism altered or transformed therewith.
  • the associated nucleotide sequence leads to the production of albicanol and/or drimenol or a mixture comprising albicanol and/or drimenol or a mixture comprising albicanol and/or drimenol and one or more terpenes in the cell or organism.
  • the nucleotide sequence encodes a bifunctional terpene synthase.
  • Target peptide refers to an amino acid sequence which targets a protein, or polypeptide to intracellular organelles, i.e., mitochondria, or plastids, or to the extracellular space (secretion signal peptide).
  • a nucleic acid sequence encoding a target peptide may be fused to the nucleic acid sequence encoding the amino terminal end, e.g., N-terminal end, of the protein or polypeptide, or may be used to replace a native targeting polypeptide.
  • primer refers to a short nucleic acid sequence that is hybridized to a template nucleic acid sequence and is used for polymerization of a nucleic acid sequence complementary to the template.
  • the term “host cell” or “transformed cell” refers to a cell (or organism) altered to harbor at least one nucleic acid molecule, for instance, a recombinant gene encoding a desired protein or nucleic acid sequence which upon transcription yields a bifunctional terpene synthase protein useful to produce albicanol and/or drimenol.
  • the host cell is particularly a bacterial cell, a fungal cell or a plant cell.
  • the host cell may contain a recombinant gene which has been integrated into the nuclear or organelle genomes of the host cell. Alternatively, the host may contain the recombinant gene extra-chromosomally.
  • Homologous sequences include orthologous or paralogous sequences. Methods of identifying orthologs or paralogs including phylogenetic methods, sequence similarity and hybridization methods are known in the art and are described herein.
  • Paralogs result from gene duplication that gives rise to two or more genes with similar sequences and similar functions. Paralogs typically cluster together and are formed by duplications of genes within related plant species. Paralogs are found in groups of similar genes using pair-wise Blast analysis or during phylogenetic analysis of gene families using programs such as CLUSTAL. In paralogs, consensus sequences can be identified characteristic to sequences within related genes and having similar functions of the genes.
  • Orthologs are sequences similar to each other because they are found in species that descended from a common ancestor. For instance, plant species that have common ancestors are known to contain many enzymes that have similar sequences and functions. The skilled artisan can identify orthologous sequences and predict the functions of the orthologs, for example, by constructing a polygenic tree for a gene family of one species using CLUSTAL or BLAST programs. A method for identifying or confirming similar functions among homologous sequences is by comparing of the transcript profiles in host cells or organisms, such as plants or microorganisms, overexpressing or lacking (in knockouts/knockdowns) related polypeptides.
  • genes having similar transcript profiles with greater than 50% regulated transcripts in common, or with greater than 70% regulated transcripts in common, or greater than 90% regulated transcripts in common will have similar functions.
  • Homologs, paralogs, orthologs and any other variants of the sequences herein are expected to function in a similar manner by making the host cells, organism such as plants or microorganisms producing bifunctional terpene synthase proteins.
  • selectable marker refers to any gene which upon expression may be used to select a cell or cells that include the selectable marker. Examples of selectable markers are described below. The skilled artisan will know that different antibiotic, fungicide, auxotrophic or herbicide selectable markers are applicable to different target species.
  • “Drimenol” for purposes of this application relates to ( ⁇ )-drimenol (CAS: 468-68-8).
  • organism refers to any non-human multicellular or unicellular organisms such as a plant, or a microorganism. Particularly, a micro-organism is a bacterium, a yeast, an algae or a fungus.
  • plant is used interchangeably to include plant cells including plant protoplasts, plant tissues, plant cell tissue cultures giving rise to regenerated plants, or parts of plants, or plant organs such as roots, stems, leaves, flowers, pollen, ovules, embryos, fruits and the like. Any plant can be used to carry out the methods of an embodiment herein.
  • a particular organism or cell is meant to be “capable of producing FPP” when it produces FPP naturally or when it does not produce FPP naturally but is transformed to produce FPP, either prior to the transformation with a nucleic acid as described herein or together with said nucleic acid.
  • Organisms or cells transformed to produce a higher amount of FPP than the naturally occurring organism or cell are also encompassed by the “organisms or cells capable of producing FPP”.
  • nucleic acid molecule comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 or comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 33,
  • the nucleic acid molecule consists of the nucleotide sequence SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66
  • the nucleic acid of an embodiment herein can be either present naturally in Cryptoporus or Laricifomes or in other fungal species, or be obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof.
  • nucleic acid is isolated or is derived from fungi of the genus Cryptoporus or Laricifomes . In a further embodiment the nucleic acid is isolated or derived from Cryptoporus volvatus or Laricifomes officinalis.
  • nucleotide sequence obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof which encompasses any sequence that has been obtained by modifying the sequence of SEQ ID NO: 3 or SEQ ID NO: 7, or of the reverse complement thereof using any method known in the art, for example, by introducing any type of mutations such as deletion, insertion and/or substitution mutations.
  • nucleic acids comprising a sequence obtained by mutation of SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof are encompassed by an embodiment herein, provided that the sequences they comprise share at least the defined sequence identity of SEQ ID NO: 3 or SEQ ID NO: 7 as defined in any of the above embodiments or the reverse complement thereof and provided that they encode a polypeptide comprising a HAD-like hydrolase domain and having a bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T).
  • the polypeptide having bifunctional terpene synthase activity may further comprise one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • Mutations may be any kind of mutations of these nucleic acids, for example, point mutations, deletion mutations, insertion mutations and/or frame shift mutations of one or more nucleotides of the DNA sequence of SEQ ID NO: 3 or SEQ ID NO: 7.
  • the nucleic acid of an embodiment herein may be truncated provided that it encodes a polypeptide as described herein.
  • a variant nucleic acid may be prepared in order to adapt its nucleotide sequence to a specific expression system.
  • bacterial expression systems are known to more efficiently express polypeptides if amino acids are encoded by particular codons.
  • nucleic acid sequences encoding the bifunctional terpene synthase may be optimized for increased expression in the host cell.
  • nucleotides of an embodiment herein may be synthesized using codons particular to a host for improved expression.
  • the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 46, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof.
  • an isolated, recombinant or synthetic nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO:
  • RNA sequences Provided herein are also cDNA, genomic DNA and RNA sequences. Any nucleic acid sequence encoding the bifunctional terpene synthase or variants thereof is referred herein as a bifunctional terpene synthase encoding sequence.
  • the nucleic acid of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 is the coding sequence of a bifunctional terpene synthase gene encoding a bifunctional terpene synthase obtained as described in the Examples.
  • a fragment of a polynucleotide of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 refers to contiguous nucleotides that is particularly at least 15 bp, at least 30 bp, at least 40 bp, at least 50 bp and/or at least 60 bp in length of the polynucleotide of an embodiment herein.
  • the fragment of a polynucleotide comprises at least 25, more particularly at least 50, more particularly at least 75, more particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 700, more particularly at least 800, more particularly at least 900, more particularly at least 1000 contiguous nucleotides of the polynucleotide of an embodiment herein.
  • fragment of the polynucleotides herein may be used as a PCR primer, and/or as a probe, or for anti-sense gene silencing or RNAi.
  • genes including the polynucleotides of an embodiment herein, can be cloned on basis of the available nucleotide sequence information, such as found in the attached sequence listing, by methods known in the art. These include e.g. the design of DNA primers representing the flanking sequences of such gene of which one is generated in sense orientations and which initiates synthesis of the sense strand and the other is created in reverse complementary fashion and generates the antisense strand. Thermo stable DNA polymerases such as those used in polymerase chain reaction are commonly used to carry out such experiments. Alternatively, DNA sequences representing genes can be chemically synthesized and subsequently introduced in DNA vector molecules that can be multiplied by e.g. compatible bacteria such as e.g. E. coli.
  • PCR primers and/or probes for detecting nucleic acid sequences encoding a polypeptide having bifunctional terpene synthase activity are provided.
  • a detection kit for nucleic acid sequences encoding the bifunctional terpene synthase may include primers and/or probes specific for nucleic acid sequences encoding the bifunctional terpene synthase, and an associated protocol to use the primers and/or probes to detect nucleic acid sequences encoding the bifunctional terpene synthase in a sample.
  • detection kits may be used to determine whether a plant, organism, microorganism or cell has been modified, i.e., transformed with a sequence encoding the bifunctional terpene synthase.
  • the sequence of interest is operably linked to a selectable or screenable marker gene and expression of the reporter gene is tested in transient expression assays, for example, with microorganisms or with protoplasts or in stably transformed plants.
  • transient expression assays for example, with microorganisms or with protoplasts or in stably transformed plants.
  • DNA sequences capable of driving expression are built as modules. Accordingly, expression levels from shorter DNA fragments may be different than the one from the longest fragment and may be different from each other.
  • nucleic acid sequence coding the bifunctional terpene synthase proteins provided herein, i.e., nucleotide sequences that hybridize under stringent conditions to the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68.
  • hybridization or hybridizes under certain conditions is intended to describe conditions for hybridization and washes under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other.
  • the conditions may be such that sequences, which are at least about 70%, such as at least about 80%, and such as at least about 85%, 90%, or 95% identical, remain bound to each other. Definitions of low stringency, moderate, and high stringency hybridization conditions are provided herein.
  • defined conditions of low stringency are as follows. Filters containing DNA are pretreated for 6 h at 40° C. in a solution containing 35% formamide, 5 ⁇ SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 ⁇ 106 32P-labeled probe is used.
  • Filters are incubated in hybridization mixture for 18-20 h at 40° C., and then washed for 1.5 h at 55° C. In a solution containing 2 ⁇ SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60° C. Filters are blotted dry and exposed for autoradiography.
  • defined conditions of moderate stringency are as follows. Filters containing DNA are pretreated for 7 h at 50° C. in a solution containing 35% formamide, 5 ⁇ SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 ⁇ 106 32P-labeled probe is used.
  • Filters are incubated in hybridization mixture for 30 h at 50° C., and then washed for 1.5 h at 55° C. In a solution containing 2 ⁇ SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60° C. Filters are blotted dry and exposed for autoradiography.
  • defined conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65° C. in buffer composed of 6 ⁇ SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65° C. in the prehybridization mixture containing 100 ⁇ g/ml denatured salmon sperm DNA and 5-20 ⁇ 106 cpm of 32P-labeled probe. Washing of filters is done at 37° C.
  • the percentage of identity between two peptide or nucleotide sequences is a function of the number of amino acids or nucleotide residues that are identical in the two sequences when an alignment of these two sequences has been generated. Identical residues are defined as residues that are the same in the two sequences in a given position of the alignment.
  • the percentage of sequence identity is calculated from the optimal alignment by taking the number of residues identical between two sequences dividing it by the total number of residues in the shortest sequence and multiplying by 100.
  • the optimal alignment is the alignment in which the percentage of identity is the highest possible. Gaps may be introduced into one or both sequences in one or more positions of the alignment to obtain the optimal alignment.
  • Alignment for the purpose of determining the percentage of amino acid or nucleic acid sequence identity can be achieved in various ways using computer programs and for instance publicly available computer programs available on the world wide web.
  • the BLAST program (Tatiana et al, FEMS Microbiol Lett., 1999, 174:247-250, 1999) set to the default parameters, available from the National Center for Biotechnology Information (NCBI) website at ncbi.nlm.nih.gov/BLAST/b12seq/wblast2.cgi, can be used to obtain an optimal alignment of protein or nucleic acid sequences and to calculate the percentage of sequence identity.
  • a related embodiment provided herein provides a nucleic acid sequence which is complementary to the nucleic acid sequence according to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 such as inhibitory RNAs, or nucleic acid sequence which hybridizes under stringent conditions to at least part of the nucleotide sequence according to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68.
  • An alternative embodiment of an embodiment herein provides a method to alter gene expression in a host cell. For instance, the polynucleotide of an embodiment herein may be enhanced or overexpressed or induced in certain contexts (e.g. upon exposure to certain temperatures or culture conditions) in a host cell or host organism.
  • Alteration of expression of a polynucleotide provided herein may also result in ectopic expression which is a different expression pattern in an altered and in a control or wild-type organism. Alteration of expression occurs from interactions of polypeptide of an embodiment herein with exogenous or endogenous modulators, or as a result of chemical modification of the polypeptide. The term also refers to an altered expression pattern of the polynucleotide of an embodiment herein which is altered below the detection level or completely suppressed activity.
  • provided herein is also an isolated, recombinant or synthetic polynucleotide encoding a polypeptide or variant polypeptide provided herein.
  • an isolated nucleic acid molecule encoding a polypeptide comprising a domain of the HAD-like hydrolase superfamily having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and the sequence as
  • an isolated polypeptide comprising a HAD-like hydrolase domain having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5 or comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
  • the polypeptide consists of the amino acid sequence of SEQ ID NO: 1 or 5.
  • the polypeptide of an embodiment herein can be present naturally in Cryptoporus or Laricifomes fungi or in other fungi species, or comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, either obtained by genetic engineering or found naturally in Cryptoporus or Laricifomes fungi or in other fungi species.
  • the polypeptide is isolated or derived from fungi of the genus Cryptoporus or Laricifomes .
  • the polypeptide is isolated or derived from Cryptoporus volvatus or Laricifomes officinalis.
  • the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, obtained by genetic engineering.
  • the polypeptide comprises an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof.
  • Polypeptides are also meant to include variants and truncated polypeptides provided that they have bifunctional terpene synthase activity.
  • the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, obtained by genetic engineering, provided that said variant has bifunctional terpene synthase activity to produce a drimane sesquiterpene and has the required percentage of identity to SEQ ID NO: 1 or SEQ ID NO: 5 as described in any of the above embodiments and comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T) and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5.
  • the polypeptide having bifunctional terpene synthase activity may further comprise one or more conserved motifs as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments is a variant of SEQ ID NO: 1 or SEQ ID NO: 5 that can be found naturally in other organisms, such as other fungal species, provided that it has bifunctional terpene synthase activity and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5.
  • the polypeptide includes a polypeptide or peptide fragment that encompasses the amino acid sequences identified herein, as well as truncated or variant polypeptides provided that they have bifunctional terpene synthase activity and that they share at least the defined percentage of identity with the corresponding fragment of SEQ ID NO: 1 or SEQ ID NO: 5 and comprise (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T) and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5.
  • variant polypeptides are naturally occurring proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the polypeptides described herein. Variations attributable to proteolysis include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides of an embodiment herein. Polypeptides encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of an embodiment herein, as described thereafter, are also encompassed by an embodiment herein.
  • Polypeptide variants resulting from a fusion of additional peptide sequences at the amino and carboxyl terminal ends can also be used in the methods of an embodiment herein.
  • a fusion can enhance expression of the polypeptides, be useful in the purification of the protein or improve the enzymatic activity of the polypeptide in a desired environment or expression system.
  • additional peptide sequences may be signal peptides, for example.
  • Another aspect encompasses methods using variant polypeptides, such as those obtained by fusion with other oligo- or polypeptides and/or those which are linked to signal peptides.
  • Polypeptides resulting from a fusion with another functional protein, such as another protein from the terpene biosynthesis pathway can also be advantageously used in the methods of an embodiment herein.
  • a variant may also differ from the polypeptide of an embodiment herein by attachment of modifying groups which are covalently or non-covalently linked to the polypeptide backbone.
  • the variant also includes a polypeptide which differs from the polypeptide provided herein by introduced N-linked or O-linked glycosylation sites, and/or an addition of cysteine residues. The skilled artisan will recognize how to modify an amino acid sequence and preserve biological activity.
  • DNA sequence polymorphisms may exist within a given population, which may lead to changes in the amino acid sequence of the polypeptides disclosed herein.
  • Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.
  • nucleic acid encoding the polypeptide or variants thereof of an embodiment herein is a useful tool to modify non-human host organisms, microorganisms or cells and to modify non-human host organisms, microorganisms or cells intended to be used in the methods described herein.
  • An embodiment provided herein provides amino acid sequences of bifunctional terpene synthase proteins including orthologs and paralogs as well as methods for identifying and isolating orthologs and paralogs of the bifunctional terpene synthases in other organisms.
  • orthologs and paralogs of the bifunctional terpene synthase retain bifunctional terpene synthase activity, may be considered a polypeptide of the HAD-like hydrolase superfamily (Interpro protein superfamily IPR023214 or Pfam protein superfamily PF13419) and which comprises a HAD-like hydrolase domain and are capable of producing a drimane sesquiterpene, such as albicanol and/or drimenol, starting from an acyclic terpene pyrophosphate precursor, e.g. FPP.
  • HAD-like hydrolase superfamily Interpro protein superfamily IPR023214 or Pfam protein superfamily PF13419
  • a drimane sesquiterpene such as albicanol and/or drimenol
  • the polypeptide to be contacted with an acyclic terpene pyrophosphate, e.g. FPP, in vitro can be obtained by extraction from any organism expressing it, using standard protein or enzyme extraction technologies. If the host organism is an unicellular organism or cell releasing the polypeptide of an embodiment herein into the culture medium, the polypeptide may simply be collected from the culture medium, for example by centrifugation, optionally followed by washing steps and re-suspension in suitable buffer solutions. If the organism or cell accumulates the polypeptide within its cells, the polypeptide may be obtained by disruption or lysis of the cells and optionally further extraction of the polypeptide from the cell lysate. The cell lysate or the extracted polypeptide can be used to contact the acyclic terpene pyrophosphate for production of a terpene or a mixture of terpenes.
  • FPP acyclic terpene pyrophosphate
  • the polypeptide having a bifunctional terpene synthase activity may then be suspended in a buffer solution at optimal pH. If adequate, salts, DTT, inorganic cations and other kinds of enzymatic co-factors, may be added in order to optimize enzyme activity.
  • the precursor FPP is added to the polypeptide suspension, which is then incubated at optimal temperature, for example between 15 and 40° C., particularly between 25 and 35° C., more particularly at 30° C.
  • the drimane sesquiterpene, such as albicanol and/or drimenol, produced may be isolated from the incubated solution by standard isolation procedures, such as solvent extraction and distillation, optionally after removal of polypeptides from the solution.
  • the at least one polypeptide having a bifunctional terpene synthase activity can be used for production of a drimane sesquiterpene comprising albicanol and/or drimenol or mixtures of terpenes comprising albicanol and/or drimenol.
  • One particular tool to carry out the method of an embodiment herein is the polypeptide itself as described herein.
  • the polypeptide is capable of producing a mixture of sesquiterpenes wherein albicanol and/or drimenol represents at least 20%, particularly at least 30%, particularly at least 35%, particularly at least 90%, particularly at least 95%, more particularly at least 98% of the sesquiterpenes produced.
  • albicanol and/or drimenol is produced with greater than or equal to 95%, more particularly 98% selectivity.
  • bifunctional terpene synthase protein variant or fragment
  • transient or stable overexpression in plant, bacterial or yeast cells can be used to test whether the protein has activity, i.e., produces albicanol and/or drimenol from FPP precursors.
  • Bifunctional terpene synthase activity may be assessed in a microbial expression system, such as the assay described in Example 3 herein on the production of albicanol and/or drimenol, indicating functionality.
  • a variant or derivative of a bifunctional terpene synthase polypeptide of an embodiment herein retains an ability to produce a drimane sesquiterpene such as albicanol and/or drimenol from FPP precursors.
  • Amino acid sequence variants of the bifunctional terpene synthases provided herein may have additional desirable biological functions including, e.g., altered substrate utilization, reaction kinetics, product distribution or other alterations.
  • a polypeptide to catalyze the synthesis of a particular sesquiterpene for example albicanol and/or drimenol
  • a particular sesquiterpene for example albicanol and/or drimenol
  • At least one vector comprising the nucleic acid molecules described herein.
  • Also provided herein is a vector selected from the group of a prokaryotic vector, viral vector and a eukaryotic vector.
  • a vector that is an expression vector is an expression vector.
  • bifunctional terpene synthases encoding nucleic acid sequences are co-expressed in a single host, particularly under control of different promoters.
  • several bifunctional terpene synthase proteins encoding nucleic acid sequences can be present on a single transformation vector or be co-transformed at the same time using separate vectors and selecting transformants comprising both chimeric genes.
  • one or more bifunctional terpene synthase encoding genes may be expressed in a single plant, cell, microorganism or organism together with other chimeric genes.
  • the nucleic acid sequences of an embodiment herein encoding bifunctional terpene synthase proteins can be inserted in expression vectors and/or be contained in chimeric genes inserted in expression vectors, to produce bifunctional terpene synthase proteins in a host cell or non-human host organism.
  • the vectors for inserting transgenes into the genome of host cells are well known in the art and include plasmids, viruses, cosmids and artificial chromosomes.
  • Binary or co-integration vectors into which a chimeric gene is inserted can also be used for transforming host cells.
  • An embodiment provided herein provides recombinant expression vectors comprising a nucleic acid sequence of a bifunctional terpene synthase gene, or a chimeric gene comprising a nucleic acid sequence of a bifunctional terpene synthase gene, operably linked to associated nucleic acid sequences such as, for instance, promoter sequences.
  • a chimeric gene comprising a nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO
  • the promoter sequence may already be present in a vector so that the nucleic acid sequence which is to be transcribed is inserted into the vector downstream of the promoter sequence.
  • Vectors can be engineered to have an origin of replication, a multiple cloning site, and a selectable marker.
  • an expression vector comprising a nucleic acid as described herein can be used as a tool for transforming non-human host organisms or host cells suitable to carry out the method of an embodiment herein in vivo.
  • the expression vectors provided herein may be used in the methods for preparing a genetically transformed non-human host organism and/or host cell, in non-human host organisms and/or host cells harboring the nucleic acids of an embodiment herein and in the methods for making polypeptides having a bifunctional terpene synthase activity, as described herein.
  • Recombinant non-human host organisms and host cells transformed to harbor at least one nucleic acid of an embodiment herein so that it heterologously expresses or over-expresses at least one polypeptide of an embodiment herein are also very useful tools to carry out the method of an embodiment herein. Such non-human host organisms and host cells are therefore provided herein.
  • a host cell, microorganism or non-human host organism comprising at least one of the nucleic acid molecules described herein or comprising at least one vector comprising at least one of the nucleic acid molecules.
  • a nucleic acid according to any of the above-described embodiments can be used to transform the non-human host organisms and cells and the expressed polypeptide can be any of the above-described polypeptides.
  • the non-human host organism or host cell is a prokaryotic cell. In another embodiment, the non-human host organism or host cell is a bacterial cell. In a further embodiment, the non-human host organism or host cell is Escherichia coli.
  • the non-human host organism or host cell is a eukaryotic cell. In another embodiment, the non-human host organism or host cell is a yeast cell. In a further embodiment, the non-human host organism or cell is Saccharomyces cerevisiae.
  • the non-human organism or host cell is a plant cell or a fungal cell.
  • the non-human host organism or host cell expresses a polypeptide, provided that the organism or cell is transformed to harbor a nucleic acid encoding said polypeptide, this nucleic acid is transcribed to mRNA and the polypeptide is found in the host organism or cell. Suitable methods to transform a non-human host organism or a host cell have been previously described and are also provided herein.
  • the host organism or host cell is cultivated under conditions conducive to the production of a drimane sesquiterpene such as albicanol and/or drimenol.
  • optimal growth conditions can be provided, such as optimal light, water and nutrient conditions, for example.
  • conditions conducive to the production of a drimane sesquiterpene such as albicanol and/or drimenol may comprise addition of suitable cofactors to the culture medium of the host.
  • a culture medium may be selected, so as to maximize drimane sesquiterpene, such as albicanol and/or drimenol, synthesis. Examples of optimal culture conditions are described in a more detailed manner in the Examples.
  • Non-human host organisms suitable to carry out the method of an embodiment herein in vivo may be any non-human multicellular or unicellular organisms.
  • the non-human host organism used to carry out an embodiment herein in vivo is a plant, a prokaryote or a fungus. Any plant, prokaryote or fungus can be used. Particularly useful plants are those that naturally produce high amounts of terpenes.
  • the non-human host organism used to carry out the method of an embodiment herein in vivo is a microorganism. Any microorganism can be used, for example, the microorganism can be a bacteria or yeast, such as E. coli or Saccharomyces cerevisiae.
  • organisms or cells that do not produce an acyclic terpene pyrophosphate precursor, e.g. FPP, naturally are transformed to produce said precursor. They can be so transformed either before the modification with the nucleic acid described according to any of the above embodiments or simultaneously, as explained above.
  • Methods to transform organisms, for example microorganisms, so that they produce an acyclic terpene pyrophosphate precursor, e.g. FPP are already known in the art.
  • Isolated higher eukaryotic cells can also be used, instead of complete organisms, as hosts to carry out the method of an embodiment herein in vivo.
  • Suitable eukaryotic cells may be any non-human cell, such as plant or fungal cells.
  • a method of producing a drimane sesquiterpene comprising: contacting an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP) with a polypeptide which comprises a HAD-like hydrolase domain and having bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)); and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T); and optionally isolating the drimane sesquiterpene.
  • FPP farnesyl diphosphate
  • the drimane sesquiterpene comprises albicanol and/or drimenol.
  • polypeptide comprises an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63 and (1) the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and (2) the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58 or comprising the amino acid sequence of SEQ ID NO:
  • the drimane sesquiterpene is albicanol and/or drimenol. In another aspect, the drimane sesquiterpene is isolated.
  • the albicanol and/or drimenol is produced with greater than or equal to, 60%, 80%, or 90% or even 95% selectivity.
  • the drimane sesquiterpene is albicanol.
  • a method comprising transforming a host cell, microorganism or a non-human host organism with a nucleic acid encoding a polypeptide comprising a HAD-like hydrolase domain having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and comprising (1) the sequence as set forth in SEQ ID NO:
  • a method provided herein comprises cultivating a non-human host organism or a host cell capable of producing FPP and transformed to express a polypeptide wherein the polypeptide comprises a sequence of amino acids that has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5 under conditions that allow for the production of the polypeptide.
  • a method provided herein comprises contacting a sesquiterpene such as albicanol and/or drimenol with at least one enzyme to produce a sesquiterpene derivative.
  • the sesquiterpene derivative can be obtained biochemically or chemically.
  • a drimenol derivative is provided. Examples of such derivatives of drimenol include but not limited to drimenyl acetate (CAS 40266-93-1), drimenal (CAS 105426-71-9), drimenic acid (CAS 111319-84-7).
  • an albicanol derivative is provided.
  • examples of such derivatives of albicanol include cryptoporic acid E (CAS 120001-10-7), cryptoporic acid D (CAS 119979-95-2), cryptoporic acid B (CAS 113592-88-4), cryptoporic acid A (CAS 113592-87-3), laricinolic acid (CAS 302355-23-3), albicanyl acetate (CAS 83679-71-4).
  • the albicanol and/or drimenol produced in any of the method described herein can be converted to derivatives such as, but not limited to hydrocarbons, esters, amides, glycosides, ethers, epoxides, aldehydes, ketons, alcohols, diols, acetals or ketals.
  • the albicanol and/or drimenol derivatives can be obtained by a chemical method such as, but not limited to oxidation, reduction, alkylation, acylation and/or rearrangement.
  • the albicanol and/or drimenol derivatives can be obtained using a biochemical method by contacting the albicanol and/or drimenol with an enzyme such as, but not limited to an oxidoreductase, a monooxygenase, a dioxygenase, a transferase.
  • an enzyme such as, but not limited to an oxidoreductase, a monooxygenase, a dioxygenase, a transferase.
  • the biochemical conversion can be performed in-vitro using isolated enzymes, enzymes from lysed cells or in-vivo using whole cells.
  • step a) comprises cultivating a non-human host organism or a host cell capable of producing FPP and transformed to express at least one polypeptide comprising an amino acid comprising SEQ ID NO: 1 or SEQ ID NO: 5 or a functional variant thereof which may be considered a polypeptide of the HAD-like hydrolase superfamily (Interpro protein superfamily IPR023214 or Pfam protein superfamily PF13419) and which comprises a HAD-like hydrolase domain and having a bifunctional terpene synthase activity, under conditions conducive to the production of drimane synthase, for example, albicanol and/or drimenol.
  • albicanol may be the only product or may be part of a mixture of sesquiterpenes.
  • drimenol may be the only product or may be part of a mixture of sesquiter
  • the method further comprises, prior to step a), transforming a non-human organism or cell capable of producing FPP with at least one nucleic acid encoding a polypeptide comprising an amino acid comprising SEQ ID NO: 1 or SEQ ID NO: 5 or encoding a polypeptide having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50,
  • An embodiment herein provides polypeptides of an embodiment herein to be used in a method to produce a drimane sesquiterpene such as albicanol and/or drimenol contacting an FPP precursor with the polypeptides of an embodiment herein either in vitro or in vivo.
  • a polypeptide as described herein for producing a drimane sesquiterpene for example, albicanol and/or drimenol.
  • Drimane sesquiterpenoids are widespread in nature (Jansen and Groot, 2004, Nat. Prod. Rep., 21, 449-477).
  • the compounds in the drimane sesquiterpeneoid family contain the sesquiterpene structure with the drimane carbon skeleton depicted in FIG. 1 .
  • commonly found drimane sesquiterpene are drimenol and albicanol ( FIG. 1 ) and compounds derived from drimenol and albicanol by enzymatic reactions such as oxidations, reduction, acylation, alkylation or rearrangement.
  • the drimane sesquiterpenoid family contains also compounds were the drimane sesquiterpene is bound to a molecule derived from another biosynthetic pathway (Jansen and Groot, 2004, Nat. Prod. Rep., 21, 449-477).
  • Cryptoporic acids A-H are drimane sequiterpenoid ethers of isocitric acid found in the fungus Cryptoporus volvatus (Hashimoto et al, 1987, Tetrahedron Let. 28, 6303-6304; Asakawa et al, 1992, Phytochemistry 31(2), 579-592; Hirotani et al, 1991, Phytochemistry 30(5), 1555-1559).
  • crypotoporic acids the sesquiterpene moiety has the structure of albicanol and thus these compounds are putatively derived biosynthetically from albicanol.
  • Laricinolic acid is a drimane type sesquiterpene which can be isolated from the wood-rotting fungus Laricifomes officinalis (Erb et al, 2000, J. Chem. Soc., Perkin Trans. 1, 2307-2309). Laricinolic acid is most likely derived from albicanol following several oxidative enzymatic steps.
  • RNA extraction 0.5 ml of culture was taken, the cells (Approximately 100 mg) were recovered by centrifugation frozen in liquid nitrogen and grinded using a mortar and pestle. The total RNA pool was extracted using the ZR Fungal/Bacterial RNA MiniPrepTM from Zymo Research Corp (Irvine, Calif. 92614, U.S.A).
  • Genomic DNA was extracted using the NucleoSpin® Soil Kit from Machery-Nagel (Duren, Germany). Cells were recovered from the culture by centrifugation and the genomic DNA was extracted following the manufacturer protocol. From 500 mg of cells 1.05 and 0.93 micrograms of genomic DNA was extracted from ATCC-12212 and ATCC-64430, respectively.
  • the genomic DNA was sequenced using a paired read protocol (Illumina).
  • the libraries were prepared to select insert sizes between 250 and 350 bp.
  • the sequencing was performed on a HiSeq 2500 Illumina sequencer.
  • the length of the reads was 125 bases.
  • a total of 21.3 and 30.4 millions of paired-reads (clusters) were sequenced for ATCC-12212 and ATCC-64430, respectively.
  • the library was prepared from the total RNA using the TruSeq Stranded mRNA Library Preparation Kit (Illumina). An additional insert size selection step (160-240 bp) was performed. The libraries were sequenced in 2 ⁇ 125 bases paired-ends on a HiSeq 2500 Illumina sequencer. For ATCC-12212 and ATCC-64430, 19.9 million and 126 millions of reads were sequences, respectively.
  • the reads were first joined on their overlapping ends.
  • the joined paired reads were then assembled using the Velvet V1.2.10 assembler (Zerbino D. R. and Birney E. 2008, Genome Res. 18(5), 821-829; www.ebi.ac.uk/ ⁇ zerbino/velvet/) and the Oases software (Schulz M. H et al., 2012, Bioinformatics 28(8), 1086-1092; www.ebi.ac.uk/ ⁇ zerbino/oases/).
  • a total of 25′866 contigs with an average length of 1,792 bases was obtained for the C. volvatus transcriptome.
  • the C. volvatus genome was assembled using the Velvet V1.2.10 assembler (Zerbino D. R. and Birney E., 2008, Genome Res. 18(5), 821-829; www.ebi.ac.uk/ ⁇ zerbino/velvet/).
  • the genome could be assembled in 1′266 contigs with an average size 20,000 bases and a total size of 25′320′421 bases.
  • An ab-initio gene prediction in the C. volvatus genomic contigs was performed by Progenus S A (Gembloux, Belgium) using the Augustus software (Stanke et al., Nucleic Acids Res . (2004) 32, W309-W312). A total of 7738 genes were predicted.
  • the genome and transcriptome of L. officinalis were assembled using the CLC Genomic Workbench (Qiagen).
  • the genome was assembled in 16′831 contigs for a total genome size of 90′591′190 bases.
  • the transcriptome assembly provided 28′633 contigs with an average length of 1′962 bases.
  • Drimane sesquiterpene are presumably produced from farnesyl-diphosphate (FPP) by an enzymatic mechanism involving a protonation-initiated cyclization followed by an ionization-initiated reaction (Henquet et al., 2017, Plant J . Mar 4. doi: 10.1111/tpj.13527; Kwon, M.et al., 2014, FEBS Letters 588, 4597-4603) ( FIG. 2 ).
  • This implies that the drimane synthases are composed of two catalytic domains, a protonation-initiated cyclization catalytic domain and an ionization-initiated cyclization catalytic domain.
  • Terpene synthases catalyzing protonation-initiated cyclization reaction are called class II (or type II) terpene synthases and are typically involved in the biosynthesis of triterpenes and labdane diterpenes.
  • class II terpene synthases the protonation-initiated reaction involves acidic amino acids donating a proton to the terminal double-bond. These residues, usually aspartic acids, are part of a conserved DxDD motif located in the active site of the enzyme.
  • Terpene synthases catalyzing ionization-initiated reactions are called class I (or type I) terpene synthases, generally monoterpene and sesquiterpene synthases, and the catalytic center contains a conserved DDxxD (part of SEQ ID NO: 53) motif.
  • the aspartic acid residues of this class I motif bind a divalent metal ion (most often Mg 2+ ) involved in the binding of the diphosphate group and catalyze the ionization and cleavage of the allylic diphosphate bond of the substrate.
  • the putative cyclization mechanism of a farnesyl-diphosphate to a drimane sesquiterpene starts with the protonation of the 10,11-double bond followed by the sequential rearrangements and carbon-bond formations.
  • the carbocation intermediate of this first (class II) reaction can then undergo deprotonation at C15 or C4 (or eventually at C2) leading to an albicanyl-diphosphate or drimenyl-diphosphate intermediate.
  • the class I catalytic domain catalyzes the ionization of the allylic diphosphate bond and quenching of the carbocation intermediated by a water molecule leading to a drimane sesquiterpene containing a primary hydroxyl group ( FIG. 2 ).
  • any traces of residual phosphorylated intermediates of the albicanol or drimenol synthesis like any albicanyl—or drimenyl-monophosphate and/or—diphosphate, may be chemically converted to the respective final product albicanol or drimenol.
  • Certain corresponding methods are known and may comprise, for example, the hydrolytic cleavage of the phosphoric acid ester bond. Additionally, certain intermediates can also be converted enzymatically as shown in Examples 7 and 8.
  • this enzyme does not have a class I terpene synthase activity and thus does not catalyze the ionization and cleavage of the allylic diphosphate group.
  • AstC we first search the amino acid sequences deduced from the genes predicted in the C. volvatus genome. Using a Blastp search against the amino acid sequences deduced from the predicted genes, 5 sequences were retrieved with an E value between 0.77 and 3e-089 (Altschul et al., 1990, J. Mol. Biol. 215, 403-410).
  • CvTps1 was selected as the most relevant for a putative albicanol synthases.
  • the amino acid sequence encoded by the CvTps1 gene shared 38% identity with the AstC amino acid sequence. Analysis of this sequence revealed the presence of a class II terpene synthase-like motif, DVDT, at position 275-279. This is a variant of the typical class II terpene synthase motif mentioned above, where the last Asp is replaced by a Thr.
  • This DxDT class II motif is found in some class II diterpene synthases (Xu M. et al., 2014, J. Nat. Prod. 77, 2144-2147; Morrone D.
  • CvTps1 was selected as putative candidate for a bi-functional albicanol synthase.
  • Protein family databases such as Pfam and Interpro (European Bioinformatic Institute (EMBL-EBI) are databases of protein families including functional annotation, protein domains and protein domain signatures.
  • the amino acid sequence of CvTps1 was searched for the occurrence of motifs characteristic of protein domains using the HMMER algorithm available on the HMMER website (Finn R. D., 2015, Nucleic Acids Research Web Server Issue 43:W30-W38; www.ebi.ac.uk/Tools/hmmer/). No domain associated with classical terpene synthases was found in the CvTps1 amino acid sequence.
  • the query identified a domain characteristic of the Haloacid dehalogenase (HAD)-like hydrolase protein superfamily (PF13419.5) in the region between residues 115 and 187.
  • a similar search using the Interpro protein family database see the ebi.ac.uk/interpro/web site) and the conserveed Domain Database (NCBI web site at ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) provided the same results: only the prediction of a domain of the HAD-like hydrolase superfamily in the N-terminal region (IPR 023214 and CL21460, respectively).
  • the HAD-like hydrolase superfamily contains a large number of proteins with various functions including enzymes with phosphatase activity (Koonin and Tatusov, 1994, J. Mol. Biol 244, 125-132; Kuznetsova et al, 2015, J Biol Chem. 290(30), 18678-18698).
  • the class I terpene synthase-like motif identified above in the CvTps1 polypeptide contains one of the HAD-like hydrolase motif signatures containing a conserved aspartic acid residues involved in the catalytic (phosphatase) activity. This analysis thus confirms that the N-terminal region of CvTps1 is involved in hydrolysis of the diphosphate group (class I terpene synthase activity).
  • the CvTps1 amino acid sequence was used to search for homologous sequences in the L. officinalis genome and transcriptome. For this search the tBlastn algorithm was used (Altschul et al 1990, J. Mol. Biol. 215, 403-410).
  • LoTps1 showed sequence similarity with CvTps1: the length of the sequence (521 amino acid) was similar to the length of the CvTps1 amino acid sequence, the overall sequence identity between the two sequences was 71%, the N-terminal region contained a typical class I terpene synthase motif (DDKLD at position 162-166), a class II terpene synthase motif (DMDT) was found in position 267-270 and the N-terminal region contain a predicted HAD-like hydrolase domain.
  • DDKLD typical class I terpene synthase motif
  • DMDT class II terpene synthase motif
  • the CvTps1 and LoTps1 coding sequences were control and the intron-exon jonctions predictions were refined using mappings of the RNA sequencing reads against the genomic contigs.
  • the coding sequences of the resulting cDNAs were codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, Calif.).
  • the enzymes were functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP). Competent E. coli cells were transformed with the plasmid pACYC-29258-4506 (described in WO2013064411 or in Schalk et al., 2013, J. Am. Chem. Soc. 134, 18900-18903) and with the pJ401-CvTps1 or pJ401-LoTps1 expression plasmid.
  • the pACYC-29258-4506 carries the cDNA encoding for a FPP synthase gene and the genes for a complete mevalonate pathway.
  • coli cells (Promega) were used as a host. Transformed cells were selected on kanamycin (50 ⁇ g/ml) and chloramphenicol (34 ⁇ g/ml) LB-agarose plates. Single colonies were used to inoculate 5 mL liquid LB medium supplemented with the same antibiotics. The culture was incubated overnight at 37° C. The next day 2 mL of TB medium supplemented with the same antibiotics were inoculated with 0.2 mL of the overnight culture. After 6 hours incubation at 37° C., the culture was cooled down to 28° C. and 0.1 mM IPTG, 0.2% rhamnose and 10% in volume (0.2 ml) of dodecane were added to each tube. The cultures were incubated for 48 hours at 28° C. The cultures were then extracted twice with 2 volumes of tert-Butyl methyl ether (MTBE), the organic phase were concentrated to 500 ⁇ L and analyzed by GC-MS.
  • MTBE tert
  • the GC-MS analysis were performed using an Agilent 6890 Series GC system connected to an Agilent 5975 mass detector.
  • the GC was equipped with 0.25 mm inner diameter by 30 m DB-1MS capillary column (Agilent).
  • the carrier gas was He at a constant flow of 1 mL/min.
  • the inlet temperature was set at 250° C.
  • the initial oven temperature was 80° C. followed by a gradient of 10° C./min to 220° C. and a second gradient of 30° C./min to 280° C.
  • the identification of the products was based on the comparison of the mass spectra and retention indices with authentic standards and internal mass spectra databases.
  • albicanol was confirmed by 1H- and 13C-NMR analysis.
  • the optical rotation was measured using a Bruker Avance 500 MHz spectrometer.
  • the value of [ ⁇ ] D 20 +3.8° (0.26%, CHCl3) confirmed the formation of (+)-albicanol (with the structure shown in FIG. 1 ) by the recombinant CvTps1 protein.
  • LoTps1 The activity of LoTps1 was evaluated in the same conditions.
  • the product profile was identical to the profile of CvTps1 with (+)-albicanol as the only detected product of the recombinant LoTps1 enzyme.
  • NCBI accession OCH93767.1 from Obba rivulosa NCBI accession EMD37666.1 from Gelatoporia subvermispora
  • NCBI accession XP_001217376.1 NCBI accession OJJ98394.1 from Aspergillus aculeatus
  • NCBI accession GAO87501.1 from Aspergillus udagawae
  • NCBI accession XP_008034151.1 from Trametes versicolor
  • NCBI accession XP_007369631.1 from Dichomitus squalens NCBI accession KIA75676.1 from Aspergillus ustus
  • NCBI accession XP_001820867.2 from Aspergillus oryzae
  • NCBI accession CEN60542.1 NCBI accession CEN60542.1 from Aspergillus calidoustus
  • sequence of EMD3766.1 was corrected by deleting the amino acids 261 to 266 present in the published sequence and probably resulting from incorrect splicing prediction (sequence EMD37666-B in table 1).
  • sequence EMD37666-B Another sequence, ACg006372 was selected from the published annotated sequence of Antrodia cinnamomea (Lu et al., 2014, Proc. Natl. Acad. Sci. USA. 111(44):E4743-52, (Dataset S1)).
  • the 15 putative terpene synthases amino acid sequences contain a class II terpene synthase-like motif with the consensus sequence D(V/M/L/F)D(T/S) as well as a class I terpene synthase-like motif with the consensus sequence DD(K/N/Q/R/S)xD (were x is a hydrophobic residue L, I, G, T or P).
  • the class I and class II motifs are easily localized using an alignment of the amino acid sequences with the sequences of CvTps1 and LoTps1 ( FIG. 6 ). Such alignment can be made using for example the program Clustal W (Thompson J. D. et al., 1994, Nucleic Acids Res. 22(22), 4673-80).
  • the presence of a HAD-like hydrolase domain was identified in the N-terminal region of the 15 amino acid sequences (between positions 1 and 183 to 243 of the sequences) (Table 3).
  • the cDNAs encoding for the 15 new putative synthases described in Example 5 were codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, California).
  • the enzymes were functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP) following the procedure described in example 4.
  • FPP farnesyl-diphosphate
  • Drimenol is produced by a mechanism similar to the formation of albicanol and involving a class II followed by class I enzymatic activity.
  • HAD-like HAD-like hydrolase hydrolase Ezyme Length Product domain start domain end CvTps1 525 Albicanol 115 187 LoTps1 521 Albicanol 62 181 OCH93767.1 527 Albicanol 51 185 EMD37666.1 533 Albicanol 54 185 EMD37555-B 528 Albicanol 54 185 XP_001217376.1 486 Albicanol 25 181 OJJ98394.1 483 Albicanol 25 181 GAO87501.1 485 Albicanol 34 186 XP_008034151.1 524 Albicanol 60 187 XP_007369631.1 527 Albicanol 120 187 ACg006372 496 Albicanol 60 198 KIA75676.1 543 Drimenol
  • Crude protein extracts containing the recombinant terpene synthases are prepared using KRX E. coli cells (Promega) or BL21 StarTM (DE3) E. coli (ThermoFisher). Single colonies of cells transformed with the expression plasmid are used to inoculate 5 ml LB medium. After 5 to 6 hours incubation at 37° C., the cultures are transferred to a 25° C. incubator and left 1 hour for equilibration. Expression of the protein is then induced by the addition of 1 mM IPTG and the cultures are incubated over-night at 25° C.
  • the cells are collected by centrifugation, resuspended in 0.1 volume of 50 mM MOPSO pH 7 (3-Morpholino-2-hydroxypropanesulfonic acid (sigma-Aldrich), 10% glycerol and lyzed by sonication.
  • the extracts are cleared by centrifugation (30 min at 20,000 g) and the supernatants containing the soluble proteins are used for further experiments.
  • the assays are performed in glass tubes in 2 mL of 50 mM MOPSO pH 7, 10% glycerol, 1 mM DTT, 15 mM MgCl2 in the presence of 80 ⁇ M of farnesyl-diphosphate (FPP, Sigma) and 0.1 to 0.5 mg of crude protein.
  • the tubes are incubated 12 to 24 hours at 25° C. and extracted twice with one volume of pentane. After concentration under a nitrogen flux, the extracts are analyzed by GC-MS as described in Example 4 and compared to extracts from assays with control proteins.
  • the aqueous phase is then treated by alkaline phosphatase (Sigma, 6 units/ml), followed by extraction with pentane and GC-MS analysis.
  • the assays without alkaline phosphatase treatment allow detecting and identifying the sesquiterpene compounds (hydrocarbons and oxygenated sesquiterpenes) present in the assay and produced by the recombinant enzymes.
  • Albicanyl-diphosphate or drimenyl-diphosphate compounds are not soluble in the organic solvent and are thus not detected in the GC-MS analysis.
  • allylic diphosphate bounds are cleaved and when albicanyl-diphosphate or drimenyl-diphosphate compounds are present, the sequiterpene moiety is released, extracted in the solvent phase and detected in the GC-MS analysis.
  • This example allows to differentiate enzymes having only class II terpene synthase activity (such as AstC, NCBI accession XP_001822013.2, Shinohara Y. et al., 2016, Sci Rep. 6, 32865) from enzyme having class II terpene synthase-like activity and class I (phosphatase) activity such as CvTps1 and LoTps1.
  • class II terpene synthase activity such as AstC, NCBI accession XP_001822013.2, Shinohara Y. et al., 2016, Sci Rep. 6, 32865
  • Synthetic operons were designed to co-express the CvTps1 protein with the AstI and AstK proteins.
  • the synthetic operon contains the optimized cDNA encoding for each of the 3 proteins separated by a ribosome binding sequence (RBS).
  • RBS ribosome binding sequence
  • a similar operon was designed to co-express AstC with AstI and AstK.
  • the operons were synthesized and cloned in the pJ401 expression plasmid (ATUM, Newark, Calif.). E coli cells were co-transformed with these expression plasmids and with the pACYC-29258-4506 plasmid (Example 4) and the cells were cultivated under conditions to produce sesquiterpenes as described in Example 4.
  • the sequiterpenes produced were analyzed by GCMS as described in Example 4 and compared to the sequiterpene profile of cells expression only CvTps1 or AstC.
  • AstC a significant higher amount (78-fold increase) of sesquiterpene is produced when the enzyme is co-expressed with enzymes (AstI and AstK) having phosphatase activity.
  • Typical concentrations of drimane sesquiterpene in the E. coli cultures were 2,600 mg/ml with cells expressing AstC, AstI and AstK and 34 mg/ml with cells expressing AstC alone.
  • the NCBI accession No XP 006461126.1 from Agaricus bisporus was selected using the method described in Example 5.
  • the XP006461126.1 amino acid (SEQ ID NO: 63) shared 48.9% and 48.1% identity with the CvTps1 and LoTps1 amino acid sequences, respectively.
  • the XP_006461126.1 contains a class II terpene synthase-like motif (DLDT) (part of SEQ ID NO: 56) located between position 278 and 271 and a class I terpene synthase-like motif (DDKLE) (part of SEQ ID NO: 55) located at position 167 to 171.
  • the amino acid contains also motifs characteristic of of the Haloacid dehalogenase-like hydrolase superfamily in the N-terminal region.
  • XP 006461126.1 The cDNA encoding for XP 006461126.1 was codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, Calif.). The enzyme was functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP) following the procedure described in Example 4. The results show that XP 006461126.1 is a bifunctional drimenol synthase producing drimenol as major compound ( FIG. 11 ).
  • the codon usage of the cDNA encoding for the different synthases was modified for optimal expression in S. cerevisiae (SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70).
  • plasmids For expression of the different genes in S. cerevisiae , a set of plasmids were constructed in vivo using yeast endogenous homologous recombination as previously described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. Each plasmid is composed by five DNA fragments which were used for S. cerevisiae co-transformation. The fragments were:
  • FPP farnesyl-diphosphate
  • tHMG1 truncated HMG1
  • GAL4 under the control of a mutated version of its own promoter, as described in Griggs and Johnston, Proc Natl Acad Sci USA, 1991, 88:8597-8601, was integrated upstream the ERG9 promoter region.
  • the endogenous promoter of ERG9 was replaced by the yeast promoter region of CTR3 generating the strain YST035.
  • YST035 was mated with the strain CEN.PK2-1D (Euroscarf, Frankfurt, Germany) obtaining a diploid strain termed YST045.
  • YST045 was transformed with the fragments required for in vivo plasmid assembly.
  • Yeast transformations were performed with the lithium acetate protocol as described in Gietz and Woods, Methods Enzymol., 2002, 350:87-96. Transformation mixtures were plated on SmLeu-media containing 6.7 g/L of Yeast Nitrogen Base without amino acids (BD Difco, New Jersey, USA), 1.6 g/L Dropout supplement without leucine (Sigma Aldrich, Missouri, USA), 20 g/L glucose and 20 g/L agar. Plates were incubated for 3-4 days at 30° C.
  • the table below shows the quantities of drimane sesquiterpene produced relative to the quantity obtained by the synthase XP 007369631.1 (under these experimental conditions, the concentration of drimane sesquiterpene produced by cells expressing XP 007369631.1 was 805 to 854 mg/L, the highest quantity produced).

Abstract

Described herein is a method of producing a drimane sesquiterpene such as albicanol, drimenol and/or derivatives thereof by contacting at least one polypeptide with farnesyl diphosphate (FPP) with a polypeptide including a Haloacid dehalogenase (HAD)-like hydrolase domain and having bifunctional terpene synthase activity. The method may be performed in vitro or in vivo. Also described herein are amino acid sequences of polypeptides useful in the methods and nucleic acids encoding the polypeptides described. The described method further provides host cells or organisms genetically modified to express the polypeptides and useful to produce a drimane sesquiterpene such as albicanol, drimenol and/or derivatives thereof.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of U.S. patent application Ser. No. 16/618,737, filed Dec. 2, 2019, which is a U.S. National Phase Application of International Patent Application No. PCT/EP2018/064344, filed May 31, 2018, which claims the benefit of priority to European Patent Application No. 17174399.0, filed Jun. 2, 2017, the entire contents of which are hereby incorporated by reference herein.
  • REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
  • The contents of the electronic sequence listing (10200PCT SequenceListingAsFiled.txt; Size: 180,406 bytes; and Date of Creation: Feb. 16, 2022) is herein incorporated by reference in its entirety.
  • TECHNICAL FIELD
  • Provided herein are biochemical methods of producing albicanol, drimenol and related compounds and derivatives, which method comprises the use of novel polypeptides.
  • BACKGROUND
  • Terpenes are found in most organisms (microorganisms, animals and plants). These compounds are made up of five carbon units called isoprene units and are classified by the number of these units present in their structure. Thus monoterpenes, sesquiterpenes and diterpenes are terpenes containing 10, 15 and 20 carbon atoms, respectively. Sesquiterpenes, for example, are widely found in the plant kingdom. Many sesquiterpene molecules are known for their flavor and fragrance properties and their cosmetic, medicinal and antimicrobial effects. Numerous sesquiterpene hydrocarbons and sesquiterpenoids have been identified. Chemical synthesis approaches have been developed but are still complex and not always cost-effective.
  • Biosynthetic production of terpenes involves enzymes called terpene synthases. There are numerous sesquiterpene synthases present in the plant kingdom, all using the same substrate (farnesyl diphosphate, FPP), but having different product profiles. Genes and cDNAs encoding sesquiterpene synthases have been cloned and the corresponding recombinant enzymes characterized.
  • Many of the main sources for sesquiterpenes, for example drimenol, are plants naturally containing the sesquiterpene; however, the content of sesquiterpenes in these natural sources can be low. There still remains a need for the discovery of new terpenes, terpene synthases and more cost-effective methods of producing sesquiterpenes such as albicanol and/or drimenol and derivatives therefrom.
  • SUMMARY
  • Provided herein is a method for producing a drimane sesquiterpene comprising:
      • a. contacting an acyclic farnesyl diphosphate (FPP) precursor with a polypeptide comprising aHaloacid dehalogenase (HAD)-like hydrolase domain and having bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises
        • i. a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)); and
        • ii. a class II terpene synthase-like motifas set forth in SEQ ID NO: 56 (DxD(T/S)T); and
      • b. optionally isolating the drimane sesquiterpene or a mixture comprising the drimane sesquiterpene.
  • In one aspect, the drimane sesquiterpene comprises albicanol and/or drimenol.
  • In a further aspect, in the above method, the polypeptide having bifunctional terpene synthase activity comprises
      • a. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and
      • b. the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
      • c. the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58.
  • In one embodiment, the above method comprises contacting the drimane sesquiterpene with at least one enzyme to produce a drimane sesquiterpene derivative. In another embodiment, the above method comprises converting the drimane sesquiterpene to a drimane sesquiterpene derivative using chemical synthesis or biochemical synthesis.
  • In one aspect, the above method comprises transforming a host cell or non-human host organism with a nucleic acid encoding the above polypeptide.
  • In one aspect, the method further comprises culturing a non-human host organism or a host cell capable of producing FPP and transformed to express a polypeptide comprising a HAD-like hydrolase domain under conditions that allow for the production of the polypeptide, wherein the polypeptide
      • a. comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; or
      • b. comprises
        • i. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and
        • ii. the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
        • iii. the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58.
  • In a further aspect, in the above method, the polypeptide comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • In one embodiment, the class I terpene synthase-like motif of the above method comprises SEQ ID NO: 54 (DD(K/Q/R)(L/I/T)(D/E)), the class II terpene synthase-like motif comprises SEQ ID NO: 57 (D(V/M/L)DTT), and the drimane sesquiterpene is albicanol.
  • In a one embodiment, in the above method the polypeptide comprises
      • a. an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, or SEQ ID NO: 32, and
      • b. the sequence of SEQ ID NO: 54 (DD(K/Q/R)(L/I/T)(D/E)), and
      • c. the sequence of SEQ ID NO: 57 (D(V/M/L/F)DTTS); and
      • the drimane sesquiterpene is albicanol.
  • In a further embodiment, in the above method the polypeptide comprises
      • a. an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63, and
      • b. the sequence of SEQ ID NO: 55, and
      • c. the sequence of SEQ ID NO: 58; and
      • the drimane sesquiterpene is drimenol.
  • Also provided is an isolated polypeptide comprising a HAD-like hydrolase domains and having bifunctional terpene synthase activity comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5 or comprising
      • a. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5; and
      • b. the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
      • c. the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 48.
  • In one aspect, the isolated polypeptide further comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • Provided herein is an isolated nucleic acid molecule
      • a. comprising a nucleotide sequence encoding the polypeptide of claim 13 or 14; or
      • b. comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68, or the reverse complement thereof; or
      • c. comprising a nucleotide molecule that hybridizes under stringent conditions to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68; or
      • d. comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof.
  • Also provided is a vector comprising the above nucleic acid molecule or a nucleic acid encoding the above polypeptide. In one aspect, the vector is an expression vector. In another aspect, the vector is a prokaryotic vector, viral vector or a eukaryotic vector.
  • Further provided is a host cell or non-human organism comprising the above nucleic acid or above vector.
  • In one aspect, the host cell or non-human organism is a prokaryotic cell or a eukaryotic cell or a microorganism or fungal cell.
  • In one aspect, the prokaryotic cell is a bacterial cell. In a further aspect, the bacterial cell is E. coli.
  • In another aspect, the host cell or non-human organism is a eukaryotic cell. In one aspect, the eukaryotic cell is a yeast cell or plant cell. In a further aspect, the yeast cell is Saccharomyces cerevisiae.
  • Provided herein is the use of the above polypeptide for producing a drimane sesquiterpene or a mixture comprising a drimane sesquiterpene and one or more terpenes.
  • In one aspect, in the above use of the polypeptide, the drimane sesquiterpene is albicanol. In another aspect, in the above use of the polypeptide, the drimane sesquiterpene is drimenol.
  • DESCRIPTION OF THE DRAWINGS
  • FIG. 1 : Structure of drimane, (+)-albicanol and (−)-drimenol.
  • FIG. 2 : Mechanism of cyclization of farnesyl-diphosphate by a class II terpene synthase and class I terpene synthase enzymatic activity.
  • FIG. 3 : GCMS analysis of the sesquiterpenes produced in-vivo by the recombinant CvTps1 enzyme in bacteria cells modified to overproduce farnesyl-diphosphate. A. Total ion chromatogram of an extract of E. coli cells expressing CvTps1 and the mevalonate pathway enzymes. B. Total ion chromatogram of an authentic standard of albicanol. C. Total ion chromatogram of an extract of E. coli cells expressing only the mevalonate pathway enzymes. 1, albicanol; 2, trans-farnesol (from hydrolysis of FPP by endogenous phosphatase enzymes).
  • FIG. 4 : Comparison of the mass spectra of the product of CvTps1 and of an authentic standard of albicanol. A. Mass spectra of peak 1 in FIG. 3A (product of CvTps1). B. Mass spectra of peak 1 in FIG. 3B (authentic standard of albicanol).
  • FIG. 5 : GCMS analysis of the sesquiterpenes produced by the LoTps1 and CvTps1 recombinant protein. Total ion chromatogram of an extract of E. coli cells expressing LoTpsl (A) and CvTps1 (B). The peak labeled ‘1’ is (+)-albicanol.
  • FIG. 6A-C: Amino acid sequences alignment of putative terpene synthases containing class I and class II motifs: CvTps1 (SEQ ID NO: 1), LoTps1 (SEQ ID NO: 5), OCH93767.1 (SEQ ID NO: 9), EMD37666.1 (SEQ ID NO: 12), EMD37666-B (SEQ ID NO: 15), XP_001217376.1 (SEQ ID NO: 17), OJJ98394.1 (SEQ ID NO: 20), GA087501.1 (SEQ ID NO: 23), XP_008034151.1 (SEQ ID NO: 26), XP_007369631.1 (SEQ ID NO: 29), ACg006372 (SEQ ID NO: 32), KIA75676.1 (SEQ ID NO: 35), XP_001820867.2 (SEQ ID NO: 38), CEN60542.1 (SEQ ID NO: 41), XP_009547469.1 (SEQ ID NO: 44), KLO09124.1 (SEQ ID NO: 47), and OJI95797.1 (SEQ ID NO: 50).
  • FIG. 7 . GCMS chromatograms of the sesquiterpenes produced by the LoTps1, CvTps1, OCH93767.1, EMD37666.1, EMD37666-B, and XP_001217376.1, recombinant proteins. The peak labeled ‘1’ is (+)-albicanol.
  • FIG. 8 . GCMS chromatograms of the sesquiterpenes produced by the OJJ98394.1, GAO87501.1, XP_008034151.1, XP_007369631.1, and ACg006372 recombinant proteins. The peak labeled ‘1’ is (+)-albicanol.
  • FIG. 9 . GCMS chromatograms of the sesquiterpenes produced by the KIA75676.1, XP_001820867.2, CEN60542.1, XP_009547469.1, KLO09124.1 and OJI95797.1 recombinant proteins. The peak labeled ‘1’ is (−)-drimenol and the peak labeled ‘2’ is farnesol.
  • FIG. 10 . GCMS chromatograms of the sesquiterpenes produced by CvTps1 and AstC expressed in E. coli cells with and without the AstI and AstK phosphatases. The major peak obtained with AstC is drim-8-ene-11-ol and the major peak obtained with CvTps1 is (+)-albicanol.
  • FIG. 11 . GCMS analysis of the sesquiterpenes produced in-vivo by the recombinant XP_006461126.1 enzyme in bacteria cells modified to overproduce farnesyl-diphosphate. A. Total ion chromatogram of an extract of E. coli cells expressing XP_006461126.1 and the mevalonate pathway enzymes. B. Mass spectra of peak 13.1 minutes identified as drimenol.
  • FIG. 12 . GC-FID analysis of drimane sesquiterpenes produced using the modified S. cereviciae strain YST045 expressing five different synthases: XP_007369631.1 from Dichomitus squalens, XP_006461126 from Agaricus bisporus, LoTps1 from Laricifomes officinalis, EMD37666.1 from Gelatoporia subvermispora and XP_001217376.1 from Aspergillus terreus.
  • Abbreviations Used
    • bp base pair
    • kb kilo base
    • DNA deoxyribonucleic acid
    • cDNA complementary DNA
    • DTT dithiothreitol
    • FPP farnesyl diphosphate
    • GC gas chromatograph
    • HAD Haloacid dehalogenase
    • IPTG isopropyl-D-thiogalacto-pyranoside
    • LB lysogeny broth
    • MS mass spectrometer/mass spectrometry
    • MVA mevalonic acid
    • PCR polymerase chain reaction
    • RNA ribonucleic acid
    • mRNA messenger ribonucleic acid
    • miRNA micro RNA
    • siRNA small interfering RNA
    • rRNA ribosomal RNA
    • tRNA transfer RNA
    Definitions
  • The term “polypeptide” means an amino acid sequence of consecutively polymerized amino acid residues, for instance, at least 15 residues, at least 30 residues, at least 50 residues. In some embodiments herein, a polypeptide comprises an amino acid sequence that is an enzyme, or a fragment, or a variant thereof.
  • The term “protein” refers to an amino acid sequence of any length wherein amino acids are linked by covalent peptide bonds, and includes oligopeptide, peptide, polypeptide and full length protein whether naturally occurring or synthetic.
  • The term “isolated” polypeptide refers to an amino acid sequence that is removed from its natural environment by any method or combination of methods known in the art and includes recombinant, biochemical and synthetic methods.
  • The terms “bifunctional terpene synthase” or “polypeptide having bifunctional terpene synthase activity” relate to a polypeptide that comprises class I and class II terpene synthase domains and has bifunctional terpene synthase activity of protonation-initiated cyclization and ionization-initiated cyclization catalytic activities. A bifunctional terpene synthase as described herein comprises a HAD-like hydrolase domain which is characteristic of polypeptides belonging to the Haloacid dehalogenase (HAD)-like hydrolase superfamily (Interpro protein superfamily IPR023214, www.ebi.ac.uk/interpro/entry/IPR023214; Pfam protein superfamily PF13419, pfam.xfam.org/family/PF13419). A HAD-like hydrolase domain is a portion of a polypeptide having amino acid sequence similarities with the members of the HAD-like hydrolase family and related function. A HAD-like hydrolase domain can be identified in a polypeptide by searching for amino acid motifs or signatures characteristic of this protein family. Tools for performing such searches are available at the following web sites: ebi.ac.uk/interpro/ or ebi.ac.uk/Tools/hmmer/. Proteins are generally composed of one or more functional regions or domains. Different combinations of domains give rise to the diverse range of proteins found in nature. The identification of domains that occur within proteins can therefore provide insights into their function. A polypeptide which comprises a HAD-like hydrolase domain and/or characteristic HAD-like hydrolase motifs functions in binding and cleavage of phosphate or diphosphate groups of a ligand. A bifunctional terpene synthase may also comprise one or more of conserved motifs A, B, C, and/or D as depicted in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • The term “drimane sesquiterpene” relates to a terpene having a drimane-like carbon skeleton structure as depicted in FIG. 1 .
  • The term “class I terpene synthase” relates to a terpene synthase that catalyses ionization-initiated reactions, for example, monoterpene and sesquiterpene synthases.
  • The term “class I terpene synthase motif” or “class I terpene synthase-like motif” relates to an active site of a terpene synthase that comprises the conserved DDxx(D/E) motif. The aspartic acid residues of this class I motif bind, for example, a divalent metal ion (most often Mg2+) involved in the binding of the diphosphate group and catalyze the ionization and cleavage of the allylic diphosphate bond of the substrate.
  • The term “class II terpene synthase” relates to a terpene synthase that catalyses protonation-initiated cyclization reactions, for example, typically involved in the biosynthesis of triterpenes and labdane diterpenes. In class II terpene synthases, the protonation-initiated reaction may involve, for example, acidic amino acids donating a proton to the terminal double-bond.
  • The term “class II terpene synthase motif” or “class II terpene synthase-like motif” relates to an active site of a terpene synthase that comprises the conserved DxDD or DxD(T/S)T motif.
  • The terms “albicanol synthase” or “polypeptide having albicanol synthase activity” or “albicanol synthase protein” relate to a polypeptide capable of catalyzing the synthesis of albicanol, in the form of any of its stereoisomers or a mixture thereof, starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP). Albicanol may be the only product or may be part of a mixture of sesquiterpenes.
  • The terms “drimenol synthase” or “polypeptide having a drimenol synthase activity” or “drimenol synthase protein” relate to a polypeptide capable of catalyzing the synthesis of drimenol, in the form of any of its stereoisomers or a mixture thereof, starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP). Drimenol may be the only product or may be part of a mixture of sesquiterpenes.
  • The terms “biological function,” “function,” “biological activity” or “activity” refer to the ability of the bifunctional terpene synthase to catalyze the formation of albicanol and/or drimenol or a mixture of compounds comprising albicanol and/or drimenol and one or more terpenes.
  • The terms “mixture of terpenes” or “mixture of sesquiterpenes” refer to a mixture of terpenes or sesquiterpenes that comprises albicanol and/or drimenol, and may also comprise one or more additional terpenes or sesquiterpenes.
  • The terms “nucleic acid sequence,” “nucleic acid,” “nucleic acid molecule” and “polynucleotide” are used interchangeably meaning a sequence of nucleotides. A nucleic acid sequence may be a single-stranded or double-stranded deoxyribonucleotide, or ribonucleotide of any length, and include coding and non-coding sequences of a gene, exons, introns, sense and anti-sense complimentary sequences, genomic DNA, cDNA, miRNA, siRNA, mRNA, rRNA, tRNA, recombinant nucleic acid sequences, isolated and purified naturally occurring DNA and/or RNA sequences, synthetic DNA and RNA sequences, fragments, primers and nucleic acid probes. The skilled artisan is aware that the nucleic acid sequences of RNA are identical to the DNA sequences with the difference of thymine (T) being replaced by uracil (U). The term “nucleotide sequence” should also be understood as comprising a polynucleotide molecule or an oligonucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid.
  • An “isolated nucleic acid” or “isolated nucleic acid sequence” relates to a nucleic acid or nucleic acid sequence that is in an environment different from that in which the nucleic acid or nucleic acid sequence naturally occurs and can include those that are substantially free from contaminating endogenous material. The term “naturally-occurring” as used herein as applied to a nucleic acid refers to a nucleic acid that is found in a cell of an organism in nature and which has not been intentionally modified by a human in the laboratory.
  • “Recombinant nucleic acid sequences” are nucleic acid sequences that result from the use of laboratory methods (for example, molecular cloning) to bring together genetic material from more than on source, creating or modifying a nucleic acid sequence that does not occur naturally and would not be otherwise found in biological organisms.
  • “Recombinant DNA technology” refers to molecular biology procedures to prepare a recombinant nucleic acid sequence as described, for instance, in Laboratory Manuals edited by Weigel and Glazebrook, 2002, Cold Spring Harbor Lab Press; and Sambrook et al, 1989, Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press.
  • The term “gene” means a DNA sequence comprising a region, which is transcribed into a RNA molecule, e.g., an mRNA in a cell, operably linked to suitable regulatory regions, e.g., a promoter. A gene may thus comprise several operably linked sequences, such as a promoter, a 5′ leader sequence comprising, e.g., sequences involved in translation initiation, a coding region of cDNA or genomic DNA, introns, exons, and/or a 3′non-translated sequence comprising, e.g., transcription termination sites.
  • A “chimeric gene” refers to any gene which is not normally found in nature in a species, in particular, a gene in which one or more parts of the nucleic acid sequence are present that are not associated with each other in nature. For example the promoter is not associated in nature with part or all of the transcribed region or with another regulatory region. The term “chimeric gene” is understood to include expression constructs in which a promoter or transcription regulatory sequence is operably linked to one or more coding sequences or to an antisense, i.e., reverse complement of the sense strand, or inverted repeat sequence (sense and antisense, whereby the RNA transcript forms double stranded RNA upon transcription). The term “chimeric gene” also includes genes obtained through the combination of portions of one or more coding sequences to produce a new gene.
  • A “3′ UTR” or “3′ non-translated sequence” (also referred to as “3′ untranslated region,” or “3′end”) refers to the nucleic acid sequence found downstream of the coding sequence of a gene, which comprises, for example, a transcription termination site and (in most, but not all eukaryotic mRNAs) a polyadenylation signal such as AAUAAA or variants thereof. After termination of transcription, the mRNA transcript may be cleaved downstream of the polyadenylation signal and a poly(A) tail may be added, which is involved in the transport of the mRNA to the site of translation, e.g., cytoplasm.
  • “Expression of a gene” encompasses “heterologous expression” and “over-expression” and involves transcription of the gene and translation of the mRNA into a protein. Overexpression refers to the production of the gene product as measured by levels of mRNA, polypeptide and/or enzyme activity in transgenic cells or organisms that exceeds levels of production in non-transformed cells or organisms of a similar genetic background.
  • “Expression vector” as used herein means a nucleic acid molecule engineered using molecular biology methods and recombinant DNA technology for delivery of foreign or exogenous DNA into a host cell. The expression vector typically includes sequences required for proper transcription of the nucleotide sequence. The coding region usually codes for a protein of interest but may also code for an RNA, e.g., an antisense RNA, siRNA and the like.
  • An “expression vector” as used herein includes any linear or circular recombinant vector including but not limited to viral vectors, bacteriophages and plasmids. The skilled person is capable of selecting a suitable vector according to the expression system. In one embodiment, the expression vector includes the nucleic acid of an embodiment herein operably linked to at least one regulatory sequence, which controls transcription, translation, initiation and termination, such as a transcriptional promoter, operator or enhancer, or an mRNA ribosomal binding site and, optionally, including at least one selection marker. Nucleotide sequences are “operably linked” when the regulatory sequence functionally relates to the nucleic acid of an embodiment herein.
  • “Regulatory sequence” refers to a nucleic acid sequence that determines expression level of the nucleic acid sequences of an embodiment herein and is capable of regulating the rate of transcription of the nucleic acid sequence operably linked to the regulatory sequence. Regulatory sequences comprise promoters, enhancers, transcription factors, promoter elements and the like.
  • “Promoter” refers to a nucleic acid sequence that controls the expression of a coding sequence by providing a binding site for RNA polymerase and other factors required for proper transcription including without limitation transcription factor binding sites, repressor and activator protein binding sites. The meaning of the term promoter also includes the term “promoter regulatory sequence”. Promoter regulatory sequences may include upstream and downstream elements that may influences transcription, RNA processing or stability of the associated coding nucleic acid sequence. Promoters include naturally-derived and synthetic sequences. The coding nucleic acid sequences is usually located downstream of the promoter with respect to the direction of the transcription starting at the transcription initiation site.
  • The term “constitutive promoter” refers to an unregulated promoter that allows for continual transcription of the nucleic acid sequence it is operably linked to.
  • As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter, or rather a transcription regulatory sequence, is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous. The nucleotide sequence associated with the promoter sequence may be of homologous or heterologous origin with respect to the plant to be transformed. The sequence also may be entirely or partially synthetic. Regardless of the origin, the nucleic acid sequence associated with the promoter sequence will be expressed or silenced in accordance with promoter properties to which it is linked after binding to the polypeptide of an embodiment herein. The associated nucleic acid may code for a protein that is desired to be expressed or suppressed throughout the organism at all times or, alternatively, at a specific time or in specific tissues, cells, or cell compartment. Such nucleotide sequences particularly encode proteins conferring desirable phenotypic traits to the host cells or organism altered or transformed therewith. More particularly, the associated nucleotide sequence leads to the production of albicanol and/or drimenol or a mixture comprising albicanol and/or drimenol or a mixture comprising albicanol and/or drimenol and one or more terpenes in the cell or organism. Particularly, the nucleotide sequence encodes a bifunctional terpene synthase.
  • “Target peptide” refers to an amino acid sequence which targets a protein, or polypeptide to intracellular organelles, i.e., mitochondria, or plastids, or to the extracellular space (secretion signal peptide). A nucleic acid sequence encoding a target peptide may be fused to the nucleic acid sequence encoding the amino terminal end, e.g., N-terminal end, of the protein or polypeptide, or may be used to replace a native targeting polypeptide.
  • The term “primer” refers to a short nucleic acid sequence that is hybridized to a template nucleic acid sequence and is used for polymerization of a nucleic acid sequence complementary to the template.
  • As used herein, the term “host cell” or “transformed cell” refers to a cell (or organism) altered to harbor at least one nucleic acid molecule, for instance, a recombinant gene encoding a desired protein or nucleic acid sequence which upon transcription yields a bifunctional terpene synthase protein useful to produce albicanol and/or drimenol. The host cell is particularly a bacterial cell, a fungal cell or a plant cell. The host cell may contain a recombinant gene which has been integrated into the nuclear or organelle genomes of the host cell. Alternatively, the host may contain the recombinant gene extra-chromosomally.
  • Homologous sequences include orthologous or paralogous sequences. Methods of identifying orthologs or paralogs including phylogenetic methods, sequence similarity and hybridization methods are known in the art and are described herein.
  • Paralogs result from gene duplication that gives rise to two or more genes with similar sequences and similar functions. Paralogs typically cluster together and are formed by duplications of genes within related plant species. Paralogs are found in groups of similar genes using pair-wise Blast analysis or during phylogenetic analysis of gene families using programs such as CLUSTAL. In paralogs, consensus sequences can be identified characteristic to sequences within related genes and having similar functions of the genes.
  • Orthologs, or orthologous sequences, are sequences similar to each other because they are found in species that descended from a common ancestor. For instance, plant species that have common ancestors are known to contain many enzymes that have similar sequences and functions. The skilled artisan can identify orthologous sequences and predict the functions of the orthologs, for example, by constructing a polygenic tree for a gene family of one species using CLUSTAL or BLAST programs. A method for identifying or confirming similar functions among homologous sequences is by comparing of the transcript profiles in host cells or organisms, such as plants or microorganisms, overexpressing or lacking (in knockouts/knockdowns) related polypeptides.
  • The skilled person will understand that genes having similar transcript profiles, with greater than 50% regulated transcripts in common, or with greater than 70% regulated transcripts in common, or greater than 90% regulated transcripts in common will have similar functions. Homologs, paralogs, orthologs and any other variants of the sequences herein are expected to function in a similar manner by making the host cells, organism such as plants or microorganisms producing bifunctional terpene synthase proteins.
  • The term “selectable marker” refers to any gene which upon expression may be used to select a cell or cells that include the selectable marker. Examples of selectable markers are described below. The skilled artisan will know that different antibiotic, fungicide, auxotrophic or herbicide selectable markers are applicable to different target species.
  • “Drimenol” for purposes of this application relates to (−)-drimenol (CAS: 468-68-8).
  • “Albicanol” for the purpose of this application relates to (+)-albicanol (CAS: 54632-04-1).
  • The term “organism” refers to any non-human multicellular or unicellular organisms such as a plant, or a microorganism. Particularly, a micro-organism is a bacterium, a yeast, an algae or a fungus.
  • The term “plant” is used interchangeably to include plant cells including plant protoplasts, plant tissues, plant cell tissue cultures giving rise to regenerated plants, or parts of plants, or plant organs such as roots, stems, leaves, flowers, pollen, ovules, embryos, fruits and the like. Any plant can be used to carry out the methods of an embodiment herein.
  • A particular organism or cell is meant to be “capable of producing FPP” when it produces FPP naturally or when it does not produce FPP naturally but is transformed to produce FPP, either prior to the transformation with a nucleic acid as described herein or together with said nucleic acid. Organisms or cells transformed to produce a higher amount of FPP than the naturally occurring organism or cell are also encompassed by the “organisms or cells capable of producing FPP”.
  • For the descriptions herein and the appended claims, the use of “or” means “and/or” unless stated otherwise. Similarly, “comprise,” “comprises,” “comprising”, “include,” “includes,” and “including” are interchangeable and not intended to be limiting.
  • It is to be further understood that where descriptions of various embodiments use the term “comprising,” those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language “consisting essentially of” or “consisting of.”
  • DETAILED DESCRIPTION
  • Provided herein is a nucleic acid molecule comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 or comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof.
  • According to one embodiment, the nucleic acid molecule consists of the nucleotide sequence SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof.
  • In one embodiment, the nucleic acid of an embodiment herein can be either present naturally in Cryptoporus or Laricifomes or in other fungal species, or be obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof.
  • In another embodiment, the nucleic acid is isolated or is derived from fungi of the genus Cryptoporus or Laricifomes. In a further embodiment the nucleic acid is isolated or derived from Cryptoporus volvatus or Laricifomes officinalis.
  • Further provided is a nucleotide sequence obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof which encompasses any sequence that has been obtained by modifying the sequence of SEQ ID NO: 3 or SEQ ID NO: 7, or of the reverse complement thereof using any method known in the art, for example, by introducing any type of mutations such as deletion, insertion and/or substitution mutations. The nucleic acids comprising a sequence obtained by mutation of SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof are encompassed by an embodiment herein, provided that the sequences they comprise share at least the defined sequence identity of SEQ ID NO: 3 or SEQ ID NO: 7 as defined in any of the above embodiments or the reverse complement thereof and provided that they encode a polypeptide comprising a HAD-like hydrolase domain and having a bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T). The polypeptide having bifunctional terpene synthase activity may further comprise one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62. Mutations may be any kind of mutations of these nucleic acids, for example, point mutations, deletion mutations, insertion mutations and/or frame shift mutations of one or more nucleotides of the DNA sequence of SEQ ID NO: 3 or SEQ ID NO: 7. In one embodiment, the nucleic acid of an embodiment herein may be truncated provided that it encodes a polypeptide as described herein.
  • A variant nucleic acid may be prepared in order to adapt its nucleotide sequence to a specific expression system. For example, bacterial expression systems are known to more efficiently express polypeptides if amino acids are encoded by particular codons.
  • Due to the degeneracy of the genetic code, more than one codon may encode the same amino acid sequence, multiple nucleic acid sequences can code for the same protein or polypeptide, all these DNA sequences being encompassed by an embodiment herein. Where appropriate, the nucleic acid sequences encoding the bifunctional terpene synthase may be optimized for increased expression in the host cell. For example, nucleotides of an embodiment herein may be synthesized using codons particular to a host for improved expression. In one embodiment, the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 46, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof.
  • In one embodiment provided herein is an isolated, recombinant or synthetic nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, encoding for a bifunctional terpene synthase comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63 or functional fragments thereof that catalyze production of a drimane sesquiterpene in a cell from a FPP precursor. In a further embodiment, the drimane sesquiterpene comprises albicanol and/or drimenol.
  • Provided herein are also cDNA, genomic DNA and RNA sequences. Any nucleic acid sequence encoding the bifunctional terpene synthase or variants thereof is referred herein as a bifunctional terpene synthase encoding sequence.
  • According to one embodiment, the nucleic acid of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 is the coding sequence of a bifunctional terpene synthase gene encoding a bifunctional terpene synthase obtained as described in the Examples.
  • A fragment of a polynucleotide of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 refers to contiguous nucleotides that is particularly at least 15 bp, at least 30 bp, at least 40 bp, at least 50 bp and/or at least 60 bp in length of the polynucleotide of an embodiment herein. Particularly the fragment of a polynucleotide comprises at least 25, more particularly at least 50, more particularly at least 75, more particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 700, more particularly at least 800, more particularly at least 900, more particularly at least 1000 contiguous nucleotides of the polynucleotide of an embodiment herein.
  • Without being limited, the fragment of the polynucleotides herein may be used as a PCR primer, and/or as a probe, or for anti-sense gene silencing or RNAi.
  • It is clear to the person skilled in the art that genes, including the polynucleotides of an embodiment herein, can be cloned on basis of the available nucleotide sequence information, such as found in the attached sequence listing, by methods known in the art. These include e.g. the design of DNA primers representing the flanking sequences of such gene of which one is generated in sense orientations and which initiates synthesis of the sense strand and the other is created in reverse complementary fashion and generates the antisense strand. Thermo stable DNA polymerases such as those used in polymerase chain reaction are commonly used to carry out such experiments. Alternatively, DNA sequences representing genes can be chemically synthesized and subsequently introduced in DNA vector molecules that can be multiplied by e.g. compatible bacteria such as e.g. E. coli.
  • In a related embodiment provided herein, PCR primers and/or probes for detecting nucleic acid sequences encoding a polypeptide having bifunctional terpene synthase activity are provided.
  • The skilled artisan will be aware of methods to synthesize degenerate or specific PCR primer pairs to amplify a nucleic acid sequence encoding the bifunctional terpene synthase or functional fragments thereof, based on SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68. A detection kit for nucleic acid sequences encoding the bifunctional terpene synthase may include primers and/or probes specific for nucleic acid sequences encoding the bifunctional terpene synthase, and an associated protocol to use the primers and/or probes to detect nucleic acid sequences encoding the bifunctional terpene synthase in a sample. Such detection kits may be used to determine whether a plant, organism, microorganism or cell has been modified, i.e., transformed with a sequence encoding the bifunctional terpene synthase.
  • To test a function of variant DNA sequences according to an embodiment herein, the sequence of interest is operably linked to a selectable or screenable marker gene and expression of the reporter gene is tested in transient expression assays, for example, with microorganisms or with protoplasts or in stably transformed plants. The skilled artisan will recognize that DNA sequences capable of driving expression are built as modules. Accordingly, expression levels from shorter DNA fragments may be different than the one from the longest fragment and may be different from each other. Provided herein are also functional equivalents of the nucleic acid sequence coding the bifunctional terpene synthase proteins provided herein, i.e., nucleotide sequences that hybridize under stringent conditions to the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68.
  • As used herein, the term hybridization or hybridizes under certain conditions is intended to describe conditions for hybridization and washes under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other. The conditions may be such that sequences, which are at least about 70%, such as at least about 80%, and such as at least about 85%, 90%, or 95% identical, remain bound to each other. Definitions of low stringency, moderate, and high stringency hybridization conditions are provided herein.
  • Appropriate hybridization conditions can be selected by those skilled in the art with minimal experimentation as exemplified in Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6). Additionally, stringency conditions are described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor
  • Press, chapters 7, 9, and 11). As used herein, defined conditions of low stringency are as follows. Filters containing DNA are pretreated for 6 h at 40° C. in a solution containing 35% formamide, 5× SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20×106 32P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40° C., and then washed for 1.5 h at 55° C. In a solution containing 2× SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60° C. Filters are blotted dry and exposed for autoradiography.
  • As used herein, defined conditions of moderate stringency are as follows. Filters containing DNA are pretreated for 7 h at 50° C. in a solution containing 35% formamide, 5× SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20×106 32P-labeled probe is used. Filters are incubated in hybridization mixture for 30 h at 50° C., and then washed for 1.5 h at 55° C. In a solution containing 2× SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60° C. Filters are blotted dry and exposed for autoradiography.
  • As used herein, defined conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65° C. in buffer composed of 6× SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65° C. in the prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20×106 cpm of 32P-labeled probe. Washing of filters is done at 37° C. for 1 h in a solution containing 2× SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1× SSC at 50° C. for 45 minutes. Other conditions of low, moderate, and high stringency well known in the art (e.g., as employed for cross-species hybridizations) may be used if the above conditions are inappropriate (e.g., as employed for cross-species hybridizations).
  • The skilled artisan will be aware of methods to identify homologous sequences in other organisms and methods to determine the percentage of sequence identity between homologous sequences. Such newly identified DNA molecules then can be sequenced and the sequence can be compared with the nucleic acid sequence of SEQ ID NO: 3 or SEQ ID NO: 7.
  • The percentage of identity between two peptide or nucleotide sequences is a function of the number of amino acids or nucleotide residues that are identical in the two sequences when an alignment of these two sequences has been generated. Identical residues are defined as residues that are the same in the two sequences in a given position of the alignment. The percentage of sequence identity, as used herein, is calculated from the optimal alignment by taking the number of residues identical between two sequences dividing it by the total number of residues in the shortest sequence and multiplying by 100. The optimal alignment is the alignment in which the percentage of identity is the highest possible. Gaps may be introduced into one or both sequences in one or more positions of the alignment to obtain the optimal alignment. These gaps are then taken into account as non-identical residues for the calculation of the percentage of sequence identity. Alignment for the purpose of determining the percentage of amino acid or nucleic acid sequence identity can be achieved in various ways using computer programs and for instance publicly available computer programs available on the world wide web. Preferably, the BLAST program (Tatiana et al, FEMS Microbiol Lett., 1999, 174:247-250, 1999) set to the default parameters, available from the National Center for Biotechnology Information (NCBI) website at ncbi.nlm.nih.gov/BLAST/b12seq/wblast2.cgi, can be used to obtain an optimal alignment of protein or nucleic acid sequences and to calculate the percentage of sequence identity.
  • A related embodiment provided herein provides a nucleic acid sequence which is complementary to the nucleic acid sequence according to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 such as inhibitory RNAs, or nucleic acid sequence which hybridizes under stringent conditions to at least part of the nucleotide sequence according to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68. An alternative embodiment of an embodiment herein provides a method to alter gene expression in a host cell. For instance, the polynucleotide of an embodiment herein may be enhanced or overexpressed or induced in certain contexts (e.g. upon exposure to certain temperatures or culture conditions) in a host cell or host organism.
  • Alteration of expression of a polynucleotide provided herein may also result in ectopic expression which is a different expression pattern in an altered and in a control or wild-type organism. Alteration of expression occurs from interactions of polypeptide of an embodiment herein with exogenous or endogenous modulators, or as a result of chemical modification of the polypeptide. The term also refers to an altered expression pattern of the polynucleotide of an embodiment herein which is altered below the detection level or completely suppressed activity.
  • In one embodiment, provided herein is also an isolated, recombinant or synthetic polynucleotide encoding a polypeptide or variant polypeptide provided herein.
  • In one embodiment is provided an isolated nucleic acid molecule encoding a polypeptide comprising a domain of the HAD-like hydrolase superfamily having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58 or comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63.
  • In one embodiment provided herein is an isolated polypeptide comprising a HAD-like hydrolase domain having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5 or comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
  • According to one embodiment, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1 or 5.
  • In one embodiment, the polypeptide of an embodiment herein can be present naturally in Cryptoporus or Laricifomes fungi or in other fungi species, or comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, either obtained by genetic engineering or found naturally in Cryptoporus or Laricifomes fungi or in other fungi species.
  • According to another embodiment, the polypeptide is isolated or derived from fungi of the genus Cryptoporus or Laricifomes. In a further embodiment, the polypeptide is isolated or derived from Cryptoporus volvatus or Laricifomes officinalis.
  • In one embodiment, the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, obtained by genetic engineering. In one embodiment the polypeptide comprises an amino acid sequence encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO: 3 or SEQ ID NO: 7 or the reverse complement thereof.
  • Polypeptides are also meant to include variants and truncated polypeptides provided that they have bifunctional terpene synthase activity.
  • According to another embodiment, the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments comprises an amino acid sequence that is a variant of SEQ ID NO: 1 or SEQ ID NO: 5, obtained by genetic engineering, provided that said variant has bifunctional terpene synthase activity to produce a drimane sesquiterpene and has the required percentage of identity to SEQ ID NO: 1 or SEQ ID NO: 5 as described in any of the above embodiments and comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T) and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5. The polypeptide having bifunctional terpene synthase activity may further comprise one or more conserved motifs as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • According to another embodiment, the at least one polypeptide having a bifunctional terpene synthase activity used in any of the herein-described embodiments or encoded by the nucleic acid used in any of the herein-described embodiments is a variant of SEQ ID NO: 1 or SEQ ID NO: 5 that can be found naturally in other organisms, such as other fungal species, provided that it has bifunctional terpene synthase activity and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5. As used herein, the polypeptide includes a polypeptide or peptide fragment that encompasses the amino acid sequences identified herein, as well as truncated or variant polypeptides provided that they have bifunctional terpene synthase activity and that they share at least the defined percentage of identity with the corresponding fragment of SEQ ID NO: 1 or SEQ ID NO: 5 and comprise (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)) and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T) and comprises domains corresponding to Pfam domains PF13419.5 and PF13242.5.
  • Examples of variant polypeptides are naturally occurring proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the polypeptides described herein. Variations attributable to proteolysis include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides of an embodiment herein. Polypeptides encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of an embodiment herein, as described thereafter, are also encompassed by an embodiment herein.
  • Polypeptide variants resulting from a fusion of additional peptide sequences at the amino and carboxyl terminal ends can also be used in the methods of an embodiment herein. In particular such a fusion can enhance expression of the polypeptides, be useful in the purification of the protein or improve the enzymatic activity of the polypeptide in a desired environment or expression system. Such additional peptide sequences may be signal peptides, for example. Another aspect encompasses methods using variant polypeptides, such as those obtained by fusion with other oligo- or polypeptides and/or those which are linked to signal peptides. Polypeptides resulting from a fusion with another functional protein, such as another protein from the terpene biosynthesis pathway, can also be advantageously used in the methods of an embodiment herein.
  • A variant may also differ from the polypeptide of an embodiment herein by attachment of modifying groups which are covalently or non-covalently linked to the polypeptide backbone. The variant also includes a polypeptide which differs from the polypeptide provided herein by introduced N-linked or O-linked glycosylation sites, and/or an addition of cysteine residues. The skilled artisan will recognize how to modify an amino acid sequence and preserve biological activity.
  • In addition to the gene sequences shown in the sequences disclosed herein, it will be apparent for the person skilled in the art that DNA sequence polymorphisms may exist within a given population, which may lead to changes in the amino acid sequence of the polypeptides disclosed herein. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.
  • Further embodiments also relate to the molecules derived by such sequence polymorphisms from the concretely disclosed nucleic acids. These natural variations usually bring about a variance of about 1 to 5% in the nucleotide sequence of a gene or in the amino acid sequence of the polypeptides disclosed herein. As mentioned above, the nucleic acid encoding the polypeptide or variants thereof of an embodiment herein is a useful tool to modify non-human host organisms, microorganisms or cells and to modify non-human host organisms, microorganisms or cells intended to be used in the methods described herein.
  • An embodiment provided herein provides amino acid sequences of bifunctional terpene synthase proteins including orthologs and paralogs as well as methods for identifying and isolating orthologs and paralogs of the bifunctional terpene synthases in other organisms. Particularly, so identified orthologs and paralogs of the bifunctional terpene synthase retain bifunctional terpene synthase activity, may be considered a polypeptide of the HAD-like hydrolase superfamily (Interpro protein superfamily IPR023214 or Pfam protein superfamily PF13419) and which comprises a HAD-like hydrolase domain and are capable of producing a drimane sesquiterpene, such as albicanol and/or drimenol, starting from an acyclic terpene pyrophosphate precursor, e.g. FPP.
  • The polypeptide to be contacted with an acyclic terpene pyrophosphate, e.g. FPP, in vitro can be obtained by extraction from any organism expressing it, using standard protein or enzyme extraction technologies. If the host organism is an unicellular organism or cell releasing the polypeptide of an embodiment herein into the culture medium, the polypeptide may simply be collected from the culture medium, for example by centrifugation, optionally followed by washing steps and re-suspension in suitable buffer solutions. If the organism or cell accumulates the polypeptide within its cells, the polypeptide may be obtained by disruption or lysis of the cells and optionally further extraction of the polypeptide from the cell lysate. The cell lysate or the extracted polypeptide can be used to contact the acyclic terpene pyrophosphate for production of a terpene or a mixture of terpenes.
  • The polypeptide having a bifunctional terpene synthase activity, either in an isolated form or together with other proteins, for example in a crude protein extract obtained from cultured cells or microorganisms, may then be suspended in a buffer solution at optimal pH. If adequate, salts, DTT, inorganic cations and other kinds of enzymatic co-factors, may be added in order to optimize enzyme activity. The precursor FPP is added to the polypeptide suspension, which is then incubated at optimal temperature, for example between 15 and 40° C., particularly between 25 and 35° C., more particularly at 30° C. After incubation, the drimane sesquiterpene, such as albicanol and/or drimenol, produced may be isolated from the incubated solution by standard isolation procedures, such as solvent extraction and distillation, optionally after removal of polypeptides from the solution.
  • According to another embodiment, the at least one polypeptide having a bifunctional terpene synthase activity can be used for production of a drimane sesquiterpene comprising albicanol and/or drimenol or mixtures of terpenes comprising albicanol and/or drimenol.
  • One particular tool to carry out the method of an embodiment herein is the polypeptide itself as described herein.
  • According to a particular embodiment, the polypeptide is capable of producing a mixture of sesquiterpenes wherein albicanol and/or drimenol represents at least 20%, particularly at least 30%, particularly at least 35%, particularly at least 90%, particularly at least 95%, more particularly at least 98% of the sesquiterpenes produced. In another aspect provided here, the albicanol and/or drimenol is produced with greater than or equal to 95%, more particularly 98% selectivity.
  • The functionality or activity of any bifunctional terpene synthase protein, variant or fragment, may be determined using various methods. For example, transient or stable overexpression in plant, bacterial or yeast cells can be used to test whether the protein has activity, i.e., produces albicanol and/or drimenol from FPP precursors. Bifunctional terpene synthase activity may be assessed in a microbial expression system, such as the assay described in Example 3 herein on the production of albicanol and/or drimenol, indicating functionality. A variant or derivative of a bifunctional terpene synthase polypeptide of an embodiment herein retains an ability to produce a drimane sesquiterpene such as albicanol and/or drimenol from FPP precursors. Amino acid sequence variants of the bifunctional terpene synthases provided herein may have additional desirable biological functions including, e.g., altered substrate utilization, reaction kinetics, product distribution or other alterations.
  • The ability of a polypeptide to catalyze the synthesis of a particular sesquiterpene (for example albicanol and/or drimenol) can be simply confirmed, for example, by performing the enzyme assay as detailed in Examples 3, 4 and 6.
  • Further provided is at least one vector comprising the nucleic acid molecules described herein.
  • Also provided herein is a vector selected from the group of a prokaryotic vector, viral vector and a eukaryotic vector.
  • Further provided here is a vector that is an expression vector.
  • In one embodiment, several bifunctional terpene synthases encoding nucleic acid sequences are co-expressed in a single host, particularly under control of different promoters. In another embodiment, several bifunctional terpene synthase proteins encoding nucleic acid sequences can be present on a single transformation vector or be co-transformed at the same time using separate vectors and selecting transformants comprising both chimeric genes. Similarly, one or more bifunctional terpene synthase encoding genes may be expressed in a single plant, cell, microorganism or organism together with other chimeric genes.
  • The nucleic acid sequences of an embodiment herein encoding bifunctional terpene synthase proteins can be inserted in expression vectors and/or be contained in chimeric genes inserted in expression vectors, to produce bifunctional terpene synthase proteins in a host cell or non-human host organism. The vectors for inserting transgenes into the genome of host cells are well known in the art and include plasmids, viruses, cosmids and artificial chromosomes. Binary or co-integration vectors into which a chimeric gene is inserted can also be used for transforming host cells.
  • An embodiment provided herein provides recombinant expression vectors comprising a nucleic acid sequence of a bifunctional terpene synthase gene, or a chimeric gene comprising a nucleic acid sequence of a bifunctional terpene synthase gene, operably linked to associated nucleic acid sequences such as, for instance, promoter sequences. For example, a chimeric gene comprising a nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70 or a variant thereof may be operably linked to a promoter sequence suitable for expression in plant cells, bacterial cells or fungal cells, optionally linked to a 3′ non-translated nucleic acid sequence.
  • Alternatively, the promoter sequence may already be present in a vector so that the nucleic acid sequence which is to be transcribed is inserted into the vector downstream of the promoter sequence. Vectors can be engineered to have an origin of replication, a multiple cloning site, and a selectable marker.
  • In one embodiment, an expression vector comprising a nucleic acid as described herein can be used as a tool for transforming non-human host organisms or host cells suitable to carry out the method of an embodiment herein in vivo.
  • The expression vectors provided herein may be used in the methods for preparing a genetically transformed non-human host organism and/or host cell, in non-human host organisms and/or host cells harboring the nucleic acids of an embodiment herein and in the methods for making polypeptides having a bifunctional terpene synthase activity, as described herein.
  • Recombinant non-human host organisms and host cells transformed to harbor at least one nucleic acid of an embodiment herein so that it heterologously expresses or over-expresses at least one polypeptide of an embodiment herein are also very useful tools to carry out the method of an embodiment herein. Such non-human host organisms and host cells are therefore provided herein.
  • In one embodiment is provided a host cell, microorganism or non-human host organism comprising at least one of the nucleic acid molecules described herein or comprising at least one vector comprising at least one of the nucleic acid molecules.
  • A nucleic acid according to any of the above-described embodiments can be used to transform the non-human host organisms and cells and the expressed polypeptide can be any of the above-described polypeptides.
  • In one embodiment, the non-human host organism or host cell is a prokaryotic cell. In another embodiment, the non-human host organism or host cell is a bacterial cell. In a further embodiment, the non-human host organism or host cell is Escherichia coli.
  • In one embodiment, the non-human host organism or host cell is a eukaryotic cell. In another embodiment, the non-human host organism or host cell is a yeast cell. In a further embodiment, the non-human host organism or cell is Saccharomyces cerevisiae.
  • In a further embodiment, the non-human organism or host cell is a plant cell or a fungal cell.
  • In one embodiment the non-human host organism or host cell expresses a polypeptide, provided that the organism or cell is transformed to harbor a nucleic acid encoding said polypeptide, this nucleic acid is transcribed to mRNA and the polypeptide is found in the host organism or cell. Suitable methods to transform a non-human host organism or a host cell have been previously described and are also provided herein.
  • To carry out an embodiment herein in vivo, the host organism or host cell is cultivated under conditions conducive to the production of a drimane sesquiterpene such as albicanol and/or drimenol. Accordingly, if the host is a transgenic plant, optimal growth conditions can be provided, such as optimal light, water and nutrient conditions, for example. If the host is a unicellular organism, conditions conducive to the production of a drimane sesquiterpene such as albicanol and/or drimenol may comprise addition of suitable cofactors to the culture medium of the host. In addition, a culture medium may be selected, so as to maximize drimane sesquiterpene, such as albicanol and/or drimenol, synthesis. Examples of optimal culture conditions are described in a more detailed manner in the Examples.
  • Non-human host organisms suitable to carry out the method of an embodiment herein in vivo may be any non-human multicellular or unicellular organisms. In one embodiment, the non-human host organism used to carry out an embodiment herein in vivo is a plant, a prokaryote or a fungus. Any plant, prokaryote or fungus can be used. Particularly useful plants are those that naturally produce high amounts of terpenes. In another embodiment the non-human host organism used to carry out the method of an embodiment herein in vivo is a microorganism. Any microorganism can be used, for example, the microorganism can be a bacteria or yeast, such as E. coli or Saccharomyces cerevisiae.
  • Some of these organisms do not produce FPP naturally. To be suitable to carry out the method of an embodiment herein, organisms or cells that do not produce an acyclic terpene pyrophosphate precursor, e.g. FPP, naturally are transformed to produce said precursor. They can be so transformed either before the modification with the nucleic acid described according to any of the above embodiments or simultaneously, as explained above. Methods to transform organisms, for example microorganisms, so that they produce an acyclic terpene pyrophosphate precursor, e.g. FPP, are already known in the art.
  • Isolated higher eukaryotic cells can also be used, instead of complete organisms, as hosts to carry out the method of an embodiment herein in vivo. Suitable eukaryotic cells may be any non-human cell, such as plant or fungal cells.
  • Further provided herein is a method of producing a drimane sesquiterpene comprising: contacting an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP) with a polypeptide which comprises a HAD-like hydrolase domain and having bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises (1) a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)); and (2) a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T); and optionally isolating the drimane sesquiterpene.
  • Also provided is the above method wherein the drimane sesquiterpene comprises albicanol and/or drimenol.
  • Additionally provided is the above method, wherein the polypeptide comprises an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63 and (1) the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and (2) the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58 or comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63 to produce a drimane sesquiterpene ; and optionally isolating the drimane sesquiterpene. In another aspect, the polypeptide further comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • In one aspect, the drimane sesquiterpene is albicanol and/or drimenol. In another aspect, the drimane sesquiterpene is isolated.
  • In another aspect provided here, the albicanol and/or drimenol is produced with greater than or equal to, 60%, 80%, or 90% or even 95% selectivity. In a further aspect the drimane sesquiterpene is albicanol.
  • Further provided here is a method comprising transforming a host cell, microorganism or a non-human host organism with a nucleic acid encoding a polypeptide comprising a HAD-like hydrolase domain having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and comprising (1) the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and (2) the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58 or comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63.
  • In one embodiment, a method provided herein comprises cultivating a non-human host organism or a host cell capable of producing FPP and transformed to express a polypeptide wherein the polypeptide comprises a sequence of amino acids that has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5 under conditions that allow for the production of the polypeptide.
  • In a another embodiment, a method provided herein comprises contacting a sesquiterpene such as albicanol and/or drimenol with at least one enzyme to produce a sesquiterpene derivative. In one embodiment, the sesquiterpene derivative can be obtained biochemically or chemically. In one embodiment, a drimenol derivative is provided. Examples of such derivatives of drimenol include but not limited to drimenyl acetate (CAS 40266-93-1), drimenal (CAS 105426-71-9), drimenic acid (CAS 111319-84-7).
  • In one embodiment, an albicanol derivative is provided. Examples of such derivatives of albicanol include cryptoporic acid E (CAS 120001-10-7), cryptoporic acid D (CAS 119979-95-2), cryptoporic acid B (CAS 113592-88-4), cryptoporic acid A (CAS 113592-87-3), laricinolic acid (CAS 302355-23-3), albicanyl acetate (CAS 83679-71-4).
  • The albicanol and/or drimenol produced in any of the method described herein can be converted to derivatives such as, but not limited to hydrocarbons, esters, amides, glycosides, ethers, epoxides, aldehydes, ketons, alcohols, diols, acetals or ketals.
  • The albicanol and/or drimenol derivatives can be obtained by a chemical method such as, but not limited to oxidation, reduction, alkylation, acylation and/or rearrangement.
  • Alternatively, the albicanol and/or drimenol derivatives can be obtained using a biochemical method by contacting the albicanol and/or drimenol with an enzyme such as, but not limited to an oxidoreductase, a monooxygenase, a dioxygenase, a transferase. The biochemical conversion can be performed in-vitro using isolated enzymes, enzymes from lysed cells or in-vivo using whole cells.
  • According to another particularly embodiment, the method of any of the above-described embodiments is carried out in vivo. In such a case, step a) comprises cultivating a non-human host organism or a host cell capable of producing FPP and transformed to express at least one polypeptide comprising an amino acid comprising SEQ ID NO: 1 or SEQ ID NO: 5 or a functional variant thereof which may be considered a polypeptide of the HAD-like hydrolase superfamily (Interpro protein superfamily IPR023214 or Pfam protein superfamily PF13419) and which comprises a HAD-like hydrolase domain and having a bifunctional terpene synthase activity, under conditions conducive to the production of drimane synthase, for example, albicanol and/or drimenol. In one embodiment, albicanol may be the only product or may be part of a mixture of sesquiterpenes. In another aspect, drimenol may be the only product or may be part of a mixture of sesquiterpenes.
  • According to a further embodiment, the method further comprises, prior to step a), transforming a non-human organism or cell capable of producing FPP with at least one nucleic acid encoding a polypeptide comprising an amino acid comprising SEQ ID NO: 1 or SEQ ID NO: 5 or encoding a polypeptide having bifunctional terpene synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, or SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and (1) the sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and (2) the sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58, so that said organism expresses said polypeptide. The polypeptide may further comprise one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and/or SEQ ID NO: 62.
  • These embodiments of an embodiment herein are particularly advantageous since it is possible to carry out the method in vivo without previously isolating the polypeptide. The reaction occurs directly within the organism or cell transformed to express said polypeptide.
  • An embodiment herein provides polypeptides of an embodiment herein to be used in a method to produce a drimane sesquiterpene such as albicanol and/or drimenol contacting an FPP precursor with the polypeptides of an embodiment herein either in vitro or in vivo.
  • Further provided is the use of a polypeptide as described herein for producing a drimane sesquiterpene, for example, albicanol and/or drimenol.
  • The following examples are illustrative only and are not intended to limit the scope of the claims an embodiments described herein.
  • EXAMPLES Example 1 Microorganism Cultivation and DNA and RNA Extraction.
  • Drimane sesquiterpenoids are widespread in nature (Jansen and Groot, 2004, Nat. Prod. Rep., 21, 449-477). The compounds in the drimane sesquiterpeneoid family contain the sesquiterpene structure with the drimane carbon skeleton depicted in FIG. 1 . For example, commonly found drimane sesquiterpene are drimenol and albicanol (FIG. 1 ) and compounds derived from drimenol and albicanol by enzymatic reactions such as oxidations, reduction, acylation, alkylation or rearrangement. The drimane sesquiterpenoid family contains also compounds were the drimane sesquiterpene is bound to a molecule derived from another biosynthetic pathway (Jansen and Groot, 2004, Nat. Prod. Rep., 21, 449-477).
  • Cryptoporic acids A-H are drimane sequiterpenoid ethers of isocitric acid found in the fungus Cryptoporus volvatus (Hashimoto et al, 1987, Tetrahedron Let. 28, 6303-6304; Asakawa et al, 1992, Phytochemistry 31(2), 579-592; Hirotani et al, 1991, Phytochemistry 30(5), 1555-1559). In crypotoporic acids, the sesquiterpene moiety has the structure of albicanol and thus these compounds are putatively derived biosynthetically from albicanol. Laricinolic acid is a drimane type sesquiterpene which can be isolated from the wood-rotting fungus Laricifomes officinalis (Erb et al, 2000, J. Chem. Soc., Perkin Trans. 1, 2307-2309). Laricinolic acid is most likely derived from albicanol following several oxidative enzymatic steps.
  • We undertook to characterize albicanol synthases and to identify nucleotide sequences encoding for albicanol synthases from Cryptoporus volvatus and Laricifomes officinalis. Strains of Laricifomes officinalis (ATCC® 64430™) and Cryptoporus volvatus (ATCC® 12212™) are conserved at the American Type Culture Collection (ATCC) under the collection numbers ATCC-64430 and ATCC-12212, respectively. The Laricifomes officinalis (ATCC® 64430™) and Cryptoporus volvatus (ATCC® 12212™) strains were purchased from LGC Standards GmbH (46485 Wesel, Germany). The cells were grown in Yeast Mold (YM) medium (Wickerham, 1939, J. Tropical Med. Hyg. 42, 176).
  • For each of the two strains, genomic DNA and total RNA were extracted in order to sequence the full genome and a transcriptome. Cells propagated on YM-agar plates were used to inoculate 100 ml liquid YM medium in glass tubes. The cultures were incubated for 6 days with at 25° C. and 180 rpm agitation. For RNA extraction 0.5 ml of culture was taken, the cells (Approximately 100 mg) were recovered by centrifugation frozen in liquid nitrogen and grinded using a mortar and pestle. The total RNA pool was extracted using the ZR Fungal/Bacterial RNA MiniPrep™ from Zymo Research Corp (Irvine, Calif. 92614, U.S.A). From 100 mg of cells 18 and 23 micrograms of total RNA were obtained for ATCC-12212 and ATCC-64430, respectively. Genomic DNA was extracted using the NucleoSpin® Soil Kit from Machery-Nagel (Duren, Germany). Cells were recovered from the culture by centrifugation and the genomic DNA was extracted following the manufacturer protocol. From 500 mg of cells 1.05 and 0.93 micrograms of genomic DNA was extracted from ATCC-12212 and ATCC-64430, respectively.
  • Example 2 Genome and Transcriptome Sequencing.
  • The genomic DNA was sequenced using a paired read protocol (Illumina). The libraries were prepared to select insert sizes between 250 and 350 bp. The sequencing was performed on a HiSeq 2500 Illumina sequencer. The length of the reads was 125 bases. A total of 21.3 and 30.4 millions of paired-reads (clusters) were sequenced for ATCC-12212 and ATCC-64430, respectively.
  • For the transcriptomes the library was prepared from the total RNA using the TruSeq Stranded mRNA Library Preparation Kit (Illumina). An additional insert size selection step (160-240 bp) was performed. The libraries were sequenced in 2×125 bases paired-ends on a HiSeq 2500 Illumina sequencer. For ATCC-12212 and ATCC-64430, 19.9 million and 126 millions of reads were sequences, respectively.
  • For assembly of the C. volvatus transcriptome, the reads were first joined on their overlapping ends. The joined paired reads were then assembled using the Velvet V1.2.10 assembler (Zerbino D. R. and Birney E. 2008, Genome Res. 18(5), 821-829; www.ebi.ac.uk/˜zerbino/velvet/) and the Oases software (Schulz M. H et al., 2012, Bioinformatics 28(8), 1086-1092; www.ebi.ac.uk/˜zerbino/oases/). A total of 25′866 contigs with an average length of 1,792 bases was obtained for the C. volvatus transcriptome.
  • The C. volvatus genome was assembled using the Velvet V1.2.10 assembler (Zerbino D. R. and Birney E., 2008, Genome Res. 18(5), 821-829; www.ebi.ac.uk/˜zerbino/velvet/). The genome could be assembled in 1′266 contigs with an average size 20,000 bases and a total size of 25′320′421 bases. An ab-initio gene prediction in the C. volvatus genomic contigs was performed by Progenus S A (Gembloux, Belgium) using the Augustus software (Stanke et al., Nucleic Acids Res. (2004) 32, W309-W312). A total of 7738 genes were predicted. Functional annotation was performed combining a Pfam domain search (Finn, R. D. et al., 2016, Nucleic Acids Research Database Issue 44:D279-D285) and a Blast search (Altschul et al., 1990, J. Mol. Biol. 215, 403-410).
  • The genome and transcriptome of L. officinalis were assembled using the CLC Genomic Workbench (Qiagen). The genome was assembled in 16′831 contigs for a total genome size of 90′591′190 bases. The transcriptome assembly provided 28′633 contigs with an average length of 1′962 bases.
  • Example 3 Identification of Drimane Sesquiterpene Synthases.
  • Using a tBlastn search (Altschul et al., 1990, J. Mol. Biol. 215, 403-410) with the amino acid sequences of known sesquiterpene synthases as query sequences, 6 and 10 putative sesquiterpene synthases sequences were identified in the C. volvatus genome and L. officinalis genome, respectively. The sequences were manually corrected, in particular for the intro-exon junction localizations, using a mapping of the RNA sequencing reads on the genomic contigs. The corresponding cDNAs were then codon-optimized for optimal E. coli expression, synthesized and cloned in an expression plasmid (pJ401, ATUM, Newark, Calif.). Functional expression E coli cells and enzyme characterization assay showed sesquiterpene synthase activities but did not reveal any formation of albicanol from FPP.
  • Drimane sesquiterpene are presumably produced from farnesyl-diphosphate (FPP) by an enzymatic mechanism involving a protonation-initiated cyclization followed by an ionization-initiated reaction (Henquet et al., 2017, Plant J. Mar 4. doi: 10.1111/tpj.13527; Kwon, M.et al., 2014, FEBS Letters 588, 4597-4603) (FIG. 2 ). This implies that the drimane synthases are composed of two catalytic domains, a protonation-initiated cyclization catalytic domain and an ionization-initiated cyclization catalytic domain.
  • Terpene synthases catalyzing protonation-initiated cyclization reaction are called class II (or type II) terpene synthases and are typically involved in the biosynthesis of triterpenes and labdane diterpenes. In class II terpene synthases the protonation-initiated reaction involves acidic amino acids donating a proton to the terminal double-bond. These residues, usually aspartic acids, are part of a conserved DxDD motif located in the active site of the enzyme.
  • Terpene synthases catalyzing ionization-initiated reactions are called class I (or type I) terpene synthases, generally monoterpene and sesquiterpene synthases, and the catalytic center contains a conserved DDxxD (part of SEQ ID NO: 53) motif. The aspartic acid residues of this class I motif bind a divalent metal ion (most often Mg2+) involved in the binding of the diphosphate group and catalyze the ionization and cleavage of the allylic diphosphate bond of the substrate.
  • The putative cyclization mechanism of a farnesyl-diphosphate to a drimane sesquiterpene (such as albicanol or drimenol) starts with the protonation of the 10,11-double bond followed by the sequential rearrangements and carbon-bond formations. The carbocation intermediate of this first (class II) reaction can then undergo deprotonation at C15 or C4 (or eventually at C2) leading to an albicanyl-diphosphate or drimenyl-diphosphate intermediate. Finally the class I catalytic domain catalyzes the ionization of the allylic diphosphate bond and quenching of the carbocation intermediated by a water molecule leading to a drimane sesquiterpene containing a primary hydroxyl group (FIG. 2 ). If necessary, any traces of residual phosphorylated intermediates of the albicanol or drimenol synthesis, like any albicanyl—or drimenyl-monophosphate and/or—diphosphate, may be chemically converted to the respective final product albicanol or drimenol. Certain corresponding methods are known and may comprise, for example, the hydrolytic cleavage of the phosphoric acid ester bond. Additionally, certain intermediates can also be converted enzymatically as shown in Examples 7 and 8.
  • Based on the above considerations, we searched the C. volvatus and L. officinalis genome and transcriptome data for sequences encoding for polypeptides containing together a class I and a class II terpene synthase motif. Recently, a drimanyl-diphosphate synthase (AstC) was identified in the fungus Aspergillus oryzea (Shinohara Y. et al., 2016, Sci Rep. 6, 32865). The enzyme contains a class II terpene synthase domain and catalyzes the protonation-initiation cyclization of farnesyl-diphosphate to drimanyl-diphosphate. However, this enzyme does not have a class I terpene synthase activity and thus does not catalyze the ionization and cleavage of the allylic diphosphate group. Using the sequence of AstC, we first search the amino acid sequences deduced from the genes predicted in the C. volvatus genome. Using a Blastp search against the amino acid sequences deduced from the predicted genes, 5 sequences were retrieved with an E value between 0.77 and 3e-089 (Altschul et al., 1990, J. Mol. Biol. 215, 403-410).
  • Amongst these 5 sequences, CvTps1 was selected as the most relevant for a putative albicanol synthases. The amino acid sequence encoded by the CvTps1 gene shared 38% identity with the AstC amino acid sequence. Analysis of this sequence revealed the presence of a class II terpene synthase-like motif, DVDT, at position 275-279. This is a variant of the typical class II terpene synthase motif mentioned above, where the last Asp is replaced by a Thr. This DxDT class II motif is found in some class II diterpene synthases (Xu M. et al., 2014, J. Nat. Prod. 77, 2144-2147; Morrone D. et al., 2009, J. FEBS Lett., 583, 475-480) and in AstC. Another interesting feature of the CvTps1 sequence is the presence of a typical class I motif in the N-terminal region (DDKLD at position 168-172). The presence of this class I motif, not present in AstC, suggests that CvTps1 can catalyze an ionization-initiated reaction in addition to the class II reaction. Another difference with AstC is the presence of a C-terminal extension, the CvTps1 peptide contains 46 additional amino acids at the C-terminal end. Thus CvTps1 was selected as putative candidate for a bi-functional albicanol synthase.
  • Protein family databases such as Pfam and Interpro (European Bioinformatic Institute (EMBL-EBI) are databases of protein families including functional annotation, protein domains and protein domain signatures. The amino acid sequence of CvTps1 was searched for the occurrence of motifs characteristic of protein domains using the HMMER algorithm available on the HMMER website (Finn R. D., 2015, Nucleic Acids Research Web Server Issue 43:W30-W38; www.ebi.ac.uk/Tools/hmmer/). No domain associated with classical terpene synthases was found in the CvTps1 amino acid sequence. The query identified a domain characteristic of the Haloacid dehalogenase (HAD)-like hydrolase protein superfamily (PF13419.5) in the region between residues 115 and 187. A similar search using the Interpro protein family database (see the ebi.ac.uk/interpro/web site) and the Conserved Domain Database (NCBI web site at ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) provided the same results: only the prediction of a domain of the HAD-like hydrolase superfamily in the N-terminal region (IPR 023214 and CL21460, respectively). The HAD-like hydrolase superfamily contains a large number of proteins with various functions including enzymes with phosphatase activity (Koonin and Tatusov, 1994, J. Mol. Biol 244, 125-132; Kuznetsova et al, 2015, J Biol Chem. 290(30), 18678-18698). The class I terpene synthase-like motif identified above in the CvTps1 polypeptide contains one of the HAD-like hydrolase motif signatures containing a conserved aspartic acid residues involved in the catalytic (phosphatase) activity. This analysis thus confirms that the N-terminal region of CvTps1 is involved in hydrolysis of the diphosphate group (class I terpene synthase activity).
  • No significant domain prediction was obtained in the C-terminal portion the polypeptide. Given the presence of a class II terpene synthase-like motif, the C-terminal part is likely involved in the protonation-initiated cyclization.
  • The CvTps1 amino acid sequence was used to search for homologous sequences in the L. officinalis genome and transcriptome. For this search the tBlastn algorithm was used (Altschul et al 1990, J. Mol. Biol. 215, 403-410). One transcript, LoTps1 showed sequence similarity with CvTps1: the length of the sequence (521 amino acid) was similar to the length of the CvTps1 amino acid sequence, the overall sequence identity between the two sequences was 71%, the N-terminal region contained a typical class I terpene synthase motif (DDKLD at position 162-166), a class II terpene synthase motif (DMDT) was found in position 267-270 and the N-terminal region contain a predicted HAD-like hydrolase domain.
  • Example 4 Heterologous Expression and Characterization of CvTps1 and LoTps1.
  • The CvTps1 and LoTps1 coding sequences were control and the intron-exon jonctions predictions were refined using mappings of the RNA sequencing reads against the genomic contigs. The coding sequences of the resulting cDNAs were codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, Calif.).
  • The enzymes were functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP). Competent E. coli cells were transformed with the plasmid pACYC-29258-4506 (described in WO2013064411 or in Schalk et al., 2013, J. Am. Chem. Soc. 134, 18900-18903) and with the pJ401-CvTps1 or pJ401-LoTps1 expression plasmid. The pACYC-29258-4506 carries the cDNA encoding for a FPP synthase gene and the genes for a complete mevalonate pathway. The KRX E. coli cells (Promega) were used as a host. Transformed cells were selected on kanamycin (50 μg/ml) and chloramphenicol (34 μg/ml) LB-agarose plates. Single colonies were used to inoculate 5 mL liquid LB medium supplemented with the same antibiotics. The culture was incubated overnight at 37° C. The next day 2 mL of TB medium supplemented with the same antibiotics were inoculated with 0.2 mL of the overnight culture. After 6 hours incubation at 37° C., the culture was cooled down to 28° C. and 0.1 mM IPTG, 0.2% rhamnose and 10% in volume (0.2 ml) of dodecane were added to each tube. The cultures were incubated for 48 hours at 28° C. The cultures were then extracted twice with 2 volumes of tert-Butyl methyl ether (MTBE), the organic phase were concentrated to 500 μL and analyzed by GC-MS.
  • The GC-MS analysis were performed using an Agilent 6890 Series GC system connected to an Agilent 5975 mass detector. The GC was equipped with 0.25 mm inner diameter by 30 m DB-1MS capillary column (Agilent). The carrier gas was He at a constant flow of 1 mL/min. The inlet temperature was set at 250° C. The initial oven temperature was 80° C. followed by a gradient of 10° C./min to 220° C. and a second gradient of 30° C./min to 280° C. The identification of the products was based on the comparison of the mass spectra and retention indices with authentic standards and internal mass spectra databases.
  • In these conditions formation of a single product was observed with the recombinant CrVo07609 protein. The final concentration for this enzyme product was 200 mg/l of culture medium. The retention time in gas chromatography as well as the mass spectrum was in accordance with the GCMS data of an authentic (+)-albicanol standard. For structure confirmation, the recombinant cells were cultivated in a larger (500 ml) volume in the conditions described above. The MTBE was distilled form the extract and the resulting suspension in dodecane was subjected to flash chromatography. The product was eluted with a mixture 1:5 of MTBE and cyclohexane. The solvent was removed by distillation providing a product with 98% purity. The structure of albicanol was confirmed by 1H- and 13C-NMR analysis. The optical rotation was measured using a Bruker Avance 500 MHz spectrometer. The value of [α]D 20=+3.8° (0.26%, CHCl3) confirmed the formation of (+)-albicanol (with the structure shown in FIG. 1 ) by the recombinant CvTps1 protein.
  • The activity of LoTps1 was evaluated in the same conditions. The product profile was identical to the profile of CvTps1 with (+)-albicanol as the only detected product of the recombinant LoTps1 enzyme.
  • This experiments show that the CvTps1 and LoTps1 are enzyme with bifunctional class II cyclase activity and class I phosphatase activity.
  • Example 5 Search for Sequences Homologous to CvTps1 and LoTps1 in Other Organisms.
  • The amino acid sequences of CvTps1 and LoTps1 were used to search for homologous sequences from other organisms present in public databases. A blastp search approach (Altschul et al., 1990, J. Mol. Biol. 215, 403-410) was first used to search in the protein database of the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov/) for sequences showing homology with CvTps1 and LoTps1. The retrieved amino acids were then analyzed for the presence of the CyTps1 and LoTps1 features described in Example 3. Fifteen sequences, all from fungi species, were selected for further analysis and enzymatic activity characterization: NCBI accession OCH93767.1 from Obba rivulosa, NCBI accession EMD37666.1 from Gelatoporia subvermispora, NCBI accession XP_001217376.1 from Aspergillus terreus, NCBI accession OJJ98394.1 from Aspergillus aculeatus, NCBI accession GAO87501.1 from Aspergillus udagawae, NCBI accession XP_008034151.1 from Trametes versicolor, NCBI accession XP_007369631.1 from Dichomitus squalens, NCBI accession KIA75676.1 from Aspergillus ustus, NCBI accession XP_001820867.2 from Aspergillus oryzae, NCBI accession CEN60542.1 from Aspergillus calidoustus, NCBI accession XP_009547469.1 from Heterobasidion irregulare, NCBI accession KLO09124.1 from Schizopora paradoxa, NCBI accession OJI95797.1 from Aspergillus versicolor.
  • The sequence of EMD3766.1 was corrected by deleting the amino acids 261 to 266 present in the published sequence and probably resulting from incorrect splicing prediction (sequence EMD37666-B in table 1). Another sequence, ACg006372 was selected from the published annotated sequence of Antrodia cinnamomea (Lu et al., 2014, Proc. Natl. Acad. Sci. USA. 111(44):E4743-52, (Dataset S1)).
  • The 15 putative terpene synthases amino acid sequences contain a class II terpene synthase-like motif with the consensus sequence D(V/M/L/F)D(T/S) as well as a class I terpene synthase-like motif with the consensus sequence DD(K/N/Q/R/S)xD (were x is a hydrophobic residue L, I, G, T or P). The class I and class II motifs are easily localized using an alignment of the amino acid sequences with the sequences of CvTps1 and LoTps1 (FIG. 6 ). Such alignment can be made using for example the program Clustal W (Thompson J. D. et al., 1994, Nucleic Acids Res. 22(22), 4673-80). In addition, the presence of a HAD-like hydrolase domain was identified in the N-terminal region of the 15 amino acid sequences (between positions 1 and 183 to 243 of the sequences) (Table 3).
  • The features of the above sequences thus suggest that the proteins contain a phosphatase or class I terpene synthase domain and a class II terpene synthase domain in the N-terminal and C-terminal region, respectively and thus have bifunctional protonation-initiated cyclization and ionization-initiated catalytic activities. Alignment of the sequences and pairwise comparisons (Table 2) of the above amino acid sequences showed a lowest sequence identity value of 37% and a highest value of 89% (without considering the two EMD37666.1 variants). Compared to CvTps1 and LoTps1, the closest sequences shared 85% identity and the most distant sequence only 42% identity.
  • TABLE 1
    List of selected sequences showing sequence homology with CyTps1 and LoTps1
    and containing a class I and a class II motifs. The source (species) of the
    sequences, SEQ ID NO, length of the sequence, sequence region containing the
    class I andclass II motifs, and positions of the class I and class II motifs
    are listed. The residues of class I and class II motifs are in bold.
    Putative Class Class
    Name or NCBI Protein Length function I motif Class I II motif Class II
    accession SEQ (amino (database region motif region motif
    number Source ID NO acids) annotation) sequence position sequence position
    CvTps1 Cryptoporus  1 525 VFVDDKLD 168-172 FPDDVDTT 273-276
    volvatus NVA S
    LoTps1 Laricifomes  5 521 VFVDDKLD 162-166 FPDDMDTT 267-270
    officinalis NVV S
    OCH93767.1 Obba ribulosa  9 527 HAD-like VFVDDKID 166-170 FPDDLDTT 271-274
    protein NVL S
    EMD37666.1 Gelatoporia 12 533 hypothetical VFVDDKID 166-170 FPDDLDTT 277-280
    subvermispora protein NVL S
    EMD37666-B Gelatoporia 15 528 hypothetical VFVDDKID 166-170 FPDDLDTT 271-274
    subvermispora protein NVL S
    XP_001217376.1 Aspergillus 17 486 Predicted MFIDDKLE 161-165 FPDDMDTT 267-270
    terreus protein NVI S
    OJJ98394.1 Aspergillus 20 483 Hypothetical VFVDDKTE 162-166 FPNDLDTT 268-271
    aculeatus protein NVL S
    GAO87501.1 Aspergillus 23 485 alpha-D- IFIDDQLE 167-171 FPDDVDTT 273-276
    udagawae glucose-1- NVV S
    phosphate
    phosphatase
    YihX
    XP_008034151.1 Trametes 26 524 HAD-like VFVDDKLD 168-172 FPDDVDTT 273-276
    versicolor protein NVV S
    XP_007369631.1 Dichomitus 29 527 HAD-like VFVDDKLD 168-172 FPDDVDTT 273-276
    squalens protein NVA S
    ACg006372 Antrodia 32 496 HAD-like VFVDDRIE 179-183 YPDDFDTT 286-289
    cinnamomea protein NVV S
    KIA75676.1 Aspergillus 35 543 Hypothetical VFVDDNLE 161-165 FPDDMDTT 267-270
    ustus protein NVTS S
    XP_001820867.2 Aspergillus 38 477 Hypothetical IFVDDQLE 167-171 FPDDVDTT 273-276
    oryzae protein NVIS S
    CEN60542.1 Aspergillus 41 528 Hypothetical VFVDDNLD 161-165 FPDDLDTT 267-270
    calidoustus protein NVT S
    XP_009547469.1 Heterobasidion 44 531 Hyopthetical VFVDDKGD 166-170 FPFDLDTT 272-275
    irregulare protein NVL S
    KLO09124.1 Schizopora 47 518 HAD-like VFVDDKLD 209-213 FPCDLDST 315-318
    paradoxa protein NVI S
    OJI95797.1 Aspergillus 50 507 hypothetical VFIDDSPE 163-167 FPNDLDTT 269-272
    versicolor protein NIL S
  • TABLE 2
    Pairwise sequence comparison of the selected putative bifunctional terpene synthases.
    The percentage of sequence identity is listed for each pairwise comparison.
    CvTps1 LoTps1 OCH93676.1 EMD37666.1 EMD37666-B XP_001217376.1
    CvTps1 100 71 60 60 60 42
    LoTps1 72 100 60 58 59 43
    OCH93767.1 61 60 100 88 89 43
    EMD37666-B 60 59 89 99 100 43
    EMD37666.1 60 58 88 100 99 43
    XP_001217376.1 42 43 43 43 43 100
    OJJ98394.1 47 48 47 47 47 54
    GAO87501.1 46 45 47 47 47 42
    XP_008034151.1 73 85 62 60 61 43
    XP_007369631.1 84 74 61 60 61 44
    ACg006372 45 48 47 46 47 37
    KIA75676.1 44 43 46 45 46 45
    XP_001820867.2 45 44 44 43 44 41
    CEN60542.1 44 45 45 46 46 44
    XP_009547469.1 54 55 54 53 54 43
    KLO09124.1 51 53 53 51 52 39
    OJI95797.1 45 43 45 45 46 55
    OJJ98394.1 GAO87501.1 XP_008034151.1 XP_007369631.1 ACg006372 KIA75676.1
    CvTps1 47 46 72 84 45 44
    LoTps1 48 45 85 74 48 43
    OCH93767.1 47 47 62 62 48 46
    EMD37666-B 47 47 61 62 47 46
    EMD37666.1 47 47 60 61 46 45
    XP_001217376.1 54 42 43 44 37 45
    OJJ98394.1 100 44 47 48 41 48
    GAO87501.1 44 100 46 47 45 46
    XP_008034151.1 47 46 100 77 49 44
    XP_007369631.1 48 48 77 100 48 45
    ACg006372 41 45 48 48 100 42
    KIA75676.1 48 46 44 43 42 100
    XP_001820867.2 44 69 45 46 44 47
    CEN60542.1 49 43 45 45 40 72
    XP_009547469.1 45 47 55 55 49 44
    KLO09124.1 44 45 51 51 55 45
    OJI95797.1 56 43 44 46 39 45
    XP_001820867.2 CEN60542.1 XP_009547469.1 KLO09124.1 OJI95797.1
    CvTps1 45 44 55 52 45
    LoTps1 44 45 55 53 43
    OCH93767.1 44 45 54 53 45
    EMD37666-B 44 46 58 52 46
    EMD37666.1 43 46 57 52 45
    XP_001217376.1 41 44 43 39 55
    OJJ98394.1 44 49 45 44 56
    GAO87501.1 69 43 47 45 43
    XP_008034151.1 45 45 55 52 44
    XP_007369631.1 46 46 56 52 46
    ACg006372 44 40 49 55 39
    KIA75676.1 46 72 44 45 45
    XP_001820867.2 100 47 46 42 41
    CEN60542.1 47 100 48 43 45
    XP_009547469.1 46 48 100 54 47
    KLO09124.1 42 44 54 100 44
    OJI95797.1 41 45 47 44 100
  • Example 6 Functional Characterisation of Other Fungal Hydrolase-Like Bifunctional Sesquiterpene Synthases.
  • The cDNAs encoding for the 15 new putative synthases described in Example 5 were codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, California). The enzymes were functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP) following the procedure described in example 4. Amongst the 15 new recombinant enzymes, 9 produced (+)-albicanol as major product: OCH93767.1, EMD37666.1, EMD37666-B, XP_001217376.1, OJJ98394.1, GAO87501.1 XP_008034151.1, XP_007369631.1 and ACg006372 (FIGS. 7 and 8 ). These results confirm that these enzymes have bifunctional albicanol synthase enzymatic activities.
  • The 6 other new synthases, KIA75676.1, XP_001820867.2, CEN60542.1, XP_009547469.1 and KLO09124.1 and OJI95797.1, produced (−)-drimenol as major product (FIG. 9 ). Drimenol is produced by a mechanism similar to the formation of albicanol and involving a class II followed by class I enzymatic activity.
  • For XP_001820867.2, the formation of a significant amount of trans-farnesol was detected (FIG. 9 ). This was likely due to lower enzymatic activity of this synthase and thus a significant amount of the farnesyl-diphosphate produced in the bacterial cell was not converted to drimenol. This excess farnesyl-diphosphate was hydrolyzed by the endogenous alkaline phosphatase and the trans-farnesol produced was released in the growing medium.
  • The two Pfam domains identified in CvTps1, i.e. PF13419.5 and PF13242.5 as described in Example 3, are also found in these new putative synthases as shown in Table 3.
  • TABLE 3
    Locations of the haloacid dehalogenase-like hydrolase domain
    in each of the bifunctional synhtases described herein.
    HAD-like HAD-like
    hydrolase hydrolase
    Ezyme Length Product domain start domain end
    CvTps1 525 Albicanol 115 187
    LoTps1 521 Albicanol 62 181
    OCH93767.1 527 Albicanol 51 185
    EMD37666.1 533 Albicanol 54 185
    EMD37555-B 528 Albicanol 54 185
    XP_001217376.1 486 Albicanol 25 181
    OJJ98394.1 483 Albicanol 25 181
    GAO87501.1 485 Albicanol 34 186
    XP_008034151.1 524 Albicanol 60 187
    XP_007369631.1 527 Albicanol 120 187
    ACg006372 496 Albicanol 60 198
    KIA75676.1 543 Drimenol 43 180
    XP_001820867.2 477 Drimenol 12 186
    CEN60542.1 528 Drimenol 20 180
    XP_009547469.1 531 Drimenol 77 185
    KLO09124.1 518 Drimenol 119 228
    OJI95797 507 Drimenol 48 180
  • Example 7
  • In-vitro assays.
  • Crude protein extracts containing the recombinant terpene synthases are prepared using KRX E. coli cells (Promega) or BL21 Star™ (DE3) E. coli (ThermoFisher). Single colonies of cells transformed with the expression plasmid are used to inoculate 5 ml LB medium. After 5 to 6 hours incubation at 37° C., the cultures are transferred to a 25° C. incubator and left 1 hour for equilibration. Expression of the protein is then induced by the addition of 1 mM IPTG and the cultures are incubated over-night at 25° C. The next day, the cells are collected by centrifugation, resuspended in 0.1 volume of 50 mM MOPSO pH 7 (3-Morpholino-2-hydroxypropanesulfonic acid (sigma-Aldrich), 10% glycerol and lyzed by sonication. The extracts are cleared by centrifugation (30 min at 20,000 g) and the supernatants containing the soluble proteins are used for further experiments.
  • These crude E. coli protein extracts containing the recombinant protein are used for the characterization of the enzymatic activities. The assays are performed in glass tubes in 2 mL of 50 mM MOPSO pH 7, 10% glycerol, 1 mM DTT, 15 mM MgCl2 in the presence of 80 μM of farnesyl-diphosphate (FPP, Sigma) and 0.1 to 0.5 mg of crude protein. The tubes are incubated 12 to 24 hours at 25° C. and extracted twice with one volume of pentane. After concentration under a nitrogen flux, the extracts are analyzed by GC-MS as described in Example 4 and compared to extracts from assays with control proteins. The aqueous phase is then treated by alkaline phosphatase (Sigma, 6 units/ml), followed by extraction with pentane and GC-MS analysis.
  • The assays without alkaline phosphatase treatment allow detecting and identifying the sesquiterpene compounds (hydrocarbons and oxygenated sesquiterpenes) present in the assay and produced by the recombinant enzymes. Albicanyl-diphosphate or drimenyl-diphosphate compounds are not soluble in the organic solvent and are thus not detected in the GC-MS analysis. Following the alkaline phosphatase treatment, allylic diphosphate bounds are cleaved and when albicanyl-diphosphate or drimenyl-diphosphate compounds are present, the sequiterpene moiety is released, extracted in the solvent phase and detected in the GC-MS analysis. This example allows to differentiate enzymes having only class II terpene synthase activity (such as AstC, NCBI accession XP_001822013.2, Shinohara Y. et al., 2016, Sci Rep. 6, 32865) from enzyme having class II terpene synthase-like activity and class I (phosphatase) activity such as CvTps1 and LoTps1.
  • Example 8 Co-Expression of Terpene Synthases and Phosphatases.
  • In Shinohara Y. et al., 2016, Sci Rep. 6, 32865 a drimane terpene synthase (AstC, NCBI accession XP_001822013.2) is described. This synthase produce a drimane sequiterpene bound to a diphosphate moiety. To produce a free drimane sesquiterpene the AstC enzyme must be combined with enzymes having phosphatase activity. The publication also describes two phosphatases AstI and AstK (XP_001822007.1 and XP_003189903.1) catalyzing the sequential cleavage of the phosphate moiety of the drimane-diphosphate produced by AstC.
  • Synthetic operons were designed to co-express the CvTps1 protein with the AstI and AstK proteins. The synthetic operon contains the optimized cDNA encoding for each of the 3 proteins separated by a ribosome binding sequence (RBS). A similar operon was designed to co-express AstC with AstI and AstK. The operons were synthesized and cloned in the pJ401 expression plasmid (ATUM, Newark, Calif.). E coli cells were co-transformed with these expression plasmids and with the pACYC-29258-4506 plasmid (Example 4) and the cells were cultivated under conditions to produce sesquiterpenes as described in Example 4. The sequiterpenes produced were analyzed by GCMS as described in Example 4 and compared to the sequiterpene profile of cells expression only CvTps1 or AstC.
  • As shown FIG. 10 , with AstC a significant higher amount (78-fold increase) of sesquiterpene is produced when the enzyme is co-expressed with enzymes (AstI and AstK) having phosphatase activity. Typical concentrations of drimane sesquiterpene in the E. coli cultures were 2,600 mg/ml with cells expressing AstC, AstI and AstK and 34 mg/ml with cells expressing AstC alone.
  • In contrast, with CvTps1 no significant difference is observed for the amount of drimane sesquiterpene produced when the enzyme is expressed alone (1,000 mg/ml) or co-expressed with the phosphatases (1,200 mg/ml). This experiment confirms that the CvTps1 polypeptide, in contrast to the previously known AstC synthase, carries phosphatase activity in addition to the cyclase activity (i.e. class I and class II terpene synthase activity).
  • Example 9 Functional Characterisation of XP 006461126.1.
  • The NCBI accession No XP 006461126.1 from Agaricus bisporus was selected using the method described in Example 5. The XP006461126.1 amino acid (SEQ ID NO: 63) shared 48.9% and 48.1% identity with the CvTps1 and LoTps1 amino acid sequences, respectively. The XP_006461126.1 contains a class II terpene synthase-like motif (DLDT) (part of SEQ ID NO: 56) located between position 278 and 271 and a class I terpene synthase-like motif (DDKLE) (part of SEQ ID NO: 55) located at position 167 to 171. The amino acid contains also motifs characteristic of of the Haloacid dehalogenase-like hydrolase superfamily in the N-terminal region.
  • The cDNA encoding for XP 006461126.1 was codon optimized and cloned in the pJ401 E. coli expression plasmid (pJ401, ATUM, Newark, Calif.). The enzyme was functionally characterized in E. coli cells engineered to overproduce farnesyl-diphosphate (FPP) following the procedure described in Example 4. The results show that XP 006461126.1 is a bifunctional drimenol synthase producing drimenol as major compound (FIG. 11 ).
  • Example 10
  • In vivo drimane sesquiterpene production in Saccharomyces cerevisiae cells using fungal hydrolase-like bifunctional sesquiterpene synthases.
  • Different hydrolase-like bifunctional sesquiterpene synthases were evaluated for the production of drimane sesquiterpenes in S. cerevisiae cells. The selected synthases were:
      • XP_007369631.1, NCBI accession No XP_007369631.1, from Dichomitus squalens
      • XP_006461126, NCBI accession No XP_006461126, from Agaricus bisporus
      • LoTps1, SEQ ID NO: 5, from Laricifomes officinalis
      • EMD37666.1, NCBI accession No EMD37666.1, from Gelatoporia subvermispora
      • XP_001217376.1, NCBI accession No XP_001217376.1, from Aspergillus terreus
  • The codon usage of the cDNA encoding for the different synthases was modified for optimal expression in S. cerevisiae (SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70).
  • For expression of the different genes in S. cerevisiae, a set of plasmids were constructed in vivo using yeast endogenous homologous recombination as previously described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. Each plasmid is composed by five DNA fragments which were used for S. cerevisiae co-transformation. The fragments were:
      • Fragment a: LEU2 yeast marker, constructed by PCR using the primers 5′-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACC GCGCCATTCGACTACGTCGTAAGGCC-3′ (SEQ ID NO: 71) and 5′-TCGTGGTCAAGGCGTGCAATTCTCAACACGAGAGTGATTCTTCGGCGTTGTTG CTGACCATCGACGGTCGAGGAGAACTT -3′ (SEQ ID NO: 72) with the plasmid pESC-LEU (Agilent Technologies, California, USA) as template;
      • Fragment b: AmpR E. coli marker, constructed by PCR using the primers 5′-TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTT GACCACGACACGTTAAGGGATTTTGGTCATGAG-3′ (SEQ ID NO: 73) and 5′-AACGCGTACCCTAAGTACGGCACCACAGTGACTATGCAGTCCGCACTTTGCC AATGCCAAAAATGTGCGCGGAACCCCTA-3′ (SEQ ID NO: 74) with the plasmid pESC-URA as template;
      • Fragment c: Yeast origin of replication, obtained by PCR using the primers 5′-TTGGCATTGGCAAAGTGCGGACTGCATAGTCACTGTGGTGCCGTACTTAGGG TACGCGTTCCTGAACGAAGCATCTGTGCTTCA-3′ (SEQ ID NO: 75) and 5′-CCGAGATGCCAAAGGATAGGTGCTATGTTGATGACTACGACACAGAACTGCG GGTGACATAATGATAGCATTGAAGGATGAGACT-3′ (SEQ ID NO: 76) with pESC-URA as template;
      • Fragment d: E. coli replication origin, obtained by PCR using the primers 5′-ATGTCACCCGCAGTTCTGTGTCGTAGTCATCAACATAGCACCTATCCTTTGGC ATCTCGGTGAGCAAAAGGCCAGCAAAAGG-3′ (SEQ ID NO: 77) and 5′-CTCAGATGTACGGTGATCGCCACCATGTGACGGAAGCTATCCTGACAGTGTA GCAAGTGCTGAGCGTCAGACCCCGTAGAA-3′ (SEQ ID NO: 78) with the plasmid pESC-URA as template and
      • Fragment e: A fragment composed by the last 60 nucleotides of the fragment “d”, 200 nucleotides downstream the stop codon of the yeast gene PGK1, one of the hydrolase-like bifunctional sesquiterpene synthase coding sequences tested, codon optimized for its expression in S. cerevisiae, the promoter of GAL1 and 60 nucleotides corresponding to the beginning of the fragment “a”. These fragments were obtained by DNA synthesis (ATUM, Newark, Calif.).
  • To increase the level of endogenous farnesyl-diphosphate (FPP) pool in S. cerevisiae cells, an extra copy of all the yeast endogenous genes involved in the mevalonate pathway, from ERG10 coding for acetyl-CoA C-acetyltransferase to ERG20 coding for FPP synthetase, were integrated in the genome of the S. cerevisiae strain CEN.PK2-1C (Euroscarf, Frankfurt, Germany) under the control of galactose-inducible promoters, similarly as described in Paddon et al., Nature, 2013, 496:528-532. Briefly, three cassettes were integrated in the LEU2, TRP1 and URA3 loci respectively. A first cassette containing the genes ERG20 and a truncated HMG1 (tHMG1 as described in Donald et al., Proc Natl Acad Sci USA, 1997, 109:E111-8) under the control of the bidirectional promoter of GAL10/GAL1 and the genes ERG19 and ERG13 also under the control of GAL10/GAL1 promoter, the cassette was flanked by two 100 nucleotides regions corresponding to the up- and down-stream sections of LEU2. A second cassette where the genes IDI1 and tHMG1 were under the control of the GAL10/GAL1 promoter and the gene ERG13 under the control of the promoter region of GAL7, the cassette was flanked by two 100 nucleotides regions corresponding to the up- and down-stream sections of TRP1. A third cassette with the genes ERG10, ERG12, tHMG1 and ERG8, all under the control of GAL10/GAL1 promoters, the cassette was flanked by two 100 nucleotides regions corresponding to the up- and down-stream sections of URA3. All genes in the three cassettes included 200 nucleotides of their own terminator regions. Also, an extra copy of GAL4 under the control of a mutated version of its own promoter, as described in Griggs and Johnston, Proc Natl Acad Sci USA, 1991, 88:8597-8601, was integrated upstream the ERG9 promoter region. In addition, the endogenous promoter of ERG9 was replaced by the yeast promoter region of CTR3 generating the strain YST035. Finally, YST035 was mated with the strain CEN.PK2-1D (Euroscarf, Frankfurt, Germany) obtaining a diploid strain termed YST045.
  • YST045 was transformed with the fragments required for in vivo plasmid assembly. Yeast transformations were performed with the lithium acetate protocol as described in Gietz and Woods, Methods Enzymol., 2002, 350:87-96. Transformation mixtures were plated on SmLeu-media containing 6.7 g/L of Yeast Nitrogen Base without amino acids (BD Difco, New Jersey, USA), 1.6 g/L Dropout supplement without leucine (Sigma Aldrich, Missouri, USA), 20 g/L glucose and 20 g/L agar. Plates were incubated for 3-4 days at 30° C. Individual colonies were used to produce drimane sesquiterpenes in tubes or shake flasks containing media as described in Westfall et al., Proc Natl Acad Sci USA, 2012, 109:E111-118 and mineral oil ((2705-01, J.T. Baker, Avantor Performance Materials, Inc. Center Valley, Pa., USA) as organic overlay. Under these culture conditions, albicanol or drimenol were produced with all hydrolase-like bifunctional sesquiterpene synthases tested. The production of drimane sesquiterpenes was identified using GC-MS analysis and quantified by GC-FID (see FIG. 12 ) with an internal standard. The table below shows the quantities of drimane sesquiterpene produced relative to the quantity obtained by the synthase XP 007369631.1 (under these experimental conditions, the concentration of drimane sesquiterpene produced by cells expressing XP 007369631.1 was 805 to 854 mg/L, the highest quantity produced).
  • Relative quantity of drimane
    Enzyme Product sesquiterpene produced
    XP_007369631.1 Albicanol 100
    XP_006461126 Drimenol 39
    LoTps1 Albicanol 31
    EMD37666.1 Albicanol 23
    XP_001217376.1 Albicanol 3
  • Sequence Listings
    CvTps1
    - CvTps1 Protein
    SEQ ID NO: 1
    MTTIHRRHTTLILDLGDVLFRWSPKTETAIPPRQLKEILTSVTWFEYERGQISQTECYERCAAEFKVDPLVIAEAFKQARES
    LRPNKAFIALIRELRHQMHGDLTVLALSNISLPDYEYIMSLSSDWATVFNRVFPSALVGERKPHLGCYRKVISEMSLEPQT
    TVFVDDKLDNVASARSLGMHGIVFDNEANVFRQLRNIFGNPVSRGQGYLRKHAGKLESSTDNGLTFEENFTQLIIYEVT
    QDRSLITLSECPRTWNFFRGQPLFSESFPDDVDTTSVALTVLQPDRALVDSILDQMLEYVDADGIMQTYFDSSRPRIDPF
    VCVNVLSLFYANGRGRELPHTLEWVYEVLLHRAYHGGSRYYLSPDCFLFFMSRLLKRANDSALQARFRPLFMERVKERV
    GAAGDSMDLAFRILAAATIGVHCPQDLERLAAAQCEDGGWDMCWFYAFGSTGIKAGNRGLTTALAVAAIRTALGRPP
    SPSPSNISSSSKLDAPNSFLGIPRPTSPIRFGELFRSWRKNKPTAKSQ
    - CvTps1 transcript (including non-coding sequences)
    SEQ ID NO: 2
    CATCCCGCCTTTTGAGCATGGCACACAAACAGCCTTTAAGGAGCTCCTTGGTTGCCTAGTCATGCCTCCACCTGCCC
    CCTCCTCACTCATCCCCTCGCATCCTAAAACATGACCACGATTCACCGTCGGCACACCACTCTCATCTTGGACCTCG
    GCGACGTCCTCTTCCGCTGGTCACCAAAGACCGAGACCGCCATCCCCCCTCGGCAGCTTAAGGAGATACTTACCTC
    CGTCACCTGGTTCGAGTACGAACGAGGCCAGATATCCCAAACAGAATGTTACGAACGATGCGCTGCAGAATTCAA
    AGTCGACCCCTTAGTGATCGCTGAAGCCTTCAAGCAAGCTCGCGAGTCATTACGGCCCAACAAAGCGTTCATCGCC
    TTGATTCGCGAACTTCGCCATCAAATGCATGGAGACCTCACGGTCCTCGCCCTTTCCAACATTTCCCTCCCCGATTAC
    GAATATATCATGTCTCTGAGCTCGGATTGGGCAACCGTCTTCAATCGCGTATTCCCTTCTGCACTTGTTGGCGAGCG
    AAAACCCCATCTGGGGTGCTACCGCAAGGTCATTTCGGAGATGAGCTTGGAACCCCAGACAACCGTATTTGTCGAT
    GATAAGCTAGACAACGTCGCCTCTGCTCGCTCACTTGGCATGCACGGCATCGTATTCGACAACGAAGCCAATGTCT
    TCCGGCAACTGCGCAATATCTTCGGGAATCCGGTTAGCCGCGGTCAAGGCTATCTTCGCAAGCATGCCGGAAAGC
    TTGAGTCTTCTACCGACAATGGCTTGACCTTTGAGGAGAACTTCACCCAGCTCATCATCTACGAGGTGACACAAGA
    CAGGAGTCTCATCACGCTCTCAGAATGTCCCCGTACCTGGAATTTCTTTCGAGGTCAACCGCTCTTCTCGGAGTCTT
    TCCCGGATGATGTGGACACAACATCCGTGGCATTGACAGTACTACAACCCGATAGAGCGCTCGTTGATTCTATTCT
    AGACCAAATGCTTGAATATGTTGACGCCGACGGCATCATGCAGACATACTTCGACAGCTCGCGACCACGCATAGA
    CCCTTTTGTTTGCGTCAATGTGCTTTCTCTGTTCTACGCAAACGGCCGGGGTCGGGAGCTCCCTCACACACTGGAGT
    GGGTCTATGAAGTACTCCTGCATCGCGCCTACCATGGAGGCTCACGTTACTACCTATCACCGGACTGCTTTTTATTC
    TTCATGAGCCGCTTGCTCAAGCGCGCCAACGACTCGGCCCTCCAGGCTCGGTTCCGCCCACTGTTCATGGAGAGAG
    TGAAAGAACGAGTAGGGGCAGCCGGAGACTCAATGGACCTGGCCTTCCGCATCCTCGCCGCGGCTACCATTGGCG
    TCCATTGCCCCCAAGATCTAGAAAGATTGGCCGCCGCGCAATGCGAGGACGGTGGATGGGACATGTGCTGGTTCT
    ACGCGTTCGGGTCGACAGGTATCAAGGCGGGCAACCGCGGCCTCACCACGGCCCTTGCCGTCGCAGCTATACGAA
    CCGCCCTCGGGCGCCCCCCCTCTCCCAGCCCCTCCAACATCTCGTCGTCGTCGAAGCTCGACGCTCCCAACAGCTTC
    TTGGGCATCCCGCGCCCAACCAGCCCCATTCGCTTTGGCGAACTTTTCCGTTCCTGGCGAAAGAACAAACCGACCG
    CAAAATCTCAATGAATCTCAGGTTCTCGTGCTCTCGTGCTATCTTCGTACTTATGCTACTCGACATTACCCGTCGCTG
    TCTACAATGATACGGGTACTTTGATGAAACTGTAGATGTATTTGTATCATATTGACCTCCATCCATAGTCACCTAGC
    TACTGTTCGTGTTATCACCTGTTGCTGTTATATGATACAAGATGCCCAAACGAGAATGTAGAAATGTTCCGTACACT
    TGTGTACCTGTGATGAAGCTACATAGGCCTTCAATCGATCACTTGGTCC
    - CvTps1 cDNA
    SEQ ID NO: 3
    ATGACCACGATTCACCGTCGGCACACCACTCTCATCTTGGACCTCGGCGACGTCCTCTTCCGCTGGTCACCAAAGAC
    CGAGACCGCCATCCCCCCTCGGCAGCTTAAGGAGATACTTACCTCCGTCACCTGGTTCGAGTACGAACGAGGCCA
    GATATCCCAAACAGAATGTTACGAACGATGCGCTGCAGAATTCAAAGTCGACCCCTTAGTGATCGCTGAAGCCTTC
    AAGCAAGCTCGCGAGTCATTACGGCCCAACAAAGCGTTCATCGCCTTGATTCGCGAACTTCGCCATCAAATGCATG
    GAGACCTCACGGTCCTCGCCCTTTCCAACATTTCCCTCCCCGATTACGAATATATCATGTCTCTGAGCTCGGATTGG
    GCAACCGTCTTCAATCGCGTATTCCCTTCTGCACTTGTTGGCGAGCGAAAACCCCATCTGGGGTGCTACCGCAAGG
    TCATTTCGGAGATGAGCTTGGAACCCCAGACAACCGTATTTGTCGATGATAAGCTAGACAACGTCGCCTCTGCTCG
    CTCACTTGGCATGCACGGCATCGTATTCGACAACGAAGCCAATGTCTTCCGGCAACTGCGCAATATCTTCGGGAAT
    CCGGTTAGCCGCGGTCAAGGCTATCTTCGCAAGCATGCCGGAAAGCTTGAGTCTTCTACCGACAATGGCTTGACCT
    TTGAGGAGAACTTCACCCAGCTCATCATCTACGAGGTGACACAAGACAGGAGTCTCATCACGCTCTCAGAATGTCC
    CCGTACCTGGAATTTCTTTCGAGGTCAACCGCTCTTCTCGGAGTCTTTCCCGGATGATGTGGACACAACATCCGTGG
    CATTGACAGTACTACAACCCGATAGAGCGCTCGTTGATTCTATTCTAGACCAAATGCTTGAATATGTTGACGCCGA
    CGGCATCATGCAGACATACTTCGACAGCTCGCGACCACGCATAGACCCTTTTGTTTGCGTCAATGTGCTTTCTCTGT
    TCTACGCAAACGGCCGGGGTCGGGAGCTCCCTCACACACTGGAGTGGGTCTATGAAGTACTCCTGCATCGCGCCT
    ACCATGGAGGCTCACGTTACTACCTATCACCGGACTGCTTTTTATTCTTCATGAGCCGCTTGCTCAAGCGCGCCAAC
    GACTCGGCCCTCCAGGCTCGGTTCCGCCCACTGTTCATGGAGAGAGTGAAAGAACGAGTAGGGGCAGCCGGAGA
    CTCAATGGACCTGGCCTTCCGCATCCTCGCCGCGGCTACCATTGGCGTCCATTGCCCCCAAGATCTAGAAAGATTG
    GCCGCCGCGCAATGCGAGGACGGTGGATGGGACATGTGCTGGTTCTACGCGTTCGGGTCGACAGGTATCAAGGC
    GGGCAACCGCGGCCTCACCACGGCCCTTGCCGTCGCAGCTATACGAACCGCCCTCGGGCGCCCCCCCTCTCCCAGC
    CCCTCCAACATCTCGTCGTCGTCGAAGCTCGACGCTCCCAACAGCTTCTTGGGCATCCCGCGCCCAACCAGCCCCAT
    TCGCTTTGGCGAACTTTTCCGTTCCTGGCGAAAGAACAAACCGACCGCAAAATCTCAATGA
    - CvTps1 optimized cDNA
    SEQ ID NO: 4
    ATGACTACGATCCACCGCCGCCATACTACGCTGATCCTGGACCTGGGTGATGTTCTGTTCCGCTGGTCCCCGAAAA
    CCGAAACCGCAATTCCGCCTCGTCAGCTGAAAGAAATCTTGACCAGCGTTACCTGGTTCGAGTATGAGCGTGGCCA
    AATTAGCCAGACCGAATGCTACGAGCGTTGTGCTGCCGAGTTTAAAGTTGATCCGCTGGTTATTGCCGAAGCGTTT
    AAACAAGCGCGTGAAAGCCTGCGTCCGAACAAAGCGTTTATCGCGTTGATCCGTGAGTTGCGCCACCAGATGCAT
    GGTGACCTGACGGTCCTGGCACTGAGCAACATTAGCCTGCCTGATTATGAGTACATTATGTCGCTGAGCTCCGATT
    GGGCGACGGTCTTTAATCGCGTGTTTCCGAGCGCACTGGTGGGTGAGCGTAAGCCACACCTGGGTTGCTACCGCA
    AGGTCATCAGCGAGATGTCTCTGGAGCCGCAGACCACGGTTTTCGTCGATGACAAACTGGACAATGTCGCAAGCG
    CTCGTAGCCTGGGCATGCATGGCATCGTGTTCGACAACGAAGCGAACGTTTTTCGTCAGCTGCGTAATATCTTCGG
    TAACCCGGTTAGCCGCGGTCAAGGTTACTTGCGTAAACACGCCGGTAAACTGGAATCTAGCACGGATAATGGTCT
    GACCTTCGAAGAGAACTTCACTCAATTAATTATTTACGAAGTCACGCAAGACCGCAGCCTGATCACCCTGAGCGAG
    TGCCCGCGTACCTGGAACTTCTTCCGCGGTCAACCACTGTTTTCTGAGAGCTTTCCGGACGACGTGGACACCACCTC
    TGTGGCGTTGACCGTTCTGCAGCCGGATCGTGCGTTGGTGGATAGCATCCTGGACCAGATGTTGGAATATGTTGA
    CGCGGATGGTATTATGCAAACCTACTTTGATTCATCCCGTCCGCGCATTGACCCGTTCGTGTGCGTGAATGTCCTGA
    GCCTGTTCTACGCCAATGGCAGAGGCCGCGAGCTGCCACACACGCTGGAATGGGTCTATGAAGTTCTGCTGCACC
    GTGCGTACCACGGCGGTAGCCGTTATTACCTGAGCCCGGACTGTTTCCTGTTCTTTATGAGCCGTCTGCTGAAGCG
    CGCGAATGACTCGGCGCTGCAGGCCCGTTTTCGCCCGCTTTTCATGGAACGTGTGAAAGAGCGTGTGGGCGCAGC
    CGGCGATAGCATGGACCTGGCGTTCCGCATTCTGGCCGCTGCAACCATCGGCGTTCATTGCCCACAAGATCTGGA
    GCGTCTGGCAGCAGCGCAGTGCGAAGATGGTGGCTGGGATATGTGTTGGTTTTATGCGTTTGGCAGCACGGGTAT
    CAAGGCTGGCAACCGCGGTCTGACCACCGCGTTGGCTGTCGCCGCAATTCGTACCGCGCTGGGTCGTCCGCCTTCC
    CCGAGCCCGAGCAATATTTCTAGCTCCAGCAAACTGGACGCGCCGAACTCCTTCCTGGGCATCCCGCGTCCGACCA
    GCCCGATCCGTTTCGGTGAACTGTTTCGTAGCTGGCGTAAGAACAAGCCGACCGCGAAAAGCCAGTAA
    LoTps1
    - LoTps1 protein
    SEQ ID NO: 5
    MYTALILDLGDVLFSWSSTTNTTIPPRQLKEILSSPAWFEYERGRITQAECYERVSAEFSLDATAVAEAFRQARDSLRPND
    KFLTLIRELRQQSHGELTVLALSNISLPDYEFIMALDSKWTSVFDRVFPSALVGERKPHLGAFRQVLSEMNLDPHTTVFVD
    DKLDNVVSARSLGMHGVVFDSQDNVFRMLRNIFGDPIHRGRDYLRQHAGRLETSTDAGVVFEENFTQLIIYELTNDKSL
    ITTSNCARTWNFFRGKPLFSASFPDDMDTTSVALTVLRLDHALVNSVLDEMLKYVDADGIMQTYFDHTRPRMDPFVC
    VNVLSLFHEQGRGHELPNTLEWVHEVLLHRAYIGGSRYYLSADCFLFFMSRLLQRITDPSVLGRFRPLFIERVRERVGATG
    DSIDLAFRIIAASTVGIQCPRDLESLLAAQCEDGGWDLCWFYQYGSTGVKAGNRGLTTALAIKAIDSAIARPPSPALSVAS
    SSKSEIPKPIQRSLRPLSPRRFGGFLMPWRRSQRNGVAVSS
    - LoTps1 transcript (including non-coding sequence)
    SEQ ID NO: 6
    GCGTCTGCTGCGGTCTCTCACCGCGCCGAGCGACGGGAAGCGGAGGCTTTTTGATGCAGCCAGCTCAGCGCCATC
    CTCTCACGCAGGGGGTTTGATCCAGATCTGATCGCCTCCGGGTTCTCATCTAGAACGCACGGCGGCTCCCAGGAA
    GTTCTATCGACCCTCTGCGCGCTGGTCGGCGGCACGATGTGGCTACACCAGTCCCAATCATATCTCACACCCAGCA
    CCATCATCTCGGGCCTCTTCGTCATGTAACCCTCCCAAGCCTATTTTTCAGGGCGTTCCCCCTCACCGGCGCGCTTCT
    TAAAGAATCCCGAAATGTATACGGCTCTTATCCTTGACCTCGGCGACGTTCTGTTCTCTTGGTCGTCGACGACCAAC
    ACGACTATTCCCCCTCGGCAGCTAAAGGAGATCCTCTCATCTCCTGCCTGGTTTGAGTACGAGCGTGGTCGCATAA
    CGCAAGCCGAATGCTACGAGCGTGTCAGCGCCGAGTTCAGCCTAGACGCCACCGCCGTCGCGGAAGCATTCCGGC
    AAGCTCGCGACTCCTTGCGCCCGAACGACAAGTTCCTCACGTTAATTCGCGAGCTTCGACAACAATCTCATGGGGA
    GCTCACGGTGCTTGCGCTGTCCAACATATCCCTTCCCGACTATGAATTCATCATGGCCCTCGACTCGAAGTGGACTT
    CTGTCTTTGACCGCGTCTTCCCTTCTGCCCTCGTGGGCGAACGGAAGCCACACCTTGGAGCGTTTCGCCAGGTTCT
    GTCCGAGATGAATCTTGACCCGCACACAACTGTGTTCGTCGATGACAAGCTGGACAATGTCGTCTCCGCACGGTCC
    CTCGGGATGCACGGCGTCGTGTTCGACTCCCAAGACAATGTCTTTCGGATGCTGAGAAACATCTTTGGCGATCCCA
    TTCATCGGGGACGTGACTATCTCCGACAGCACGCCGGACGTCTGGAGACCTCCACGGATGCCGGTGTGGTCTTCG
    AAGAGAATTTCACGCAACTCATCATCTACGAACTGACGAATGACAAGTCTCTCATCACGACATCAAACTGTGCTCG
    TACTTGGAATTTCTTTCGTGGGAAGCCTTTGTTCTCAGCATCGTTCCCTGACGACATGGACACGACCTCGGTTGCCT
    TGACTGTATTACGTTTAGACCACGCCCTCGTGAACTCGGTTTTGGACGAGATGCTAAAGTATGTCGACGCAGACGG
    CATCATGCAGACCTACTTCGACCATACACGCCCACGCATGGATCCATTTGTCTGCGTCAATGTGCTCTCGTTGTTTC
    ACGAACAAGGTCGTGGCCACGAGCTTCCGAACACCCTCGAATGGGTCCATGAGGTCCTCCTCCACCGCGCGTACA
    TCGGGGGCTCGCGGTACTACCTCTCCGCGGACTGCTTCCTCTTTTTCATGAGCCGCCTCCTGCAGCGCATCACCGAC
    CCGTCCGTCCTTGGCCGCTTCCGTCCACTATTCATAGAGCGCGTTCGGGAGCGTGTAGGTGCGACCGGGGACTCCA
    TCGATCTCGCATTCCGCATCATCGCCGCGTCCACAGTAGGCATCCAGTGTCCACGCGACTTGGAAAGTCTCCTCGC
    CGCACAGTGTGAAGACGGTGGCTGGGACCTGTGCTGGTTCTACCAGTACGGATCGACCGGTGTCAAGGCGGGCA
    ACCGCGGGCTCACCACCGCTCTGGCGATCAAAGCTATTGACTCCGCCATTGCGAGGCCACCTTCGCCTGCCCTCTC
    AGTCGCTTCGTCGTCCAAATCGGAGATACCGAAACCCATACAACGGTCCCTTAGGCCCCTTAGCCCCCGCCGGTTT
    GGCGGTTTCCTGATGCCGTGGCGCAGGTCACAGCGCAATGGCGTGGCGGTCTCTAGTTGAACACTTGACCCTTGA
    CACTTCGCTTTGCACTGCCTGCTCCCCTGCCAATCCTCCCCTACGATCGTATCATCCCTCTCTTGCCCTCGCCTCCCCC
    TCGTACCCCCTCTCATGGGGTGCCATTTGTAGATATGTACGTAGCGTGATGTAGCGGTACTCGGATCGTTCTCGTA
    CTCGTCTTGCTCTGCCGTCGCTTCCAGCCCGTGCTGTTCTCTCGTTCAGGCTATTCGTTGGTTACGCGTATATCGTAA
    TAGACCGCCCCGGTTCCTCGCCTACAGACACTCGCCCGTCTCGCCACGGACTCGGCTACGGATTCAGACTACATGA
    GTGGCAGTTATCACACGCAGATCCCTCCTTGGTCGTTCTGTAGTACCCACATATGTAATTGTACCAGTCCACTGTTG
    CAGATC
    - LoTps1 cDNA
    SEQ ID NO: 7
    ATGTATACGGCTCTTATCCTTGACCTCGGCGACGTTCTGTTCTCTTGGTCGTCGACGACCAACACGACTATTCCCCCT
    CGGCAGCTAAAGGAGATCCTCTCATCTCCTGCCTGGTTTGAGTACGAGCGTGGTCGCATAACGCAAGCCGAATGC
    TACGAGCGTGTCAGCGCCGAGTTCAGCCTAGACGCCACCGCCGTCGCGGAAGCATTCCGGCAAGCTCGCGACTCC
    TTGCGCCCGAACGACAAGTTCCTCACGTTAATTCGCGAGCTTCGACAACAATCTCATGGGGAGCTCACGGTGCTTG
    CGCTGTCCAACATATCCCTTCCCGACTATGAATTCATCATGGCCCTCGACTCGAAGTGGACTTCTGTCTTTGACCGC
    GTCTTCCCTTCTGCCCTCGTGGGCGAACGGAAGCCACACCTTGGAGCGTTTCGCCAGGTTCTGTCCGAGATGAATC
    TTGACCCGCACACAACTGTGTTCGTCGATGACAAGCTGGACAATGTCGTCTCCGCACGGTCCCTCGGGATGCACGG
    CGTCGTGTTCGACTCCCAAGACAATGTCTTTCGGATGCTGAGAAACATCTTTGGCGATCCCATTCATCGGGGACGT
    GACTATCTCCGACAGCACGCCGGACGTCTGGAGACCTCCACGGATGCCGGTGTGGTCTTCGAAGAGAATTTCACG
    CAACTCATCATCTACGAACTGACGAATGACAAGTCTCTCATCACGACATCAAACTGTGCTCGTACTTGGAATTTCTT
    TCGTGGGAAGCCTTTGTTCTCAGCATCGTTCCCTGACGACATGGACACGACCTCGGTTGCCTTGACTGTATTACGTT
    TAGACCACGCCCTCGTGAACTCGGTTTTGGACGAGATGCTAAAGTATGTCGACGCAGACGGCATCATGCAGACCT
    ACTTCGACCATACACGCCCACGCATGGATCCATTTGTCTGCGTCAATGTGCTCTCGTTGTTTCACGAACAAGGTCGT
    GGCCACGAGCTTCCGAACACCCTCGAATGGGTCCATGAGGTCCTCCTCCACCGCGCGTACATCGGGGGCTCGCGG
    TACTACCTCTCCGCGGACTGCTTCCTCTTTTTCATGAGCCGCCTCCTGCAGCGCATCACCGACCCGTCCGTCCTTGGC
    CGCTTCCGTCCACTATTCATAGAGCGCGTTCGGGAGCGTGTAGGTGCGACCGGGGACTCCATCGATCTCGCATTCC
    GCATCATCGCCGCGTCCACAGTAGGCATCCAGTGTCCACGCGACTTGGAAAGTCTCCTCGCCGCACAGTGTGAAG
    ACGGTGGCTGGGACCTGTGCTGGTTCTACCAGTACGGATCGACCGGTGTCAAGGCGGGCAACCGCGGGCTCACC
    ACCGCTCTGGCGATCAAAGCTATTGACTCCGCCATTGCGAGGCCACCTTCGCCTGCCCTCTCAGTCGCTTCGTCGTC
    CAAATCGGAGATACCGAAACCCATACAACGGTCCCTTAGGCCCCTTAGCCCCCGCCGGTTTGGCGGTTTCCTGATG
    CCGTGGCGCAGGTCACAGCGCAATGGCGTGGCGGTCTCTAGTTGA
    - LoTps1 optimized cDNA
    SEQ ID NO: 8
    ATGTACACGGCGCTGATTTTGGATTTGGGTGATGTTCTGTTTAGCTGGAGCTCAACGACTAACACCACCATTCCGC
    CGCGTCAGCTGAAAGAAATCTTGAGCTCCCCGGCGTGGTTCGAGTACGAGCGTGGCCGTATCACCCAGGCAGAGT
    GTTATGAGCGTGTCAGCGCAGAGTTTAGCCTGGATGCGACGGCCGTGGCTGAGGCTTTTCGTCAGGCACGTGATA
    GCCTGCGTCCGAACGACAAATTTCTGACCCTGATCCGTGAGCTGCGTCAACAGAGCCACGGTGAATTGACCGTTCT
    GGCCTTGTCTAACATCAGCCTGCCGGATTACGAATTTATTATGGCACTGGACTCGAAGTGGACCAGCGTGTTTGAT
    CGTGTGTTCCCGAGCGCCCTGGTGGGCGAACGCAAGCCGCACCTGGGCGCGTTCCGCCAAGTCCTGTCCGAGATG
    AATTTGGACCCGCATACCACCGTTTTTGTGGACGACAAACTGGACAATGTTGTCAGCGCACGCAGCCTGGGTATGC
    ACGGTGTCGTGTTCGACAGCCAAGACAATGTTTTTCGTATGCTGCGTAACATTTTCGGTGACCCAATTCACCGCGG
    TCGTGACTATCTGCGCCAGCACGCTGGTCGTCTTGAAACGTCCACCGATGCGGGCGTTGTGTTCGAAGAGAACTTC
    ACCCAACTGATCATTTACGAACTGACCAACGATAAGAGCCTGATCACCACCTCTAATTGCGCCCGCACCTGGAACTT
    CTTCCGCGGCAAACCTCTGTTCTCCGCGAGCTTTCCGGACGATATGGACACTACGTCGGTAGCGCTGACCGTGCTG
    CGTCTGGACCATGCGCTGGTGAATAGCGTTCTGGATGAAATGCTGAAATACGTCGATGCTGACGGTATTATGCAG
    ACCTACTTTGATCATACGCGTCCTCGTATGGACCCGTTCGTTTGCGTCAATGTGCTGAGCCTGTTTCACGAGCAAGG
    TCGCGGTCATGAACTGCCGAATACGCTGGAATGGGTGCATGAAGTCCTGCTGCACCGTGCGTATATCGGTGGCAG
    CCGCTATTATCTGAGCGCGGATTGTTTCCTGTTCTTTATGAGCCGTCTGTTGCAACGTATTACCGACCCGAGCGTTT
    TAGGTAGATTTCGCCCGCTGTTCATCGAGCGTGTTCGCGAGCGCGTTGGCGCGACTGGCGACAGCATCGACCTGG
    CATTCCGTATCATCGCGGCCAGCACGGTCGGCATTCAATGCCCGCGTGACCTGGAGTCTCTGCTGGCAGCACAGTG
    CGAAGATGGTGGCTGGGATCTGTGTTGGTTTTACCAGTACGGCAGCACGGGTGTTAAGGCCGGTAACCGTGGTCT
    GACCACGGCGTTGGCGATCAAAGCGATTGACAGCGCCATCGCGCGTCCGCCAAGCCCGGCCCTGTCCGTTGCAAG
    CTCCAGCAAGAGCGAGATTCCGAAGCCGATTCAGCGTAGCCTCCGCCCGTTGAGCCCGCGTCGCTTCGGTGGCTTC
    CTGATGCCGTGGCGTCGTAGCCAACGCAATGGTGTCGCGGTGAGCTCTTAA
    OCH93767.1
    - OCH93767.1 protein
    SEQ ID NO: 9
    MSAAVRYTTLILDLGDVLFTWSPKTKTSISPRILKEILNSATWYEYERGSITQHECYERVGVEFGIAPSEIHNAFKQARDSM
    ESNDELIALVRELKEQSDGELLVFALSNISLPDYEYVLTKPADWSIFDKVFPSALVGERKPHLGIYKHVIAETGVDPRTTVFV
    DDKIDNVLSARSLGMHGIVFDKHEDVMRALRNIFGDPVRRGREYLRRNARKLESITDHGVAFGENFTQLLILELTSDASL
    VTLPDRPRTWNFFRGKPLFSEAFPDDLDTTSLALTVLKRDAATVSSVMDEMLKYRDADGIMQTYFDNGRQRLDPFVN
    ANVLTLFYANGRGHELDQSLSWVREVLLYRAYLGGSRYYPSADCFLYFISRLFACTSDPVLHHQLKPLFVERVHERIGVQ
    GDALELAFRLLVCASFNISNQPDMRKLLEMQCQDGGWDGGNLYRFGTTGLKVTNRGLTTAAAVQAIEATQLRPPSPA
    FSVESPKSPVTPVTPMLEIPALGLSISRPSSPLLGYFKLPWKKSAEVH
    - OCH93767.1 cDNA
    SEQ ID NO: 10
    ATGTCCGCAGCAGTTCGGTACACGACCCTCATCCTCGACCTTGGCGACGTCTTGTTCACTTGGTCACCGAAGACGA
    AGACCAGCATCTCGCCTCGTATTCTGAAGGAGATCCTGAATTCCGCGACCTGGTATGAGTACGAGCGCGGTAGTA
    TCACTCAGCACGAATGTTACGAACGCGTTGGCGTGGAGTTCGGTATTGCGCCGAGCGAGATCCACAACGCGTTCA
    AGCAGGCTCGGGACTCTATGGAGTCGAATGACGAGCTGATCGCCCTTGTTCGGGAACTGAAGGAGCAGTCAGAT
    GGAGAGCTTCTCGTCTTCGCATTATCGAACATCTCACTGCCGGACTACGAATACGTCCTGACGAAGCCCGCGGACT
    GGTCCATCTTCGACAAAGTCTTTCCTTCCGCTCTCGTCGGCGAGCGCAAGCCCCATCTCGGCATCTACAAACACGTC
    ATCGCAGAGACGGGCGTTGATCCGCGAACAACCGTCTTCGTGGACGACAAGATCGACAATGTGCTTTCGGCGCGG
    TCGCTCGGTATGCACGGCATTGTCTTCGACAAACACGAAGACGTAATGCGCGCTCTGCGAAACATTTTCGGTGACC
    CCGTGCGAAGAGGACGAGAATATTTGCGTCGAAATGCAAGGAAATTGGAATCCATCACAGATCACGGCGTCGCCT
    TCGGGGAGAACTTCACCCAGCTTCTGATCCTCGAACTTACTAGTGATGCGTCCCTCGTTACTCTCCCTGATCGTCCT
    CGGACATGGAATTTTTTCCGAGGGAAGCCGCTCTTTTCGGAGGCCTTCCCCGATGACCTTGATACTACTTCCTTGGC
    ACTCACTGTCCTGAAAAGAGATGCCGCCACTGTATCGTCCGTGATGGACGAGATGCTGAAATACAGGGACGCGGA
    CGGCATCATGCAGACATACTTCGACAACGGTCGGCAACGACTCGATCCGTTCGTCAACGCCAACGTTTTGACCCTC
    TTCTACGCCAACGGTCGCGGACACGAGCTGGATCAGAGCCTCAGCTGGGTTCGCGAAGTCTTGCTCTACCGCGCTT
    ACCTCGGCGGTTCCCGCTACTACCCCTCCGCCGACTGCTTCCTATATTTCATCAGCCGCCTCTTCGCCTGCACCAGCG
    ACCCGGTCCTCCATCATCAACTTAAGCCCCTCTTTGTTGAGCGTGTGCACGAGCGGATAGGAGTGCAGGGCGACG
    CGCTGGAGCTCGCCTTCCGCCTGCTTGTATGCGCGAGCTTCAACATCTCGAACCAGCCTGACATGCGCAAGCTGCT
    CGAGATGCAGTGCCAGGACGGAGGCTGGGATGGCGGAAACCTGTATCGTTTCGGCACCACGGGCCTCAAGGTCA
    CGAACCGGGGTCTGACCACCGCAGCAGCCGTGCAAGCCATCGAGGCGACGCAGCTGCGTCCACCATCACCGGCG
    TTCTCTGTCGAGTCGCCTAAGAGCCCGGTGACGCCGGTGACGCCCATGCTGGAGATTCCAGCGCTGGGTCTCAGC
    ATCTCGCGGCCCTCCAGTCCTCTGTTGGGGTATTTCAAGCTCCCGTGGAAGAAGTCAGCCGAGGTTCATTGA
    - OCH93767 optimized cDNA
    SEQ ID NO: 11
    ATGTCTGCAGCTGTTCGTTATACTACTCTGATCCTGGATTTGGGCGATGTTCTGTTCACCTGGTCCCCGAAAACCAA
    GACCTCTATCAGCCCACGTATCCTGAAAGAAATCCTGAACAGCGCGACCTGGTACGAGTATGAGCGTGGCAGCAT
    CACCCAGCACGAGTGCTACGAGCGTGTTGGCGTCGAATTTGGTATTGCGCCGAGCGAGATTCACAACGCGTTCAA
    ACAAGCCCGCGACAGCATGGAATCCAACGACGAACTGATTGCTCTGGTGCGTGAGCTGAAAGAACAGAGCGATG
    GTGAGCTGCTGGTCTTTGCCCTGAGCAATATCTCTCTGCCGGATTACGAATACGTTCTGACCAAACCAGCGGACTG
    GTCAATCTTCGATAAAGTCTTTCCGAGCGCTTTGGTCGGTGAGCGTAAACCGCATCTGGGTATTTACAAACACGTT
    ATTGCGGAAACCGGTGTTGACCCGAGAACGACCGTTTTTGTTGACGATAAGATTGACAACGTCCTGAGCGCACGC
    AGCCTGGGTATGCATGGTATTGTCTTTGATAAACACGAAGATGTGATGCGTGCTCTGCGCAATATCTTTGGCGACC
    CGGTGCGTCGCGGTCGTGAGTATTTGCGCCGCAACGCGCGCAAATTGGAGTCCATTACCGATCATGGTGTCGCAT
    TTGGTGAGAATTTCACCCAGCTCCTGATTCTGGAACTGACCAGCGACGCGTCCCTGGTGACGCTGCCGGATCGTCC
    GCGTACGTGGAACTTCTTCCGCGGCAAGCCGCTGTTTAGCGAAGCGTTCCCGGATGACCTGGACACCACGAGCCT
    GGCACTGACGGTGCTGAAACGCGATGCAGCAACTGTGAGCTCCGTCATGGACGAAATGCTGAAGTACCGCGACG
    CGGATGGCATCATGCAGACGTATTTCGACAACGGTCGTCAGCGTCTGGACCCGTTTGTCAACGCCAATGTTCTGAC
    GCTGTTTTACGCGAATGGCCGTGGTCATGAACTGGACCAGAGCTTATCATGGGTGCGTGAAGTGCTGCTGTATCG
    CGCCTATCTGGGTGGCAGCCGCTACTATCCGAGCGCGGACTGTTTTCTGTACTTCATTAGCCGCTTGTTCGCCTGCA
    CCAGCGATCCGGTTCTGCATCACCAACTGAAGCCATTGTTCGTCGAGCGTGTGCACGAGCGTATTGGTGTTCAGGG
    CGACGCACTGGAACTGGCGTTCCGTCTGTTGGTGTGTGCGAGCTTCAACATTAGCAATCAGCCGGATATGCGTAA
    GCTGCTGGAAATGCAATGCCAAGATGGCGGCTGGGACGGTGGTAATCTGTACCGTTTTGGCACCACCGGTTTAAA
    AGTGACGAATCGTGGTTTGACCACCGCTGCGGCCGTTCAAGCAATTGAAGCAACGCAACTGCGTCCGCCGAGCCC
    AGCATTTAGCGTAGAGTCGCCTAAGAGCCCGGTTACGCCGGTGACGCCGATGCTGGAAATCCCGGCGCTGGGTCT
    GTCTATCAGCCGTCCGTCGAGCCCGCTGCTGGGCTATTTCAAGTTGCCGTGGAAGAAAAGCGCCGAAGTGCACTA
    A
    EMD37666.1
    - EMD37666.1 protein
    SEQ ID NO: 12
    MSAAAQYTTLILDLGDVLFTWSPKTKTSIPPRTLKEILNSATWYEYERGRISQDECYERVGTEFGIAPSEIDNAFKQARDS
    MESNDELIALVRELKTQLDGELLVFALSNISLPDYEYVLTKPADWSIFDKVFPSALVGERKPHLGVYKHVIAETGIDPRTTV
    FVDDKIDNVLSARSVGMHGIVFEKQEDVMRALRNIFGDPVRRGREYLRRNAMRLESVTDHGVAFGENFTQLLILELTN
    DPSLVTLPDRPRTWNFFRGNGGRPSKPLFSEAFPDDLDTTSLALTVLQRDPGVISSVMDEMLNYRDPDGIMQTYFDDG
    RQRLDPFVNVNVLTFFYTNGRGHELDQCLTWVREVLLYRAYLGGSRYYPSADCFLYFISRLFACTNDPVLHHQLKPLFVE
    RVQEQIGVEGDALELAFRLLVCASLDVQNAIDMRRLLEMQCEDGGWEGGNLYRFGTTGLKVTNRGLTTAAAVQAIEA
    SQRRPPSPSPSVESTKSPITPVTPMLEVPSLGLSISRPSSPLLGYFRLPWKKSAEVH
    - EMD37666.1 cDNA
    SEQ ID NO: 13
    ATGTCCGCGGCAGCTCAATACACGACCCTCATTCTCGACCTTGGCGACGTCCTGTTCACCTGGTCACCGAAAACCA
    AGACGAGCATCCCCCCTCGGACTCTGAAGGAGATTCTCAATTCCGCGACATGGTATGAGTATGAGCGCGGCCGCA
    TCTCTCAGGACGAATGTTACGAACGCGTTGGCACGGAGTTCGGAATCGCGCCTAGCGAAATCGACAACGCGTTCA
    AGCAAGCTCGGGATTCCATGGAATCCAACGACGAACTGATCGCCCTTGTTCGGGAACTCAAGACGCAGTTGGACG
    GCGAACTCCTTGTCTTCGCACTCTCAAATATCTCGTTGCCTGACTACGAGTACGTCCTCACGAAACCGGCCGACTGG
    TCCATCTTCGACAAGGTCTTCCCTTCCGCCCTCGTGGGCGAGCGCAAGCCGCACCTCGGCGTTTACAAGCACGTCA
    TTGCAGAAACGGGCATTGATCCGCGAACCACCGTTTTCGTGGACGACAAGATCGACAACGTGCTCTCAGCGCGGT
    CTGTAGGTATGCATGGGATCGTTTTCGAGAAGCAGGAAGACGTAATGCGCGCTCTCCGAAACATCTTCGGAGACC
    CGGTTCGGCGAGGGCGCGAGTACTTGCGCCGTAATGCCATGAGGCTTGAATCGGTTACAGACCATGGTGTGGCGT
    TTGGCGAGAACTTCACACAACTCCTTATCCTCGAACTAACGAACGATCCCTCCCTCGTTACGCTCCCTGATCGTCCTC
    GAACATGGAATTTCTTCCGAGGTAACGGGGGACGACCAAGCAAACCATTATTCTCGGAGGCCTTCCCCGATGACTT
    GGACACTACTTCACTAGCGTTGACTGTCCTCCAAAGAGATCCCGGCGTCATCTCTTCTGTGATGGACGAAATGTTG
    AACTACAGGGATCCGGACGGCATTATGCAGACATACTTCGACGATGGTCGGCAAAGACTCGATCCATTTGTCAAT
    GTCAATGTCTTAACGTTCTTCTACACCAACGGACGTGGTCATGAACTGGACCAATGCCTTACATGGGTCCGCGAAG
    TTTTGCTCTATCGCGCCTATCTCGGCGGCTCACGTTATTACCCCTCCGCCGACTGCTTTCTCTACTTCATCAGCCGCC
    TTTTCGCATGCACGAATGACCCCGTGCTACACCACCAACTCAAACCGCTCTTCGTCGAGCGCGTGCAGGAGCAAAT
    CGGCGTGGAGGGCGATGCGCTCGAGTTGGCGTTCCGATTGCTCGTCTGTGCAAGCCTGGACGTCCAAAACGCGAT
    CGACATGCGCAGGCTGCTCGAGATGCAATGCGAAGATGGCGGCTGGGAGGGCGGGAACCTTTATAGGTTTGGCA
    CGACCGGGCTCAAGGTGACTAACCGGGGCCTGACGACTGCAGCGGCCGTACAGGCCATCGAGGCGTCCCAACGG
    CGCCCACCATCACCGTCCCCCTCCGTCGAATCTACAAAGAGCCCAATAACCCCTGTGACGCCCATGCTGGAGGTCC
    CCTCGCTCGGCCTGAGCATCTCGAGGCCGTCCAGCCCTTTACTCGGCTACTTCAGGCTCCCGTGGAAGAAGTCGGC
    CGAAGTACACTGA
    - EMD37666.1 optimized cDNA
    SEQ ID NO: 14
    ATGTCTGCGGCGGCTCAATACACGACTTTGATTCTGGATCTGGGTGATGTTCTGTTCACTTGGTCCCCGAAAACCA
    AGACCAGCATCCCTCCGCGTACCCTGAAAGAAATCCTGAATAGCGCTACCTGGTATGAGTACGAGCGTGGTCGCA
    TTTCCCAAGACGAGTGTTACGAACGTGTGGGCACCGAGTTCGGCATTGCGCCGAGCGAGATTGACAACGCGTTCA
    AACAAGCGCGCGATTCGATGGAAAGCAATGATGAACTGATCGCACTGGTCCGTGAGCTGAAAACGCAGCTGGAC
    GGTGAGCTGCTGGTTTTCGCACTGTCCAATATTAGCCTGCCGGATTACGAATACGTCTTGACCAAACCGGCGGACT
    GGAGCATCTTTGACAAAGTGTTCCCTAGCGCCTTGGTGGGCGAGCGTAAGCCGCATCTGGGCGTTTATAAACACG
    TTATTGCGGAAACGGGCATTGATCCGCGCACGACGGTTTTCGTGGACGACAAGATTGACAATGTGTTAAGCGCAC
    GCAGCGTCGGTATGCATGGTATCGTGTTTGAGAAACAAGAAGATGTCATGCGTGCACTGCGTAACATCTTTGGTG
    ATCCGGTCCGTCGTGGTCGTGAGTATCTGCGTAGAAACGCAATGCGTCTGGAGTCCGTGACCGACCACGGCGTGG
    CGTTTGGTGAGAACTTTACCCAGTTGCTGATTCTGGAATTGACGAACGACCCGAGCCTGGTCACCCTGCCTGATCG
    TCCGCGTACCTGGAACTTTTTTCGCGGCAATGGTGGCCGCCCGAGCAAGCCGCTGTTCAGCGAAGCGTTCCCGGAT
    GATCTGGATACCACGAGCCTGGCGCTGACCGTGCTGCAGCGCGACCCGGGTGTTATCAGCAGCGTTATGGACGAA
    ATGCTGAATTACCGTGACCCGGACGGTATCATGCAGACTTATTTCGATGACGGTCGCCAACGCTTGGACCCATTTG
    TGAACGTCAATGTTCTGACCTTTTTCTATACGAACGGCCGTGGTCACGAACTGGACCAGTGTCTGACGTGGGTGCG
    TGAAGTCCTCTTGTATCGTGCGTACCTTGGTGGCTCACGCTACTACCCATCGGCGGATTGCTTCCTGTACTTCATCT
    CTCGTCTGTTTGCGTGTACCAATGACCCGGTGCTGCACCATCAGCTGAAGCCACTGTTTGTTGAGCGTGTCCAAGA
    GCAAATTGGTGTCGAGGGTGATGCACTGGAACTGGCTTTTCGTCTGCTGGTCTGCGCCAGCCTGGATGTCCAGAA
    TGCCATCGACATGCGCCGTCTGCTGGAAATGCAGTGCGAAGATGGCGGTTGGGAGGGTGGTAACCTCTACCGCTT
    CGGCACCACGGGCCTGAAAGTTACCAACCGCGGTCTGACGACCGCAGCCGCCGTTCAAGCGATCGAAGCGAGCC
    AACGCCGTCCGCCGAGCCCGAGCCCGTCTGTAGAGAGCACGAAAAGCCCGATTACCCCGGTGACCCCGATGCTGG
    AAGTTCCAAGCCTGGGCTTATCTATCAGCCGTCCGTCCAGCCCGCTGCTGGGTTATTTCCGTTTGCCGTGGAAGAA
    AAGCGCAGAAGTGCACTAA
    EMD37666-B
    - EMD37666-B protein
    SEQ ID NO: 15
    MSAAAQYTTLILDLGDVLFTWSPKTKTSIPPRTLKEILNSATWYEYERGRISQDECYERVGTEFGIAPSEIDNAFKQARDS
    MESNDELIALVRELKTQLDGELLVFALSNISLPDYEYVLTKPADWSIFDKVFPSALVGERKPHLGVYKHVIAETGIDPRTTV
    FVDDKIDNVLSARSVGMHGIVFEKQEDVMRALRNIFGDPVRRGREYLRRNAMRLESVTDHGVAFGENFTQLLILELTN
    DPSLVTLPDRPRTWNFFRGKPLFSEAFPDDLDTTSLALTVLQRDPGVISSVMDEMLNYRDPDGIMQTYFDDGRQRLDP
    FVNVNVLTFFYTNGRGHELDQCLTWVREVLLYRAYLGGSRYYPSADCFLYFISRLFACTNDPVLHHQLKPLFVERVQEQI
    GVEGDALELAFRLLVCASLDVQNAIDMRRLLEMQCEDGGWEGGNLYRFGTTGLKVTNRGLTTAAAVQAIEASQRRPP
    SPSPSVESTKSPITPVTPMLEVPSLGLSISRPSSPLLGYFRLPWKKSAEVH
    - EMD37666-B optimized cDNA
    SEQ ID NO: 16
    ATGTCTGCGGCTGCTCAATATACTACTTTGATTCTGGATCTGGGCGACGTTCTGTTCACGTGGAGCCCGAAAACCA
    AGACCAGCATTCCACCGCGTACCCTGAAGGAGATCCTCAATAGCGCGACTTGGTACGAGTATGAGCGTGGCCGCA
    TCAGCCAAGACGAGTGCTACGAACGCGTCGGTACGGAATTTGGCATTGCACCAAGCGAGATTGACAATGCGTTTA
    AACAAGCGCGTGACAGCATGGAAAGCAATGACGAACTGATCGCGCTGGTCCGTGAGCTGAAAACCCAGCTGGAT
    GGTGAGCTGTTGGTGTTTGCGCTGTCGAACATCTCTCTGCCGGACTACGAGTATGTTCTGACCAAACCGGCGGATT
    GGAGCATTTTTGATAAAGTGTTTCCGAGCGCGCTGGTTGGTGAGCGCAAGCCGCACCTGGGTGTGTACAAACACG
    TTATTGCAGAGACTGGCATCGACCCGCGTACGACGGTTTTCGTTGACGACAAGATCGATAACGTTCTGAGCGCAC
    GTAGCGTCGGTATGCACGGTATTGTTTTCGAAAAACAAGAAGATGTTATGCGCGCACTGCGTAATATCTTCGGCGA
    TCCGGTCAGACGTGGCCGTGAGTATCTGCGCCGCAATGCGATGCGTCTGGAATCGGTGACCGATCATGGTGTCGC
    CTTTGGCGAGAATTTCACCCAGCTGCTGATTTTAGAGCTGACCAATGATCCTAGCCTGGTGACGCTGCCGGATCGT
    CCGCGTACCTGGAACTTTTTCCGCGGCAAGCCGTTGTTCTCCGAAGCCTTCCCGGACGACCTGGACACGACCAGCC
    TGGCGCTGACCGTGCTGCAACGTGATCCGGGTGTGATCTCTTCCGTAATGGACGAAATGCTGAACTACCGTGACCC
    GGACGGTATCATGCAGACCTATTTTGACGACGGTCGTCAGCGTCTGGACCCGTTTGTGAACGTGAATGTCCTGACG
    TTCTTTTACACCAATGGTCGCGGTCACGAACTGGATCAGTGTCTGACCTGGGTCCGCGAAGTGCTGCTGTATCGTG
    CATACCTGGGTGGCAGCCGTTATTACCCGAGCGCCGATTGCTTTCTGTACTTTATCAGCCGTCTGTTCGCGTGCACG
    AACGATCCGGTTCTGCATCACCAGCTGAAGCCGTTATTTGTTGAGCGCGTTCAGGAACAAATTGGTGTCGAGGGT
    GATGCGCTGGAATTGGCATTCCGCCTGTTGGTCTGCGCCAGCCTTGATGTCCAGAACGCCATTGACATGCGTCGCT
    TGCTCGAAATGCAGTGTGAGGACGGCGGTTGGGAGGGTGGCAACCTGTACCGTTTCGGTACGACCGGCCTGAAA
    GTCACGAACCGTGGTCTGACGACGGCAGCTGCGGTGCAAGCAATTGAAGCCAGCCAACGTCGTCCGCCATCCCCG
    TCACCGAGCGTTGAGTCCACCAAGAGCCCGATTACCCCTGTGACCCCGATGCTTGAAGTTCCGAGCCTGGGTCTGA
    GCATCTCCCGTCCTAGCAGCCCGCTGTTGGGTTACTTCCGCCTGCCGTGGAAGAAAAGCGCTGAGGTGCATTAA
    XP_001217376.1
    - XP_001217376.1 protein
    SEQ ID NO: 17
    MAITKGPVKALILDFSNVLCSWKPPSNVAVPPQILKMIMSSDIWHDYECGRYSREDCYARVADRFHISAADMEDTLKQ
    ARKSLQVHHETLLFIQQVKKDAGGELMVCGMTNTPRPEQDVMHSINAEYPVFDRIYISGLMGMRKPSICFYQRVMEEI
    GLSGDAIMFIDDKLENVIAAQSVGIRGVLFQSQQDLRRVVLNFLGDPVHRGLQFLAANAKKMDSVTNTGDTIQDNFA
    QLLILELAQDRELVKLQAGKRTWNYFIGPPKLTTATFPDDMDTTSMALSVLPVAEDVVSSVLDEMLKFVTDDGIFMTYF
    DSSRPRVDPVVCINVLGVFCRHNRERDVLPTFHWIRDILINRAYLSGTRYYPSPDLFLFFLARLCLAVRNQSLREQLVLPLV
    DRLRERVGAPGEAVSLAARILACRSFGIDSARDMDSLRGKQCEDGGWPVEWVYRFASFGLNVGNRGLATAFAVRALE
    SPYGESAVKVMRRIV
    - XP_001217376.1 cDNA
    SEQ ID NO: 18
    ATGGCTATCACCAAGGGTCCAGTTAAGGCGCTTATTCTTGACTTTTCCAATGTTCTCTGCTCGTGGAAGCCTCCCAG
    CAATGTTGCGGTGCCGCCCCAGATACTCAAAATGATCATGTCCTCTGACATATGGCATGACTACGAGTGCGGACG
    GTACTCGAGAGAGGACTGCTATGCCAGAGTGGCAGACCGTTTTCATATCAGCGCCGCGGACATGGAAGACACGCT
    GAAACAGGCGCGCAAGAGCCTGCAGGTTCACCATGAGACACTGTTGTTTATCCAGCAAGTCAAGAAGGATGCCGG
    GGGCGAGTTGATGGTGTGTGGGATGACCAACACGCCCCGGCCAGAGCAAGACGTAATGCATTCAATCAACGCGG
    AGTATCCTGTGTTTGATAGGATATATATATCCGGTCTCATGGGCATGAGGAAGCCGAGCATCTGCTTCTACCAGCG
    GGTGATGGAGGAGATTGGCCTATCAGGCGATGCGATCATGTTTATAGATGACAAGTTGGAGAATGTCATCGCCGC
    CCAGTCGGTAGGGATCCGAGGCGTTCTATTTCAGAGTCAGCAAGATCTCCGTCGGGTTGTATTAAATTTCTTGGGC
    GATCCGGTCCATCGCGGCCTGCAGTTCCTAGCGGCCAATGCGAAAAAGATGGATAGTGTGACCAACACCGGCGAT
    ACTATCCAAGATAATTTTGCTCAGCTCCTCATCTTGGAGCTGGCCCAGGACAGGGAATTGGTGAAGCTTCAGGCTG
    GAAAAAGGACTTGGAATTACTTCATAGGGCCTCCCAAGCTCACAACAGCCACGTTCCCCGATGACATGGACACCAC
    ATCTATGGCTCTCTCGGTCCTTCCTGTGGCCGAGGATGTGGTCTCTTCTGTCCTGGATGAGATGCTTAAATTCGTCA
    CCGATGACGGTATCTTTATGACTTACTTCGATTCCTCGCGCCCTCGAGTCGACCCAGTCGTATGTATCAACGTCTTG
    GGTGTTTTCTGCAGGCATAACCGAGAGCGAGACGTCCTTCCAACGTTCCATTGGATTCGAGACATCCTGATCAACC
    GGGCATATCTCTCGGGCACCCGATACTACCCATCGCCCGATTTGTTTTTGTTTTTCCTTGCACGCCTCTGCCTGGCA
    GTCCGGAATCAGAGCCTACGGGAACAACTTGTCTTGCCTCTGGTAGACCGACTGCGTGAGCGGGTGGGCGCACCT
    GGAGAAGCGGTCTCATTGGCAGCGCGGATCCTTGCCTGCCGTAGCTTTGGTATCGACAGTGCGAGAGACATGGAC
    AGCTTGAGGGGAAAACAATGCGAGGATGGCGGCTGGCCAGTGGAGTGGGTTTACCGGTTTGCCTCTTTCGGCCT
    GAACGTAGGCAATCGGGGTCTTGCTACTGCCTTCGCGGTCAGGGCGCTCGAAAGCCCCTATGGTGAGTCGGCGGT
    GAAGGTTATGAGACGCATCGTCTGA
    - XP_001217376.1 optimized cDNA
    SEQ ID NO: 19
    ATGGCAATCACTAAGGGCCCAGTTAAAGCGCTGATTCTTGATTTTTCTAACGTTCTGTGTAGCTGGAAGCCGCCGA
    GCAATGTTGCGGTCCCGCCTCAAATTCTGAAGATGATTATGTCGAGCGACATCTGGCATGATTATGAGTGTGGCCG
    TTACAGCCGTGAGGACTGCTACGCCCGTGTTGCTGACCGTTTTCATATCAGCGCAGCGGACATGGAAGATACCCTG
    AAACAGGCACGTAAGTCCCTGCAAGTGCACCACGAAACGCTGCTGTTCATCCAACAGGTGAAGAAAGACGCGGGT
    GGTGAGCTGATGGTTTGCGGCATGACCAACACGCCGCGTCCGGAACAAGACGTGATGCATTCCATCAATGCTGAG
    TATCCGGTGTTCGACCGTATTTACATTAGCGGCCTGATGGGCATGCGTAAACCGAGCATTTGTTTCTACCAACGCG
    TAATGGAAGAGATTGGTCTGAGCGGTGACGCCATCATGTTCATTGACGATAAACTGGAAAATGTGATTGCCGCAC
    AGAGCGTGGGTATCCGCGGTGTGCTGTTCCAAAGCCAGCAAGATCTGCGTCGTGTCGTGCTGAACTTTCTGGGCG
    ATCCGGTCCACCGTGGTCTGCAGTTCTTGGCGGCGAACGCAAAGAAAATGGACAGCGTCACGAATACCGGCGACA
    CTATCCAAGACAATTTCGCACAGCTGTTGATCTTAGAGCTGGCGCAGGATCGCGAATTGGTGAAATTGCAGGCCG
    GTAAACGTACCTGGAACTACTTTATTGGTCCGCCGAAGCTGACCACGGCGACGTTTCCGGATGATATGGACACGA
    CCAGCATGGCGCTGTCGGTGCTGCCTGTCGCGGAAGATGTCGTGAGCTCTGTTCTGGACGAGATGCTGAAGTTCG
    TGACCGATGATGGTATCTTTATGACCTATTTCGACTCTAGCCGTCCGCGTGTCGATCCGGTTGTCTGCATTAATGTG
    TTGGGTGTTTTCTGCCGCCACAATCGTGAGCGCGACGTGTTGCCGACCTTTCACTGGATTCGTGATATTCTGATCAA
    CCGCGCATATCTGAGCGGCACGCGCTATTACCCGTCCCCGGATCTGTTTCTGTTTTTCCTGGCTCGTCTGTGCCTGG
    CCGTTCGCAACCAGAGCCTGCGCGAACAACTGGTTCTCCCGCTGGTTGATCGTCTGCGCGAGCGTGTTGGTGCTCC
    GGGTGAGGCTGTGAGCCTGGCGGCACGTATCCTGGCGTGCCGTAGCTTCGGTATCGACTCAGCCCGCGACATGGA
    CTCCTTGCGTGGCAAACAGTGTGAAGATGGTGGTTGGCCGGTCGAATGGGTCTATCGCTTCGCGAGCTTTGGTCT
    GAACGTTGGCAACCGTGGTTTGGCCACCGCGTTTGCGGTTAGAGCGCTGGAGTCCCCATACGGCGAGAGCGCAGT
    TAAGGTTATGCGCCGTATCGTGTAA
    OJJ98394.1
    - OJJ98394.1 protein
    SEQ ID NO: 20
    MPSVKALVLDFAGVLCSWTPPAESPLSPAQLKQLMSSEIWFEYERGRYSEEECYAKLVERFSISAADMASTMEQARQSL
    ELNHAVLQLVSEIRKRNPGLKVYGMTNTPHAEQDCVNRIVNSYPVFDHVYLSGLVGMRKPDLGFYRFVLAETGLRPDE
    VVFVDDKTENVLVAQSVGMHGVVFQNVTDFKQQIINVTGDPVSRGLRYLRSNAKSLLTVTSNNSVIHENFAQLLILELT
    GDRDLIELEPWDRTWNYFIGVPQSPTSTFPNDLDTTSIALSVLPIHKDVVADVMDEIMLLLDNDGIVPTYFDPTRPRVDP
    VVCVNVLSLFAQNGRESELLATFNWVLDVLRHRAYLQGTRYYISPDAFLYFLARLSVFLRMSPLRARLMPLLEERVYERIG
    AHGDAISLAMRIYTCKLLGMSNMLDERALRDMQCEDGGFPTSWVYRFGSTGVKIGNRGLTTALAIKAIEMPLASLWKS
    WGLTTDIR
    - OJJ98394.1 cDNA
    SEQ ID NO: 21
    ATGCCCTCCGTCAAAGCACTGGTCCTGGACTTCGCCGGAGTTCTATGCTCATGGACCCCGCCAGCCGAGAGCCCGC
    TCTCCCCAGCCCAGCTCAAACAACTCATGTCCTCCGAGATATGGTTCGAATACGAGCGCGGGAGATATTCCGAAGA
    AGAATGTTATGCGAAGCTCGTCGAACGGTTCTCCATCAGCGCTGCGGACATGGCTTCCACCATGGAACAGGCCCG
    TCAGAGCCTGGAACTGAACCACGCCGTACTTCAGCTTGTCAGCGAGATAAGGAAGCGGAACCCCGGGCTCAAAGT
    TTATGGCATGACGAACACGCCCCATGCGGAACAGGATTGTGTGAATCGCATCGTGAACAGCTATCCTGTTTTCGAC
    CATGTGTATCTCTCCGGGCTCGTTGGGATGCGCAAACCAGATCTTGGATTCTATCGGTTTGTTCTCGCAGAGACCG
    GGTTGAGGCCTGACGAGGTCGTGTTCGTCGACGACAAAACGGAGAATGTGTTGGTCGCGCAGTCCGTGGGGATG
    CACGGCGTGGTGTTCCAGAACGTTACGGATTTCAAGCAGCAGATCATAAACGTGACGGGAGACCCTGTCTCTCGG
    GGCTTGAGGTATCTCCGCTCGAATGCAAAGAGCCTCCTCACTGTGACTAGCAATAACTCCGTGATCCACGAAAACT
    TTGCGCAGTTGCTGATTCTGGAGCTGACGGGCGACCGAGACTTGATCGAACTCGAGCCTTGGGATCGAACATGGA
    ACTACTTCATCGGGGTTCCTCAGTCGCCGACGAGCACCTTCCCCAACGACCTGGACACCACCTCTATCGCGCTCTCG
    GTCCTTCCCATTCATAAGGACGTCGTTGCCGATGTGATGGACGAGATTATGCTTCTCCTAGACAACGACGGGATAG
    TCCCAACATATTTTGATCCCACTCGCCCTCGAGTCGACCCAGTCGTGTGTGTGAATGTACTCAGCCTGTTTGCCCAA
    AACGGCCGAGAATCCGAGTTACTCGCCACCTTCAACTGGGTGCTGGACGTGCTGCGACATAGAGCCTACCTGCAG
    GGCACGAGATATTACATCAGTCCGGACGCCTTCTTGTACTTTCTAGCCAGACTCTCGGTCTTTCTGAGGATGAGTCC
    ACTCCGCGCTCGGCTAATGCCTCTCCTGGAAGAAAGAGTGTATGAGCGAATTGGTGCCCATGGCGACGCCATTTC
    GCTGGCTATGCGGATCTATACGTGTAAGCTGCTCGGGATGTCGAATATGCTCGATGAAAGAGCATTGCGGGACAT
    GCAGTGTGAGGATGGCGGCTTCCCTACAAGTTGGGTCTATAGATTTGGATCGACCGGAGTGAAGATTGGGAACA
    GGGGGTTGACTACTGCACTTGCAATAAAGGCCATTGAGATGCCTCTCGCTTCGCTTTGGAAGTCGTGGGGATTGA
    CGACTGACATTCGATAA
    - OJJ98394.1 optimized cDNA
    SEQ ID NO: 22
    ATGCCGTCGGTTAAAGCGTTGGTTCTGGATTTTGCGGGTGTGTTGTGTTCTTGGACTCCACCGGCGGAAAGCCCGT
    TGTCCCCAGCGCAGCTGAAGCAGCTGATGAGCAGCGAGATCTGGTTTGAGTATGAGCGTGGCCGCTATAGCGAA
    GAAGAGTGTTATGCAAAATTGGTGGAGCGTTTCTCTATCTCGGCCGCAGATATGGCGAGCACGATGGAACAGGCC
    CGTCAATCGCTGGAGTTGAACCACGCCGTGCTGCAATTAGTTTCCGAGATTCGTAAACGTAATCCGGGCTTAAAGG
    TTTACGGTATGACTAATACCCCGCATGCAGAGCAAGATTGTGTGAACCGTATTGTCAATAGCTATCCGGTTTTTGAT
    CATGTCTACCTGAGCGGTCTGGTGGGTATGCGCAAACCGGATCTGGGCTTTTACCGTTTCGTTCTGGCAGAGACTG
    GTCTGCGCCCGGATGAAGTCGTGTTCGTTGACGACAAGACCGAAAATGTCCTGGTGGCTCAATCCGTTGGCATGC
    ATGGTGTGGTGTTCCAAAATGTAACCGACTTCAAACAACAGATTATCAATGTCACGGGTGATCCTGTCAGCCGTGG
    TTTGCGCTACTTGCGTTCCAACGCGAAGTCTCTGCTCACTGTTACCAGCAATAACAGCGTTATCCATGAGAATTTCG
    CGCAGCTGCTGATCCTGGAACTGACGGGCGACCGTGACCTGATTGAACTGGAACCGTGGGACCGTACGTGGAACT
    ACTTTATCGGCGTGCCGCAAAGCCCGACCAGCACCTTTCCGAACGACCTGGATACGACCAGCATTGCCCTGAGCGT
    TCTGCCGATTCACAAAGATGTGGTTGCGGACGTGATGGATGAGATTATGCTGCTGCTGGACAATGACGGTATTGT
    CCCGACCTACTTCGATCCAACCCGTCCGCGTGTTGATCCTGTTGTGTGCGTCAACGTTCTGAGCCTGTTCGCACAGA
    ACGGTCGCGAGTCCGAATTGCTGGCGACGTTCAACTGGGTTTTGGACGTTCTGAGACACCGTGCGTATTTGCAGG
    GTACGCGCTATTATATCAGCCCGGATGCCTTTCTGTATTTTCTGGCGCGCCTGTCTGTGTTTCTGCGTATGTCTCCGT
    TGCGCGCTCGTCTGATGCCGCTGCTGGAAGAACGCGTTTATGAGCGTATCGGCGCACACGGCGATGCTATTAGCC
    TGGCGATGCGCATTTACACCTGTAAGCTGCTGGGCATGAGCAATATGCTGGACGAGCGTGCACTGCGTGACATGC
    AGTGTGAAGATGGTGGTTTCCCAACCAGCTGGGTGTACCGTTTTGGTAGCACGGGCGTGAAAATTGGTAACCGTG
    GCTTGACGACCGCACTGGCCATTAAGGCCATCGAAATGCCGCTGGCCAGCCTTTGGAAAAGCTGGGGCCTGACCA
    CCGATATTCGCTAA
    GAO87501.1
    - GAO87501.1 protein
    SEQ ID NO: 23
    MTRQKSPQYKAIIFDLGDVFFTWDAPKDTAVLPNLFKKMLTSPTWSDYERGKLSEESCYERLAEQFDVDSSEIARSLRKA
    QQSLTTDAAIVSLISEIRALAGHIAIYAMSNISAPAYAAVLQTQPEMGIFDGVFPSGCYGTRKPELLFYKKVLQEIAVPPNQ
    IIFIDDQLENVVSAQSTGMHGIVYTGAGELSRQLRNLVLDPVQRGREFLRRNAGALYSICETGQVIRENFSQLLILEATGD
    RSLVNLEYQQRSWNFFQGGPPSTSETFPDDVDTTSIALMILPADDNTVNSVLGEISEVANDEGIVNTYFDQTRQRIDPA
    VCVNVLRLFYTYGRGATLPLTLQWVSDVLEHRAHLHGTRYYPSPEVFLYFVSQLCRFSKREPTLQLLETLLTDRLKERIQVK
    ADTLSLAMRILACLSVGISQVEVDVRELLALQCKDGSWEPGSFYRFGSSKMNVGNRGLTTALATRAVELYQGTRIRSKG
    TE
    - GAO87501.1 cDNA
    SEQ ID NO: 24
    ATGACCCGACAGAAATCGCCTCAATACAAAGCAATCATCTTTGACCTAGGGGATGTCTTTTTCACCTGGGACGCCC
    CCAAAGACACTGCTGTCTTGCCCAACCTCTTCAAGAAAATGCTTACCTCGCCAACCTGGTCAGATTACGAGCGCGG
    CAAGTTGAGCGAAGAAAGCTGCTACGAGAGACTGGCCGAACAGTTTGACGTTGACTCGTCGGAAATCGCGCGCA
    GCTTAAGGAAAGCACAGCAGTCTCTTACCACAGACGCAGCAATCGTGAGCCTGATATCAGAGATCAGAGCGTTGG
    CCGGACATATTGCCATCTACGCCATGTCCAACATTTCCGCCCCAGCTTATGCAGCTGTGCTCCAGACTCAGCCCGAA
    ATGGGCATCTTTGACGGAGTGTTCCCGTCTGGATGCTATGGGACGAGGAAGCCGGAGCTGTTGTTCTATAAGAAA
    GTCTTGCAGGAGATTGCAGTGCCGCCAAATCAGATCATCTTTATTGATGATCAGCTAGAGAATGTAGTTTCTGCGC
    AGTCAACAGGTATGCACGGCATTGTCTACACCGGTGCGGGTGAGCTCAGTCGACAGCTCAGAAATCTGGTGTTGG
    ACCCTGTACAAAGGGGTCGAGAGTTTCTACGGCGCAATGCTGGGGCATTGTATAGTATCTGCGAGACTGGTCAAG
    TCATCCGGGAAAACTTCTCGCAGCTGCTCATCCTAGAGGCGACGGGTGATAGAAGCCTGGTCAACCTTGAATATCA
    GCAGCGGAGCTGGAATTTCTTTCAAGGAGGTCCCCCTTCTACGTCGGAAACATTCCCAGATGATGTCGACACAACA
    TCCATTGCCTTGATGATTCTCCCTGCCGATGATAACACAGTCAACTCGGTTCTCGGCGAGATTTCCGAGGTAGCTAA
    TGACGAGGGCATTGTAAATACGTACTTTGACCAGACCCGACAGCGAATCGACCCAGCAGTCTGCGTCAATGTCCTC
    CGTCTCTTTTATACCTACGGCCGGGGCGCCACTCTCCCATTGACCCTCCAGTGGGTGTCCGACGTTCTTGAGCATCG
    TGCGCACTTACATGGTACGCGATACTACCCCAGCCCGGAGGTTTTCCTCTACTTTGTCAGTCAACTCTGCCGGTTCT
    CCAAGAGGGAACCGACGCTGCAGCTGCTGGAGACGTTGCTCACGGATCGCCTCAAGGAGCGCATTCAGGTCAAG
    GCAGACACTCTGTCACTGGCTATGCGGATCCTGGCATGCTTGTCTGTGGGTATATCACAAGTTGAAGTGGATGTCC
    GAGAGCTGCTCGCCTTGCAATGCAAGGATGGATCGTGGGAACCCGGCTCGTTTTACCGGTTTGGGTCGTCCAAGA
    TGAACGTTGGTAATCGAGGTCTTACGACTGCGTTGGCGACTAGGGCGGTTGAGTTGTACCAGGGGACTAGAATAC
    GCTCTAAGGGCACCGAGTAG
    - GAO87501.1 optimized cDNA
    SEQ ID NO: 25
    ATGACTCGCCAAAAAAGCCCTCAATACAAAGCAATTATCTTCGATCTGGGTGACGTTTTCTTCACCTGGGATGCGC
    CGAAAGATACGGCCGTACTGCCGAACCTGTTCAAGAAAATGCTGACCTCGCCGACCTGGAGCGACTATGAGCGTG
    GTAAGCTGTCTGAGGAAAGCTGTTACGAACGCTTGGCCGAGCAATTTGACGTGGACAGCAGCGAGATCGCGCGT
    AGCCTCCGTAAAGCGCAGCAAAGCCTGACGACCGACGCAGCCATCGTGAGCCTGATCAGCGAGATCCGCGCATTG
    GCGGGTCACATTGCTATCTATGCTATGTCTAACATTTCTGCGCCAGCATACGCAGCGGTGTTACAGACCCAGCCGG
    AAATGGGTATCTTTGATGGTGTTTTTCCGAGCGGCTGCTATGGTACGCGTAAACCGGAACTGCTGTTTTACAAAAA
    AGTGCTTCAAGAAATTGCGGTTCCGCCGAATCAGATTATCTTCATTGACGATCAGCTGGAAAACGTCGTCAGCGCA
    CAGTCCACGGGCATGCATGGCATTGTTTACACCGGTGCCGGTGAGCTGAGCCGTCAACTGCGTAATCTGGTCCTG
    GACCCGGTGCAGCGTGGTCGTGAGTTCCTGCGCCGTAATGCTGGCGCCCTGTACAGCATTTGTGAGACTGGCCAA
    GTTATCCGTGAGAACTTCAGCCAGCTGCTGATTCTGGAAGCAACCGGCGATCGTTCGCTGGTGAACCTGGAGTATC
    AACAACGTTCCTGGAACTTCTTTCAGGGTGGCCCTCCATCCACGAGCGAAACTTTTCCGGATGATGTTGACACGAC
    CTCAATCGCGCTGATGATTTTACCGGCGGACGATAATACCGTCAATAGCGTCCTGGGTGAAATCAGCGAAGTCGC
    GAATGACGAGGGCATTGTGAATACCTATTTCGATCAGACCCGCCAACGTATCGATCCGGCCGTGTGTGTCAACGT
    GTTGCGCCTGTTTTACACCTATGGTCGTGGCGCTACGCTGCCGTTGACCCTGCAATGGGTTAGCGACGTGCTGGAG
    CACCGTGCGCATCTGCACGGCACCCGCTACTATCCGTCCCCAGAGGTTTTCCTGTACTTTGTCTCTCAGCTGTGCCG
    TTTTTCCAAGCGCGAACCGACCCTGCAGCTGCTGGAAACGCTGTTGACCGACAGACTGAAGGAACGCATCCAAGT
    TAAGGCAGATACGCTGAGCTTGGCAATGCGTATTTTGGCGTGCCTGAGCGTGGGCATCAGCCAGGTTGAGGTTGA
    CGTCCGCGAACTGCTGGCGCTGCAGTGCAAGGACGGTAGCTGGGAGCCGGGTAGCTTCTACCGTTTCGGTAGCA
    GCAAGATGAATGTCGGTAACCGCGGTCTGACGACCGCTTTGGCGACCCGTGCGGTTGAGCTGTACCAGGGTACGC
    GTATTCGTAGCAAGGGCACCGAGTAA
    XP_008034151.1
    - XP_008034151.1 protein
    SEQ ID NO: 26
    MASPHRRYTTLILDLGDVLFSWSSKTNTPIPPKKLKEILSSLTWFEYERGRISQAECYDRVSSEFSLDAATIAEAFQQARDS
    LRPNEEFLALIRELRQQTHGQLTVLALSNISLPDYEYIMALDSDWTSVFDRVFPSALVGERKPHLGAYRRVISEMHLDPET
    TVFVDDKLDNVVSARSLGMHGVVFDSQENVFQTLRNIFGDPIHRGRDYLRRHAGRLETSTDAGVVFEENFTQLIIYELT
    NDKSLITTSDCPRTWNFFRGKPLFSASFPDDVDTTSVALTVLRPPRTLVNSILDEMLEYVDADGIMQTYFDHSRPRMDP
    FVCVNVLSLFYEYGRGQDLPKTLEWVYEVLLHRAYIGGSRYYMSADCFLFFMSRLLQRITDPAVLNRLRPLFVERMHERV
    SAPGDSMELAFRILAGSSVGIQFPRDLEKLLAAQCADGGWDLCWFYQYGSTGVKAGNRGLTTALAIKAIESAIARPPSP
    ALSAVSSSKLEVPKPILQRPLSPRRLGDFLMPWRRAQREVAVSS
    - XP_008034151.1 - cDNA
    SEQ ID NO: 27
    ATGGCTTCACCTCACCGCAGGTATACGACACTCATCCTAGACCTGGGCGACGTCCTCTTCTCTTGGTCATCCAAGAC
    CAACACACCTATCCCTCCCAAGAAGCTGAAGGAGATCCTCTCGTCCCTGACCTGGTTCGAGTACGAGCGCGGTCGG
    ATATCACAGGCCGAGTGCTATGACCGGGTCAGCTCCGAGTTCAGTCTTGACGCTGCCACCATCGCAGAAGCGTTCC
    AGCAGGCTCGCGACTCTCTGCGACCGAACGAAGAGTTCCTGGCGTTGATTCGCGAACTCCGCCAACAAACGCATG
    GTCAGCTTACCGTCCTCGCGCTCTCGAACATCTCACTCCCCGACTATGAATACATCATGGCTCTCGACTCGGACTGG
    ACGTCGGTCTTCGACCGCGTCTTCCCTTCTGCCCTCGTCGGCGAGCGCAAGCCACATCTGGGGGCGTACCGCCGTG
    TCATCTCTGAGATGCACCTAGACCCAGAAACGACCGTCTTTGTGGACGACAAGCTGGACAACGTGGTGTCCGCGC
    GATCGCTCGGGATGCACGGCGTGGTCTTCGACTCCCAGGAGAACGTCTTCCAGACGCTGAGGAATATCTTCGGCG
    ACCCGATACATCGCGGACGTGACTATCTCCGCAGGCATGCCGGTCGTCTGGAGACATCTACGGACGCCGGCGTTG
    TCTTCGAGGAAAACTTTACGCAGCTCATCATCTACGAACTAACAAATGACAAATCCCTCATCACGACATCAGACTGT
    CCCCGCACTTGGAACTTCTTCCGCGGGAAGCCCTTGTTCTCGGCCTCGTTTCCCGACGATGTGGACACGACGTCGG
    TTGCCCTGACAGTGTTGCGCCCACCCCGCACGCTTGTCAACTCGATCTTGGACGAGATGCTAGAGTATGTCGACGC
    CGACGGCATCATGCAGACCTACTTCGACCACTCGCGCCCGCGGATGGATCCGTTCGTCTGTGTCAACGTCCTGTCG
    CTGTTCTACGAGTACGGCCGGGGACAGGACCTCCCGAAGACCCTCGAATGGGTATACGAGGTTCTGCTGCACCGC
    GCCTACATCGGCGGCTCGCGGTACTACATGTCCGCGGACTGCTTCCTCTTCTTCATGAGCCGCCTTCTCCAACGTAT
    CACCGACCCAGCCGTCCTGAACCGCCTCCGCCCGTTGTTCGTCGAGCGCATGCACGAACGTGTCAGCGCACCGGG
    CGACTCCATGGAGCTCGCGTTCCGCATCCTCGCTGGCTCGTCCGTCGGCATCCAGTTCCCACGTGACCTGGAGAAG
    CTCCTCGCCGCGCAGTGCGCCGACGGCGGCTGGGACCTGTGCTGGTTCTACCAGTATGGGTCCACCGGCGTGAAG
    GCAGGCAACCGCGGGCTCACCACCGCGCTCGCCATCAAGGCTATCGAGAGCGCTATCGCGCGCCCTCCGTCCCCC
    GCTCTATCAGCTGTATCGTCGTCGAAACTGGAAGTGCCGAAACCAATTCTCCAGCGTCCCCTCAGCCCGCGCCGGC
    TTGGCGACTTCCTGATGCCCTGGAGGAGAGCACAGCGCGAGGTCGCGGTTTCCAGCTAG
    - XP_008034151 - optimized cDNA
    SEQ ID NO: 28
    ATGGCTAGCCCGCACCGTCGCTATACTACTCTGATTCTGGATTTGGGTGATGTTTTGTTTAGCTGGAGCAGCAAAA
    CCAATACGCCTATTCCGCCGAAAAAGCTGAAAGAAATCCTGTCTAGCCTGACCTGGTTCGAGTACGAGCGCGGTC
    GCATTTCTCAAGCCGAGTGCTATGACCGTGTGAGCTCTGAGTTTAGCCTGGACGCAGCGACCATTGCAGAGGCATT
    CCAACAGGCTCGTGACTCGCTGCGCCCGAACGAAGAATTTCTGGCGTTGATTCGTGAGCTGCGCCAGCAGACCCA
    CGGCCAACTCACCGTTCTGGCACTGAGCAACATCTCCCTGCCGGATTACGAGTACATCATGGCTCTGGATAGCGAT
    TGGACCAGCGTCTTTGATAGAGTTTTCCCGAGCGCGCTGGTTGGTGAGCGTAAGCCGCATCTGGGTGCTTACCGTC
    GTGTCATTAGCGAGATGCATCTGGACCCGGAGACTACGGTGTTTGTGGACGACAAACTGGACAACGTTGTCTCCG
    CGCGCAGCCTGGGTATGCACGGCGTCGTTTTTGACTCACAAGAAAATGTTTTCCAGACGCTGCGTAACATTTTCGG
    TGACCCTATCCACCGTGGCCGCGACTATTTGCGTCGTCATGCCGGTCGTTTGGAAACCAGCACCGACGCGGGCGTT
    GTTTTTGAAGAAAACTTCACCCAGCTGATCATCTACGAACTGACGAATGACAAGAGCCTGATCACCACGAGCGATT
    GTCCGCGCACCTGGAACTTCTTCCGTGGTAAGCCGCTGTTTAGCGCGTCCTTCCCAGACGATGTCGATACGACTTC
    GGTGGCCCTGACCGTTCTGCGCCCACCGCGCACCCTGGTAAACAGCATCCTGGACGAAATGTTAGAATACGTCGA
    TGCGGATGGTATTATGCAGACCTATTTCGACCACAGCCGTCCGCGCATGGACCCGTTTGTGTGTGTGAATGTGTTG
    AGCCTGTTCTATGAGTACGGCCGTGGTCAAGATCTGCCAAAAACCCTGGAATGGGTCTACGAAGTCCTTCTGCATC
    GTGCCTACATCGGTGGCTCCCGTTATTACATGAGCGCAGATTGCTTTTTGTTCTTTATGTCTCGTCTGCTGCAGCGC
    ATCACGGACCCTGCCGTGCTGAATCGTCTGCGTCCGCTGTTCGTGGAGCGTATGCACGAGCGCGTGTCTGCCCCG
    GGTGACAGCATGGAACTGGCGTTCCGTATCCTGGCGGGCAGCAGCGTGGGTATTCAATTTCCGCGTGATTTGGAG
    AAACTGCTGGCTGCGCAGTGTGCGGACGGTGGCTGGGATCTGTGCTGGTTTTATCAATACGGTAGCACCGGCGTT
    AAGGCCGGCAATCGTGGCCTGACGACGGCACTGGCAATTAAGGCCATTGAGTCCGCGATTGCGCGTCCGCCGAG
    CCCGGCATTGAGCGCGGTCAGCAGCAGCAAACTGGAAGTGCCGAAGCCGATCTTGCAGCGTCCACTGAGCCCGC
    GTCGTCTGGGTGACTTCCTGATGCCGTGGCGCCGTGCGCAACGCGAAGTCGCGGTTAGCTCCTAA
    XP_007369631.1
    - XP_007369631.1 protein
    SEQ ID NO: 29
    MASIHRRYTTLILDLGDVLFRWSPKTETAIPPQQLKDILSSVTWFEYERGRLSQEACYERCAEEFKIEASVIAEAFKQARGS
    LRPNEEFIALIRDLRREMHGDLTVLALSNISLPDYEYIMSLSSDWTTVFDRVFPSALVGERKPHLGCYRKVISEMNLEPQT
    TVFVDDKLDNVASARSLGMHGIVFDNQANVFRQLRNIFGDPIRRGQEYLRGHAGKLESSTDNGLIFEENFTQLIIYELTQ
    DRTLISLSECPRTWNFFRGEPLFSETFPDDVDTTSVALTVLQPDRALVNSVLDEMLEYVDADGIMQTYFDRSRPRMDPF
    VCVNVLSLFYENGRGHELPRTLDWVYEVLLHRAYHGGSRYYLSPDCFLFFMSRLLKRADDPAVQARLRPLFVERVNERV
    GAAGDSMDLAFRILAAASVGVQCPRDLERLTAGQCDDGGWDLCWFYVFGSTGVKAGNRGLTTALAVTAIQTAIGRPP
    SPSPSAASSSFRPSSPYKFLGISRPASPIRFGDLLRPWRKMSRSNLKSQ
    - XP_007369631.1 cDNA
    SEQ ID NO: 30
    ATGGCCTCAATCCACCGTCGATACACTACTCTCATCCTCGACCTCGGCGACGTACTCTTTCGTTGGTCTCCAAAGAC
    TGAGACCGCCATTCCACCTCAACAACTCAAGGATATCCTCTCCTCTGTCACCTGGTTTGAGTACGAACGCGGCAGA
    CTATCCCAGGAAGCATGCTACGAGCGCTGCGCCGAGGAGTTCAAGATAGAGGCCTCGGTCATTGCAGAAGCCTTT
    AAGCAGGCTCGCGGGTCACTGCGGCCCAACGAGGAGTTCATCGCCTTGATCCGTGACCTCCGCCGTGAGATGCAC
    GGTGACCTTACCGTTCTTGCCCTCTCCAACATCTCCCTCCCCGACTACGAATACATCATGTCGCTAAGCTCAGATTG
    GACGACCGTCTTCGATCGCGTATTCCCCTCTGCACTCGTTGGCGAGCGCAAGCCTCATCTGGGATGCTATCGCAAG
    GTCATCTCGGAGATGAACCTAGAACCTCAGACGACTGTGTTCGTGGATGACAAGCTTGACAACGTCGCGTCTGCTC
    GCTCACTTGGTATGCACGGCATCGTGTTTGACAACCAAGCCAACGTCTTCCGCCAACTCCGCAATATCTTCGGAGA
    CCCCATCCGCCGTGGCCAAGAGTATCTCCGTGGGCATGCTGGCAAACTCGAGTCTTCGACCGACAACGGGTTGAT
    CTTCGAGGAGAACTTCACACAGCTGATCATCTACGAGTTGACGCAAGACAGGACTCTCATCTCGCTTTCAGAATGT
    CCTCGTACTTGGAATTTCTTCCGAGGCGAACCGCTATTCTCGGAGACCTTCCCGGATGATGTCGACACAACATCTGT
    GGCGTTGACGGTATTGCAACCGGACAGAGCACTGGTCAACTCCGTTCTAGACGAGATGCTGGAGTATGTCGACGC
    CGATGGCATCATGCAGACATACTTCGATCGTTCACGACCACGCATGGACCCCTTCGTCTGCGTGAACGTACTCTCCC
    TGTTCTACGAGAACGGTCGTGGTCACGAGCTCCCTCGCACATTGGACTGGGTCTACGAGGTGCTCCTCCATCGCGC
    GTACCACGGCGGTTCGCGTTATTACCTGTCGCCCGACTGCTTTCTATTCTTCATGAGCCGCCTACTCAAGCGCGCAG
    ACGATCCAGCAGTCCAGGCTCGGCTCCGCCCGCTCTTCGTCGAGCGGGTGAACGAGCGAGTAGGCGCCGCTGGC
    GACTCGATGGACCTCGCCTTCCGCATCCTCGCCGCAGCGTCTGTTGGCGTCCAGTGCCCCCGCGATCTGGAAAGGT
    TGACTGCCGGGCAATGCGACGACGGTGGATGGGACCTCTGCTGGTTCTACGTGTTCGGCTCGACGGGCGTGAAG
    GCGGGCAACCGCGGCCTCACAACGGCCCTCGCTGTCACGGCCATACAGACGGCCATCGGACGCCCCCCTTCGCCC
    AGTCCCTCCGCGGCCTCCTCGTCTTTCAGACCTAGTTCCCCTTACAAATTCCTAGGCATTTCGCGCCCAGCTAGCCCC
    ATTCGCTTTGGCGACTTACTTCGCCCATGGCGGAAGATGAGCAGGTCGAACTTGAAGTCTCAATGA
    - XP_007369631.1 optimized cDNA
    SEQ ID NO: 31
    ATGGCAAGCATTCATCGTCGCTATACTACGCTGATTCTGGACCTGGGTGATGTTTTGTTCCGCTGGAGCCCGAAAA
    CCGAGACTGCGATTCCTCCGCAACAACTGAAAGACATCCTGAGCAGCGTCACCTGGTTCGAGTACGAGCGTGGCC
    GTCTGAGCCAAGAGGCTTGCTACGAGCGTTGCGCCGAAGAGTTCAAGATTGAAGCCAGCGTGATTGCGGAAGCG
    TTCAAACAAGCGCGTGGTAGCCTGCGTCCGAACGAAGAATTTATCGCACTGATCCGTGATCTGCGTCGCGAGATG
    CATGGTGACCTGACCGTTCTGGCTCTGAGCAATATCTCGTTGCCGGATTACGAGTATATTATGTCTCTGAGCAGCG
    ACTGGACGACGGTCTTTGATCGTGTGTTCCCGTCAGCTCTGGTGGGCGAGCGTAAACCGCACTTGGGTTGCTATCG
    CAAGGTCATCAGCGAGATGAACCTGGAACCTCAGACCACGGTCTTTGTGGACGATAAACTGGATAATGTCGCAAG
    CGCGCGTAGCCTGGGTATGCACGGTATCGTGTTTGATAATCAAGCGAATGTGTTTCGCCAGCTGCGTAATATTTTC
    GGTGATCCAATCCGTCGCGGTCAAGAGTATCTGCGTGGCCATGCCGGTAAATTGGAGAGCAGCACGGACAATGG
    TTTGATCTTTGAAGAGAACTTCACCCAGCTGATCATTTATGAACTGACCCAGGACCGCACGTTGATCAGCCTGTCG
    GAGTGTCCGCGTACCTGGAACTTCTTCCGTGGCGAGCCGTTGTTTTCTGAAACCTTCCCGGACGACGTGGACACCA
    CGTCCGTTGCACTGACGGTTCTGCAACCGGATCGCGCACTGGTTAACAGCGTGCTGGACGAAATGCTGGAATATG
    TCGATGCGGATGGCATCATGCAGACGTATTTCGACCGCTCGCGTCCGCGTATGGACCCGTTTGTTTGCGTCAACGT
    ACTGAGCCTGTTTTACGAGAACGGTCGTGGTCACGAACTGCCGCGCACTCTGGATTGGGTGTACGAAGTCCTGCTC
    CACCGCGCCTACCACGGTGGTTCCCGTTACTACCTGAGCCCGGACTGTTTCTTGTTTTTTATGAGCCGTCTGCTGAA
    ACGTGCAGACGACCCAGCGGTTCAGGCGAGATTGCGTCCGCTGTTTGTGGAACGCGTTAACGAACGTGTTGGCGC
    GGCCGGTGATAGCATGGACCTGGCGTTTCGCATTCTGGCCGCAGCGAGCGTGGGTGTGCAGTGTCCGCGCGACCT
    GGAGCGTCTGACCGCTGGTCAATGCGATGATGGCGGCTGGGATCTGTGTTGGTTCTACGTTTTCGGCAGCACCGG
    CGTTAAGGCCGGTAATCGTGGTCTGACCACGGCGCTGGCAGTCACCGCGATCCAGACCGCCATCGGCCGTCCGCC
    TAGCCCGAGCCCGTCCGCGGCAAGCTCCAGCTTCCGCCCGAGCAGCCCGTACAAGTTTCTGGGTATTAGCCGTCCG
    GCGTCCCCAATTCGCTTCGGTGACCTTCTGCGTCCGTGGCGTAAAATGTCTCGCTCTAACCTGAAGTCCCAGTAA
    ACg006372
    - ACg006372 protein
    SEQ ID NO: 32
    MRRNVLNKATHSQSPLKPNITTLIFDLGDVLLTWSDSTPKSPLPPKIVKGILRSLTWFEYEKGNLTESQTYGQVAQEFGV
    DASEVKASFEAARDSLKSNPMLLQLIRSLKDSGHVIYAMSNISAPDWEFLKTRADLSDWALFDRVFPSAEAHDRKPNIG
    FYQHVINETGLNPSNTVFVDDRIENVVSARSAGMHGIVFDDINNVIRQLKNLCEDPIHRARSFLYANKKCLNTVSTDGTI
    VSENFSQLLILEAIGDESLVDFVRHEGRFNFFQGEAKLIMTNHYPDDFDTTSIGLTVVPYIDDKTRNRVMDEILAYQSEDG
    IVLVYFDHKRPRIDPVVCVNVLTLFYRYGRGHQLQKTLDWVEQVLINRACASGTFYYATEEQFLFFLSRLIQSSPDVRQRL
    EGVFKRRVVERFGADGDALAMAMRIHTAASVGLVDHVDLDKLFALQQNDGSWRDSAFYRFPSARQLASNDGLTTAIA
    IQAIQAAERLREDGNVL
    - ACg006372 cDNA
    SEQ ID NO: 33
    ATGAGGCGAAACGTACTCAACAAAGCAACACATTCTCAGTCACCATTGAAGCCCAACATCACGACGCTCATATTTG
    ACTTGGGCGACGTACTTCTCACGTGGTCCGACTCAACACCTAAATCTCCACTGCCCCCAAAAATTGTCAAGGGAAT
    ACTACGTTCACTGACCTGGTTTGAGTACGAGAAAGGGAACTTGACAGAGTCCCAGACCTACGGGCAAGTTGCTCA
    GGAATTTGGAGTGGATGCTTCCGAAGTCAAAGCTTCCTTCGAAGCAGCTCGCGACTCGCTCAAGAGCAACCCAAT
    GCTTCTCCAGTTGATCCGTAGCCTCAAAGACTCTGGCCACGTCATTTACGCAATGTCTAACATATCTGCTCCCGACT
    GGGAATTTTTGAAGACGCGGGCAGACCTCTCAGATTGGGCTCTTTTTGACAGAGTCTTCCCTTCTGCCGAAGCGCA
    TGACCGCAAGCCGAACATTGGTTTCTATCAGCACGTCATAAACGAGACTGGTCTGAACCCGTCCAACACTGTCTTT
    GTCGATGACAGGATCGAGAATGTTGTATCCGCACGCTCAGCAGGAATGCACGGGATCGTGTTTGACGACATAAAT
    AATGTGATCCGACAGTTGAAAAACCTCTGCGAGGATCCGATTCACCGCGCACGATCTTTTCTTTATGCAAATAAGA
    AGTGTTTGAATACGGTTAGCACAGATGGCACAATTGTGAGCGAGAACTTCTCGCAATTGTTGATCCTTGAGGCCAT
    TGGCGACGAAAGCCTAGTCGACTTTGTGAGGCATGAGGGCCGATTCAACTTCTTCCAGGGGGAGGCCAAACTCAT
    CATGACGAATCACTACCCCGATGATTTCGATACTACATCCATAGGTTTAACCGTTGTTCCATATATTGACGACAAGA
    CTAGAAATAGAGTTATGGATGAGATCCTGGCCTACCAAAGCGAAGACGGCATTGTGCTGGTATACTTTGACCACA
    AGCGCCCCAGGATTGATCCTGTTGTCTGTGTCAATGTCCTCACCCTCTTCTATAGGTATGGCCGTGGGCACCAGCTT
    CAAAAGACACTGGATTGGGTCGAACAGGTCCTGATCAACCGTGCGTGTGCGTCCGGCACGTTCTATTACGCAACA
    GAGGAACAATTCCTCTTTTTCCTCTCCCGCCTGATCCAAAGCTCTCCGGACGTACGACAGCGGTTGGAAGGGGTCT
    TTAAAAGAAGAGTAGTCGAGCGGTTTGGTGCAGACGGCGACGCTCTCGCTATGGCGATGCGCATTCACACCGCGG
    CGAGCGTGGGCCTCGTTGACCATGTCGATCTTGACAAGCTGTTCGCATTGCAGCAAAATGACGGTTCTTGGAGAG
    ACAGCGCTTTCTACAGATTTCCGTCGGCCAGGCAACTGGCTAGTAACGACGGCTTGACGACTGCAATCGCTATTCA
    GGCCATTCAAGCTGCGGAGAGGCTCAGGGAGGATGGGAACGTGCTTTGA
    - ACg006372 optimized cDNA
    SEQ ID NO: 34
    ATGCGCCGTAATGTCCTGAACAAAGCAACCCATAGCCAGTCACCGTTGAAACCGAATATCACCACGCTGATTTTTG
    ACTTGGGCGATGTCCTGCTGACCTGGAGCGACAGCACTCCGAAATCTCCGTTGCCGCCGAAGATCGTCAAGGGCA
    TCCTGCGTAGCCTGACTTGGTTCGAGTACGAAAAGGGCAATTTGACCGAAAGCCAAACGTATGGTCAGGTCGCGC
    AAGAATTTGGTGTGGATGCCTCTGAAGTGAAGGCCAGCTTTGAGGCTGCGCGTGATAGCTTGAAATCGAATCCGA
    TGCTGCTGCAGCTGATTCGCAGCCTGAAAGATTCCGGTCACGTGATCTACGCCATGAGCAACATCAGCGCGCCTGA
    TTGGGAATTTCTGAAAACCCGCGCTGACCTGTCTGACTGGGCCCTGTTTGACCGCGTGTTCCCGTCTGCCGAGGCA
    CATGACCGCAAACCGAACATTGGCTTTTACCAACACGTGATCAATGAAACGGGTCTGAATCCATCCAATACCGTGT
    TCGTTGACGACCGTATTGAAAACGTTGTTAGCGCACGTAGCGCTGGTATGCACGGTATCGTTTTCGATGACATTAA
    CAACGTCATTCGCCAGCTGAAGAATCTGTGCGAGGACCCAATTCACCGTGCACGTTCCTTTTTGTATGCGAACAAA
    AAGTGCCTGAATACCGTGAGCACCGATGGTACGATCGTCAGCGAGAACTTTAGCCAGCTTCTGATTCTGGAAGCC
    ATTGGTGACGAGTCCCTGGTAGACTTCGTCCGCCATGAGGGCCGTTTTAACTTCTTCCAGGGTGAGGCAAAGCTGA
    TCATGACCAATCACTACCCGGACGATTTCGATACCACGAGCATTGGTCTGACCGTTGTCCCGTATATCGATGACAA
    AACGCGTAATCGTGTGATGGATGAAATCCTGGCGTATCAGTCCGAGGATGGTATCGTTCTGGTGTACTTCGATCAC
    AAGCGTCCGCGCATTGACCCGGTCGTTTGTGTGAACGTTCTGACGCTGTTCTACCGCTATGGTCGTGGCCATCAAC
    TGCAGAAAACCCTGGACTGGGTTGAGCAAGTCCTGATTAATCGTGCGTGTGCGAGCGGCACGTTCTACTACGCGA
    CCGAAGAACAGTTCCTGTTTTTCCTGAGCCGTCTGATTCAGTCGAGCCCTGACGTGCGCCAACGTCTGGAAGGCGT
    GTTCAAGCGTCGTGTCGTTGAGCGCTTTGGTGCGGACGGTGATGCCCTGGCAATGGCGATGCGTATCCATACCGC
    AGCGAGCGTTGGCCTGGTGGACCACGTGGATCTGGATAAGCTGTTCGCGCTGCAACAGAACGACGGTAGCTGGC
    GCGATAGCGCGTTTTATCGTTTTCCGAGCGCGCGTCAACTCGCGAGCAACGACGGCTTGACCACGGCAATTGCTAT
    TCAGGCCATCCAAGCGGCTGAGAGATTACGTGAGGATGGTAACGTTCTGTAA
    KIA75676.1
    - KIA75676.1 protein
    SEQ ID NO: 35
    MVRALILDLGDVLFNWDAPKSTPVSRKTLSQMLHSDIWGEYECGQLTEPESYKALASRYSCQAQDVADTFYLARESLRL
    DATFKTFLQDLKQRANGSLRVYGMSNISQPDYEVLLSKADDLSLFDKIFPSGHVGMRKPDLAFFRHVLREISTASEDIVFV
    DDNLENVTSARSLGMQGIVFRDKEDVQRQLRNLFGSPAERGREYLSINKTKLQSVTTTNIPILDNFGQLLILEATRDPDLV
    SMHPGQRTWNFFIGSPTLTTDAFPDDMDTTSLGLSIIPPSPEIAASVMDEIVTRLNKDGIVPTYFDSTRPRVDPIVCVNVL
    TLFAKYGREDELSGTIAWVRDVLYHRAYLAGTRYYASPEAFLFFFTRFTRNLRPGPRKQELTALLSQRLQERNKTPVDALA
    LSMRIIACLTLGIESPADDVATLTGMQCGDGGWPACVIYKYGAGGLGITNRGVSTAFAVKAITTTPLAVQPEVSVSAGA
    GGSSRPVGADAAAVSLRPRWRAVVQSLHPLSRVGGLVAVIFAALHFNLAWLYNVSLASRIV
    - KIA75676.1 cDNA
    SEQ ID NO: 36
    ATGGTCCGCGCACTGATTCTCGATCTCGGCGACGTCCTCTTCAACTGGGACGCCCCAAAGTCAACCCCCGTTTCCCG
    CAAGACACTCAGCCAGATGCTGCATAGCGACATCTGGGGCGAATACGAATGTGGCCAACTGACAGAGCCGGAAA
    GCTACAAGGCGCTTGCCAGCCGCTATTCTTGCCAGGCTCAAGATGTTGCAGATACCTTCTATCTAGCCCGCGAATC
    GCTGAGGCTCGATGCGACCTTCAAGACCTTCCTGCAGGACTTGAAGCAGAGGGCCAACGGCTCACTTCGCGTATA
    TGGGATGTCCAACATCTCCCAGCCCGATTATGAGGTCCTGCTGTCCAAGGCGGATGACTTGAGCCTGTTTGACAAG
    ATCTTCCCATCCGGCCACGTCGGGATGCGTAAGCCTGACCTTGCGTTTTTTCGACATGTCCTGCGTGAGATCTCGAC
    GGCCAGCGAGGATATTGTGTTTGTTGACGACAACCTGGAGAACGTGACATCTGCCCGGTCTCTGGGCATGCAGGG
    GATTGTCTTTCGCGACAAGGAGGATGTACAGAGACAGCTGCGGAACCTCTTTGGCAGTCCTGCTGAACGTGGAAG
    GGAGTATTTGTCCATCAACAAGACAAAGCTCCAGAGCGTCACGACGACCAATATCCCCATTCTCGACAACTTTGGC
    CAGCTCCTTATCCTCGAAGCCACCAGAGACCCAGACCTGGTGTCCATGCATCCTGGACAGAGGACCTGGAACTTTT
    TCATCGGATCTCCAACTCTGACAACGGACGCCTTCCCAGACGATATGGACACCACCTCACTTGGCCTTTCTATTATA
    CCCCCAAGTCCCGAGATTGCAGCGTCCGTGATGGATGAGATTGTGACCCGCCTGAACAAGGACGGCATTGTCCCA
    ACATATTTTGACAGCACCAGACCCCGCGTCGACCCGATCGTCTGCGTCAACGTTCTCACCCTCTTCGCTAAATACGG
    CCGCGAAGACGAGCTGTCCGGGACCATAGCCTGGGTGCGCGATGTGCTGTATCACAGGGCCTACCTTGCAGGGA
    CCAGATACTACGCATCCCCAGAAGCATTCCTTTTCTTCTTCACGCGCTTCACCCGAAACCTGCGCCCGGGCCCGCGC
    AAGCAGGAGCTCACGGCGCTGCTGTCCCAGCGCCTGCAGGAGCGCAACAAGACGCCCGTTGACGCACTTGCGCTC
    TCGATGCGGATTATTGCGTGCCTCACGCTGGGTATTGAATCCCCCGCTGACGACGTGGCTACCCTCACGGGCATGC
    AGTGTGGGGATGGCGGGTGGCCGGCCTGTGTCATCTACAAGTACGGCGCCGGTGGGCTGGGGATCACGAACAG
    GGGGGTCTCGACCGCGTTTGCTGTCAAGGCAATCACTACTACTCCTTTGGCGGTGCAGCCTGAAGTTAGTGTCAGC
    GCAGGTGCAGGAGGCAGCAGTCGCCCTGTGGGTGCCGATGCTGCTGCAGTCTCGCTCCGCCCGAGATGGCGAGC
    TGTTGTGCAGAGTCTCCATCCGCTCTCTCGGGTTGGTGGGTTGGTGGCCGTCATTTTTGCTGCACTGCATTTCAACT
    TGGCCTGGCTTTATAATGTGTCCCTTGCTAGTAGGATCGTTTAG
    - KIA75676.1 optimized cDNA
    SEQ ID NO: 37
    ATGGTTCGTGCATTGATTTTGGATTTGGGTGATGTGTTGTTTAACTGGGATGCGCCTAAGAGCACCCCGGTTTCCC
    GCAAGACTCTGAGCCAAATGCTGCACTCGGATATTTGGGGCGAGTACGAGTGTGGTCAACTGACTGAGCCGGAGT
    CCTATAAAGCCCTGGCGAGCCGCTATAGCTGCCAGGCGCAAGATGTCGCTGACACCTTTTACCTGGCGCGTGAGA
    GCCTGCGTCTGGACGCAACGTTTAAGACCTTCCTGCAAGATCTGAAGCAACGCGCCAACGGTTCTCTGCGTGTCTA
    TGGTATGAGCAATATCAGCCAGCCGGATTACGAAGTCCTGCTGAGCAAAGCTGACGATCTCAGCCTGTTTGACAA
    AATCTTTCCGTCGGGTCACGTTGGTATGAGAAAGCCTGACCTGGCGTTTTTCCGTCACGTTCTGCGTGAGATCAGC
    ACGGCTAGCGAAGATATTGTGTTTGTTGACGACAATTTGGAAAACGTCACGTCTGCACGCTCCCTGGGTATGCAAG
    GCATCGTCTTTCGTGATAAGGAAGATGTCCAGCGCCAGCTGCGCAATCTGTTCGGTTCCCCGGCAGAGCGCGGTC
    GTGAGTATCTGAGCATTAATAAGACCAAACTGCAGAGCGTGACCACCACCAATATCCCGATTCTGGACAACTTCGG
    TCAGTTGCTGATCCTGGAAGCTACCCGTGACCCGGATTTAGTCAGCATGCATCCAGGCCAACGTACGTGGAACTTC
    TTCATTGGCAGCCCGACCTTGACGACCGACGCGTTTCCGGACGATATGGACACGACTTCTCTGGGCCTGAGCATCA
    TCCCGCCGAGCCCGGAAATTGCAGCAAGCGTTATGGACGAAATCGTCACCCGTCTGAATAAAGATGGTATTGTGC
    CGACCTACTTCGACAGCACGCGTCCACGTGTGGACCCGATCGTCTGCGTTAACGTCCTGACCTTGTTTGCGAAATA
    TGGTCGTGAAGATGAACTGAGCGGCACGATTGCGTGGGTCCGCGACGTTCTGTATCATCGCGCATACCTGGCGGG
    CACGCGCTACTACGCGTCCCCAGAGGCCTTCCTGTTCTTCTTTACGCGTTTCACCCGCAATCTGCGTCCGGGTCCGC
    GTAAACAAGAACTTACGGCGCTGCTGAGCCAGCGTCTGCAGGAACGCAACAAGACGCCGGTTGACGCTCTGGCCC
    TGAGCATGCGTATCATCGCCTGTCTGACCCTGGGCATTGAGAGCCCGGCAGACGACGTGGCCACCCTGACCGGTA
    TGCAGTGTGGTGATGGTGGCTGGCCGGCGTGCGTGATCTACAAATATGGTGCGGGTGGCTTGGGTATCACGAAT
    CGTGGCGTTAGCACTGCCTTCGCGGTGAAAGCGATTACGACCACCCCGCTGGCAGTGCAGCCAGAAGTCAGCGTC
    AGCGCTGGTGCCGGCGGCTCCAGCCGCCCGGTTGGTGCGGATGCGGCAGCGGTTAGCTTGCGTCCGCGTTGGCG
    TGCGGTTGTGCAGAGCCTGCATCCGCTGAGCCGCGTGGGTGGCCTGGTTGCCGTGATCTTCGCGGCACTGCACTT
    TAACCTGGCGTGGCTGTACAACGTAAGCCTGGCTAGCCGTATTGTGTAA
    XP_001820867.2
    - XP_001820867.2 protein
    SEQ ID NO: 38
    MTRWKSSQYQAIIFDLGGVILTWDLPEDTVISAQIFKRMLTSQTWSDYERGNLSENGCYQRLAEDFGIDSADIAHTVRQ
    ARESLVTDTAIMNIISEIRAGANHIAIFAMSNISQPDYAALLLDHRGMCSFDRVFPSGCYGTRKPELSFYNKVLREIDTPPE
    NVIFVDDQLENVISAQSIGIHGIAYTNAAELGRQLRNLIFDPVERGREFLRRNAGEFHSITETDQIVRENFSQLLILEATGD
    KSLVSLEYHQKSWNFFQGNPILTTETFPDDVDTTSLALMTLPTDTKTANLLLDQILGLVNADEIVTTYFDQTRERIDPVVC
    VNVLRLFCTYGRGIALPLTLQWVYDVLAHRAYINGTRYYTSPESFLYFVGQLCRFSTGVLALRPLETLLIDRLKERLQVKAD
    PLSLAMRILTCLSVGVSQVEVDLRELLSMQCEDGSWEHCPFTRYGLSKVSIGNRGLTTAFVVKAVEMCRGS
    - XP_001820867.2 cDNA
    SEQ ID NO: 39
    ATGACTCGATGGAAATCGTCCCAATACCAAGCAATTATCTTTGACCTAGGCGGTGTCATTTTAACATGGGACCTCCC
    GGAAGACACTGTGATATCGGCCCAGATCTTTAAGAGAATGCTCACATCGCAGACATGGTCAGATTATGAGCGCGG
    AAATCTCAGCGAAAATGGTTGCTACCAGAGGTTGGCCGAGGATTTTGGCATTGACTCTGCCGACATTGCACATACC
    GTTAGACAAGCACGGGAATCCCTTGTCACTGATACCGCTATCATGAACATTATATCTGAGATCAGAGCTGGGGCTA
    ACCATATTGCTATCTTCGCTATGTCGAACATCTCCCAACCAGATTATGCGGCTCTGCTCCTTGATCATCGCGGGATG
    TGCAGTTTTGACCGGGTGTTCCCATCTGGATGCTACGGGACAAGGAAACCAGAGCTCTCATTCTATAACAAAGTCT
    TGCGGGAGATTGACACGCCACCGGAAAACGTCATCTTTGTCGATGATCAGCTGGAAAATGTGATCTCTGCGCAGT
    CCATTGGCATACACGGGATTGCCTATACGAATGCTGCTGAACTCGGTCGACAGCTTAGGAACCTAATATTTGACCC
    TGTAGAGAGGGGTAGGGAATTCTTACGGCGCAATGCTGGAGAGTTCCATAGCATCACTGAAACCGATCAAATTGT
    TCGGGAAAATTTCTCACAGTTGCTCATTCTAGAAGCGACTGGTGATAAGAGTCTGGTATCTCTTGAATATCACCAG
    AAGAGCTGGAATTTCTTCCAAGGAAACCCTATTCTCACGACAGAGACATTCCCAGATGATGTTGACACAACATCTC
    TTGCCTTGATGACTCTACCTACAGACACAAAAACTGCAAATTTGTTACTCGACCAGATTTTGGGGCTAGTCAACGCT
    GATGAAATCGTAACAACATACTTTGACCAGACCCGAGAACGGATCGATCCAGTAGTCTGCGTCAATGTCCTTCGTC
    TCTTTTGCACCTACGGCCGGGGCATTGCGCTCCCTTTGACTCTTCAGTGGGTGTACGACGTCCTCGCTCATCGGGCA
    TATATAAACGGTACACGTTACTACACAAGTCCCGAAAGCTTCCTATACTTCGTCGGTCAACTTTGTCGATTCTCAAC
    AGGGGTACTGGCACTTCGGCCGCTGGAAACGTTGCTTATAGATCGTCTCAAGGAACGTCTTCAGGTCAAAGCAGA
    TCCTCTATCACTCGCTATGCGGATCTTGACCTGTTTGTCCGTTGGTGTGTCTCAAGTTGAAGTCGATCTCCGAGAGT
    TGCTCTCGATGCAGTGTGAAGATGGCTCGTGGGAACATTGTCCATTCACCCGGTATGGTTTGTCCAAAGTGAGCAT
    TGGCAATCGGGGCCTTACAACTGCTTTTGTGGTCAAGGCGGTTGAAATGTGTCGAGGCAGTTAG
    - XP_001820867.2 optimized cDNA
    SEQ ID NO: 40
    ATGACTCGTTGGAAAAGCTCTCAATATCAGGCAATCATTTTCGATCTGGGCGGTGTTATTCTGACCTGGGACTTGC
    CGGAAGATACGGTTATCTCCGCGCAAATCTTTAAGCGTATGCTGACCAGCCAGACCTGGTCCGATTATGAGCGCG
    GTAATCTGAGCGAGAACGGCTGCTATCAACGTTTGGCGGAAGATTTCGGCATCGATAGCGCCGATATTGCCCACA
    CCGTCCGTCAGGCACGTGAGTCCCTGGTGACCGACACCGCCATCATGAATATCATCTCCGAGATCCGTGCAGGCGC
    GAACCACATCGCAATTTTCGCGATGAGCAACATCTCACAGCCGGATTACGCTGCGCTGCTGCTGGACCATCGCGGT
    ATGTGCAGCTTTGACCGCGTCTTTCCGAGCGGTTGTTACGGCACCCGTAAGCCTGAGCTGAGCTTCTACAATAAAG
    TGCTGCGTGAAATTGACACCCCGCCGGAAAATGTTATTTTCGTTGACGATCAATTGGAAAATGTGATTAGCGCGCA
    AAGCATTGGTATTCATGGCATTGCGTATACGAATGCCGCGGAACTGGGCCGCCAGCTGAGAAACCTGATCTTCGA
    TCCGGTGGAGCGCGGTCGTGAGTTCCTGCGTCGTAACGCTGGTGAGTTTCACTCTATTACGGAAACGGACCAGAT
    TGTGCGCGAGAACTTCAGCCAGCTGCTGATTCTGGAAGCGACCGGTGACAAAAGCCTGGTTAGCCTGGAATACCA
    CCAAAAGTCGTGGAACTTCTTCCAAGGTAACCCAATCCTGACGACGGAAACCTTCCCGGACGATGTTGACACTACT
    AGCCTGGCTCTGATGACGCTGCCGACGGACACCAAGACCGCGAATCTGTTGCTGGACCAGATTCTGGGTTTGGTT
    AATGCCGATGAAATTGTGACTACGTACTTCGACCAGACCCGTGAGCGTATCGATCCAGTGGTCTGTGTGAATGTCC
    TGCGCCTGTTCTGTACGTACGGCCGCGGCATCGCGCTGCCGCTGACCCTGCAATGGGTCTACGATGTGCTGGCGC
    ACCGCGCATACATTAACGGTACGCGTTATTACACCAGCCCGGAGAGCTTTCTGTATTTTGTCGGTCAGCTCTGTCGT
    TTTAGCACCGGTGTGCTGGCACTGCGTCCGCTGGAGACTCTGCTGATTGATCGTCTGAAAGAGCGCCTGCAAGTTA
    AAGCTGACCCGCTGAGCCTGGCAATGCGCATCCTTACGTGCTTATCTGTCGGTGTCAGCCAGGTTGAAGTGGACTT
    GCGTGAGTTGTTGAGCATGCAGTGCGAGGACGGTAGCTGGGAGCATTGCCCGTTCACCCGCTACGGCCTGAGCA
    AGGTTTCCATCGGTAACCGTGGCCTGACCACGGCGTTTGTGGTTAAAGCCGTCGAGATGTGCCGTGGCAGCTAA
    CEN60542.1
    - CEN60542.1 protein
    SEQ ID NO: 41
    MVRALILDLGDVLFNWDAPASTPISRKTLGQMLHSEIWGEYERGHLTEDEAYNALAKRYSCEAKDVAHTFVLARESLRL
    DTKFKTFLQTLKQNANGSLRVYGMSNISKPDFEVLLGKADDWTLFDKIFPSGHVGMRKPDLAFFRYVLKDISTPVEDVV
    FVDDNLDNVTSARSLGMRSVLFHKKDEVQRQLTNIFGSPAERGLEYLSANKTNLQSATTTDIPIQDNFGQLLILEATEDP
    SLVRMEPGKRTWNFFIGSPSLTTDTFPDDLDTTSLALSIVPTSPDVVNSVIDEIISRRDKDGIVPTYFDNTRPRVDPIVCVN
    VLSMFAKYGREHDLPATVAWVRDVLYHRAYLGGTRYYGSAEAFLFFFTRFVRNLRPGTLKQDLHALLSERVRERLNTPV
    DALALSMRIQACHALGFDAPADIATLITMQDEDGGWPAAVIYKYGAGGLGITNRGVSTAFAVKAITGSPVKTETNIGGD
    GARAVSAMSSLEARRLQPISSVGDWVRFIIASLHVHLAWLWNVLLLSKVV
    - CEN60542.1 cDNA
    SEQ ID NO: 42
    ATGGTCCGCGCACTCATCCTCGATCTCGGCGATGTCCTCTTCAACTGGGACGCGCCTGCGTCCACCCCCATTTCACG
    CAAGACCCTCGGCCAGATGCTGCATAGTGAGATCTGGGGTGAGTATGAACGTGGCCATTTGACAGAAGACGAGG
    CATACAACGCACTCGCGAAGCGGTATTCCTGCGAGGCCAAGGATGTCGCACATACCTTTGTCCTGGCACGAGAAT
    CGCTGCGGCTCGACACGAAATTCAAAACGTTTCTGCAGACTCTAAAGCAGAATGCCAACGGCTCCCTTCGTGTCTA
    TGGCATGTCGAATATATCGAAACCGGATTTCGAAGTCCTGCTGGGCAAGGCCGATGACTGGACTCTGTTTGACAA
    GATCTTCCCCTCTGGCCATGTCGGTATGCGCAAGCCAGATCTTGCCTTCTTCCGCTATGTGCTCAAGGACATTTCAA
    CGCCTGTCGAGGATGTGGTGTTTGTTGACGATAACCTGGACAACGTGACGAGTGCTCGGTCTCTGGGCATGCGCA
    GCGTCCTCTTTCATAAGAAAGACGAGGTCCAGCGACAGCTCACCAACATCTTTGGCAGCCCTGCTGAGCGGGGCTT
    GGAGTATCTCTCCGCCAACAAGACGAATCTGCAGAGTGCTACCACGACAGATATCCCAATCCAGGATAACTTTGGC
    CAACTTCTGATTCTCGAGGCCACTGAAGACCCATCGCTGGTCCGCATGGAGCCCGGTAAGCGAACCTGGAATTTCT
    TCATCGGTTCTCCATCCCTCACAACCGACACCTTCCCCGACGATCTCGACACCACATCCCTTGCCCTCTCCATCGTAC
    CCACAAGCCCCGACGTCGTCAACTCGGTCATCGACGAGATTATCAGCCGTCGCGACAAGGACGGTATCGTCCCGA
    CTTACTTCGACAACACCCGCCCCCGCGTGGACCCAATCGTCTGCGTAAACGTCCTCTCCATGTTCGCAAAGTACGGC
    CGCGAGCACGACCTCCCCGCAACAGTTGCGTGGGTCCGCGACGTCTTGTATCATCGAGCATACCTCGGCGGAACA
    CGGTACTACGGGTCAGCTGAGGCCTTCCTCTTCTTCTTCACTCGCTTCGTTCGCAACCTCCGACCGGGAACTCTCAA
    GCAGGATCTACACGCATTGCTATCAGAGCGCGTGCGCGAGCGACTCAATACCCCCGTCGACGCACTCGCCCTGTCA
    ATGCGCATCCAGGCCTGTCATGCGCTGGGCTTTGACGCCCCCGCAGACATTGCGACGCTCATCACAATGCAGGAC
    GAGGACGGCGGGTGGCCGGCAGCCGTCATCTACAAGTACGGGGCCGGGGGGTTGGGGATCACGAACCGGGGTG
    TTTCGACTGCGTTTGCCGTAAAGGCGATTACAGGGTCGCCCGTGAAGACTGAAACCAACATAGGCGGCGATGGAG
    CTCGCGCTGTCTCGGCCATGTCCTCCTTGGAGGCGAGGAGGCTACAGCCGATCTCGTCGGTTGGGGACTGGGTGC
    GGTTTATCATTGCGTCGTTGCATGTCCATCTGGCTTGGCTTTGGAATGTTTTGCTTTTGAGCAAGGTTGTTTGA
    - CEN60542.1 optimized cDNA
    SEQ ID NO: 43
    ATGGTTCGTGCGTTGATTTTGGATTTGGGTGATGTGTTGTTTAATTGGGACGCCCCTGCAAGCACTCCGATCAGCC
    GTAAGACCCTGGGCCAGATGCTGCATTCCGAGATTTGGGGTGAGTATGAGCGTGGTCACCTGACCGAAGATGAA
    GCGTACAACGCGCTGGCAAAGCGCTACAGCTGCGAGGCAAAAGACGTGGCGCATACTTTTGTTTTGGCGCGTGAA
    AGCCTGCGCCTGGATACCAAGTTTAAGACTTTTCTGCAGACCCTGAAACAGAACGCGAACGGCTCGCTGCGTGTTT
    ATGGTATGTCCAATATCAGCAAACCGGATTTTGAAGTGCTGCTGGGTAAAGCTGACGACTGGACCTTGTTCGACAA
    GATCTTCCCGAGCGGTCATGTCGGTATGCGCAAACCGGACCTGGCTTTCTTTCGTTACGTGCTGAAAGACATCAGC
    ACCCCGGTTGAGGATGTTGTGTTTGTTGACGATAACCTGGATAATGTGACGTCTGCCCGTTCCCTGGGTATGCGTA
    GCGTCCTGTTCCACAAAAAAGACGAAGTCCAACGTCAGCTGACCAACATTTTCGGTAGCCCTGCTGAGCGCGGTCT
    GGAGTATCTGTCCGCGAACAAGACCAATCTGCAAAGCGCAACCACCACCGACATCCCTATCCAAGACAACTTTGGT
    CAATTACTGATTCTGGAAGCCACCGAAGATCCGAGCCTGGTACGCATGGAACCGGGCAAGCGTACCTGGAATTTC
    TTCATTGGCTCTCCGAGCCTGACGACGGATACCTTCCCGGATGACCTGGACACGACGAGCCTCGCACTGTCCATCG
    TGCCGACCAGCCCAGATGTTGTTAATAGCGTGATCGATGAGATCATCAGCCGTCGCGACAAGGACGGTATTGTGC
    CGACGTACTTTGATAACACGCGCCCGCGTGTGGACCCGATTGTTTGTGTTAACGTTCTGTCTATGTTCGCGAAATAT
    GGCCGTGAGCACGATCTGCCGGCGACGGTCGCGTGGGTCCGCGACGTCCTCTATCATCGCGCATACCTGGGTGGC
    ACCAGATACTACGGTAGCGCGGAAGCCTTCCTTTTCTTCTTTACGCGCTTTGTGCGTAATCTGCGTCCGGGCACGCT
    GAAACAAGATCTGCACGCGTTGCTGAGCGAGCGTGTCCGTGAGCGCCTGAATACCCCGGTGGATGCGCTGGCGCT
    GAGCATGCGCATTCAGGCTTGCCACGCACTGGGCTTTGACGCCCCAGCTGACATCGCGACGCTGATTACCATGCAA
    GATGAAGATGGTGGCTGGCCGGCGGCAGTTATCTACAAATATGGTGCGGGTGGCCTGGGCATTACGAACCGTGG
    TGTGTCCACGGCATTCGCGGTGAAGGCAATCACGGGTAGCCCGGTTAAAACCGAAACCAACATCGGCGGCGACG
    GTGCCCGTGCAGTGTCGGCCATGAGCAGCCTGGAAGCCCGTCGTTTGCAGCCGATTTCTAGCGTCGGCGACTGGG
    TCCGTTTCATCATCGCATCACTGCACGTCCACCTGGCGTGGCTGTGGAATGTCCTGCTGCTGAGCAAAGTCGTTTAA
    XP_009547469.1
    - XP_009547469.1 protein
    SEQ ID NO: 44
    MSMIPRCSNLILDIGDVLFTWSPKTSTSISPRTMKSILSSTTWHQYETGHISQGDCYRLIGNQFSIDPQEVGLAFQQARD
    SLQPNVDFIHFIRALKAESHGTLRVFAMSNISQPDYAVLRTKDADWAVFDDIFTSADAGVRKPHLGFYKLVLGKIGADP
    NDTVFVDDKGDNVLSARSLGLHGIVFDSMDNVKRALRYLISDPIRRGREFLQARAGHLESETNTGIEIGDNFAQLLILEAT
    KDRTLVNYMDHPNKWNFFRDQPLLTTEEFPFDLDTTSIGTLATQRDDGTANLVMDEMLQYRDEDGIIQTYFDHERPRI
    DPIVCVNVLSLFYSRGRGSELAPTLEWVRGVLKHRAYLDGTRYYETGECFLFFLSRLLQSTKDAALHASLKSLFAERVKERI
    GAPGDALALAMRILACAAVGVRDEIDLRSLLPLQCEDGGWEAGWVYKYGSSGVKIGNRGLTTALALNAIEAVEGRRTR
    PKSGKISRVSRHSEVAAAPRSSTSSHRSNRSISRTFQAYFKASWTSMKQVAVA
    - XP_009547469.1 cDNA
    SEQ ID NO: 45
    ATGTCCATGATACCCAGATGCTCGAATCTCATCCTCGACATCGGGGATGTTCTCTTCACATGGTCTCCGAAGACGTC
    CACTTCGATCTCCCCCCGCACCATGAAGAGCATACTGTCATCGACGACCTGGCACCAATACGAGACCGGGCACATT
    TCACAGGGCGACTGCTACCGCCTCATAGGCAACCAGTTCTCCATCGATCCTCAGGAAGTCGGACTTGCATTCCAAC
    AAGCTCGGGACTCATTGCAGCCTAATGTTGACTTCATTCACTTCATCCGCGCCCTCAAGGCGGAATCACACGGGAC
    GCTGCGCGTCTTCGCTATGTCCAACATCTCTCAGCCCGATTACGCAGTTCTTCGGACTAAGGACGCCGACTGGGCC
    GTTTTTGACGATATATTCACGTCTGCAGATGCTGGGGTTCGAAAGCCACACCTTGGGTTCTACAAGTTGGTACTCG
    GAAAGATCGGCGCCGATCCAAACGATACCGTCTTCGTCGATGACAAGGGGGACAATGTCCTCTCTGCACGGTCTC
    TCGGCCTTCATGGAATCGTCTTTGACAGTATGGACAACGTCAAGCGAGCCCTGCGCTACTTGATCAGCGACCCCAT
    ACGGCGAGGACGAGAGTTTCTCCAAGCGCGAGCCGGCCATTTGGAGTCGGAGACCAATACGGGCATCGAAATCG
    GTGATAATTTTGCCCAGCTCCTTATTCTCGAGGCCACGAAGGATAGGACACTCGTCAATTATATGGACCATCCGAA
    CAAATGGAATTTCTTCCGAGATCAACCGCTCCTCACAACGGAGGAGTTCCCTTTCGATCTCGATACGACATCTATTG
    GAACGCTTGCGACGCAGCGCGATGATGGGACTGCCAATCTAGTAATGGATGAGATGCTTCAGTACCGTGATGAG
    GATGGCATAATACAAACATATTTCGATCATGAACGACCGAGGATAGATCCCATCGTCTGTGTCAACGTCTTGAGCC
    TTTTCTACTCCCGGGGTCGTGGTTCGGAGCTAGCACCGACACTAGAGTGGGTGCGTGGTGTCCTCAAGCACCGCG
    CGTATCTCGATGGAACGCGATACTACGAGACAGGCGAATGCTTCCTTTTCTTCCTCAGCCGGCTCTTGCAATCAACC
    AAGGACGCCGCCTTGCACGCATCGTTGAAATCTTTGTTCGCCGAACGGGTCAAGGAGCGCATAGGGGCACCAGG
    GGACGCGCTGGCGCTGGCGATGCGTATACTGGCATGCGCAGCAGTGGGCGTGCGGGACGAGATCGATCTTCGAT
    CACTATTACCTCTGCAGTGCGAGGATGGGGGGTGGGAGGCAGGCTGGGTGTACAAGTATGGGTCTTCGGGAGTC
    AAGATCGGCAATCGTGGCCTCACGACTGCGCTTGCGCTCAATGCCATCGAGGCTGTGGAGGGACGTCGCACGAG
    GCCGAAGTCGGGTAAGATCAGCCGAGTCAGCCGTCATTCTGAGGTCGCAGCAGCGCCACGGTCTTCCACCAGCAG
    TCATCGTTCTAATCGCTCGATCTCAAGGACATTCCAGGCGTACTTCAAGGCGTCGTGGACATCGATGAAACAGGTG
    GCCGTGGCGTGA
    - XP_009547469.1 optimized cDNA
    SEQ ID NO: 46
    ATGAGCATGATTCCACGTTGTAGCAATCTGATTCTCGACATCGGTGATGTGTTGTTTACGTGGAGCCCGAAAACCA
    GCACCAGCATTAGCCCGCGTACCATGAAATCTATCCTGAGCTCTACCACCTGGCATCAATATGAGACTGGCCACAT
    CAGCCAGGGTGATTGCTACCGCCTGATCGGTAATCAGTTCTCCATCGACCCGCAAGAGGTCGGTTTGGCCTTCCAG
    CAAGCCAGAGACAGCCTGCAACCGAATGTTGATTTCATCCATTTCATTCGTGCCCTGAAAGCTGAGTCGCACGGCA
    CCCTGCGCGTTTTTGCGATGAGCAATATCAGCCAACCTGACTATGCAGTCCTGCGTACGAAAGACGCGGACTGGG
    CTGTTTTTGATGATATCTTCACGAGCGCGGATGCTGGTGTTCGTAAACCGCACCTGGGTTTTTATAAACTGGTCTTA
    GGCAAGATTGGCGCGGACCCTAACGACACCGTTTTTGTGGATGATAAGGGTGACAACGTCCTCTCTGCACGTTCCC
    TGGGTCTGCACGGTATCGTTTTTGATTCAATGGACAACGTGAAGCGCGCACTGCGCTACCTGATTAGCGACCCGAT
    CCGCCGCGGCCGTGAATTTCTGCAGGCCCGTGCGGGTCACCTGGAGTCCGAAACGAACACGGGTATTGAGATTGG
    TGATAATTTCGCGCAATTGCTGATCCTGGAAGCGACCAAAGATCGTACTCTGGTGAACTACATGGACCACCCGAAC
    AAGTGGAACTTCTTCCGTGACCAGCCGCTGCTGACCACCGAAGAATTTCCGTTCGACCTGGACACGACCAGCATTG
    GCACGCTGGCCACCCAACGTGACGATGGTACGGCGAATCTGGTAATGGACGAAATGTTGCAGTATCGTGACGAA
    GATGGCATCATTCAGACCTATTTCGATCATGAGCGCCCGCGTATTGATCCGATTGTTTGTGTGAATGTGCTGTCTCT
    GTTCTACAGCCGTGGCCGTGGCTCTGAGTTGGCGCCGACGCTGGAATGGGTGCGCGGTGTGTTGAAACATCGTGC
    GTACCTGGATGGTACGCGTTATTACGAGACTGGTGAGTGTTTCCTGTTTTTCCTGAGCCGTCTGCTGCAGAGCACC
    AAAGACGCAGCCCTGCACGCGAGCCTGAAGTCCCTGTTTGCAGAGCGTGTTAAAGAGCGCATCGGTGCGCCGGG
    CGATGCTCTGGCGCTGGCTATGCGCATCCTGGCGTGCGCCGCTGTTGGTGTGCGCGATGAAATTGATTTGCGTAG
    CCTGCTGCCGCTGCAATGCGAAGATGGCGGCTGGGAAGCGGGCTGGGTCTACAAATACGGCAGCAGCGGTGTGA
    AGATTGGCAATCGCGGTCTTACCACGGCGCTGGCATTGAATGCTATCGAAGCCGTTGAGGGCCGTCGCACCCGCC
    CAAAGTCCGGTAAGATCAGCCGTGTTAGCCGTCATAGCGAAGTCGCAGCGGCACCGCGTTCCTCGACGAGCAGCC
    ACCGTAGCAACCGTAGCATTAGCCGCACCTTCCAGGCATATTTTAAAGCGAGCTGGACCAGCATGAAACAAGTCG
    CAGTGGCGTAA
    KLO09124.1
    - KLO09124.1 protein
    SEQ ID NO: 47
    MSIHGSSMSSYSSTVPSMTSSPASTSTPSSPASSIHEIGPVPEARRKGQCNALIFDLGDVLFTWSAETKTTISPKLLKKILNS
    LTWFEYEKGNIGEQEAYDAVAKEFGVPSSEVGAAFQCARDSLQSNPRLVSLIRELKSQYDLKVYAMSNISAPDWEVLRT
    KATPEEWAMFDRVFTSAAARERKPNLGFYRQVVEATGVDPARSVFVDDKLDNVISARSVGLNAIIFDSFENVARQLKN
    YVADPIGRAEAWLRDNAKKMLSITDAGVVVYENFGQMLILEATGDRSLVDYVEYPRLFNFFQGNGVFTTESFPCDLDST
    SIGLTVTNHVDEKTRHSVMDEMLTYKNEDGIIATYFDATRPRIDPVVCANVLTFFYKNGRGEELNETLDWVYDILLHRAY
    LDGTRYYFGSDTFLFFLSRLLSESPSVYARFAPVFQERVKERMGATGDAMSLAMRIIAAATVKIQDRVDCDALLQTQED
    DGGFPIGWMYKYGATGMLLGNKGLSTALAIQAIKAVESFP
    - KLO09124.1 cDNA
    SEQ ID NO: 48
    ATGTCGATTCACGGTTCTTCTATGTCCTCCTATTCCTCGACTGTGCCGTCAATGACTTCCTCTCCCGCGTCCACTTCTA
    CTCCGTCGTCTCCTGCATCGTCGATCCATGAGATTGGTCCTGTCCCAGAAGCTCGACGAAAGGGACAGTGCAACGC
    GCTGATCTTCGACCTCGGAGACGTCCTCTTCACCTGGTCGGCAGAGACTAAGACCACCATTTCCCCGAAACTCCTG
    AAAAAGATCCTTAACTCCTTAACATGGTTCGAATACGAGAAGGGAAACATCGGGGAGCAGGAGGCGTATGACGC
    AGTCGCAAAGGAGTTTGGCGTCCCGTCGTCCGAGGTCGGGGCCGCTTTCCAGTGCGCGCGCGATTCGCTACAGAG
    CAATCCCCGCCTCGTCTCGCTCATCCGTGAGCTGAAGTCGCAATATGATCTCAAGGTGTACGCCATGTCCAACATCT
    CTGCGCCGGACTGGGAAGTCCTAAGGACGAAGGCGACCCCTGAGGAGTGGGCAATGTTTGACCGCGTCTTCACG
    AGCGCGGCCGCGCGCGAGCGTAAGCCAAACCTCGGATTCTACAGACAGGTTGTTGAGGCGACCGGCGTCGACCC
    CGCTCGCTCCGTGTTCGTCGACGATAAACTCGACAATGTCATCTCTGCGCGTTCAGTCGGATTAAATGCGATCATCT
    TCGACTCATTTGAGAACGTCGCCCGGCAGCTCAAAAACTATGTCGCTGATCCTATCGGACGGGCGGAGGCGTGGT
    TGCGCGATAACGCAAAGAAGATGTTGTCAATTACGGATGCCGGGGTGGTCGTATACGAGAATTTCGGCCAGATGC
    TGATCTTGGAGGCAACAGGCGATAGGTCGCTTGTGGACTACGTCGAGTACCCTCGTCTCTTCAACTTCTTCCAAGG
    CAATGGCGTCTTTACGACCGAGTCATTCCCTTGCGACCTTGATTCGACTTCCATCGGCTTAACCGTCACGAACCACG
    TCGATGAGAAAACAAGGCACAGCGTCATGGATGAGATGCTGACCTACAAAAATGAGGATGGTATCATTGCGACTT
    ACTTTGATGCCACGCGTCCCCGAATTGACCCCGTCGTCTGCGCCAATGTCTTGACGTTCTTCTACAAGAACGGCCGA
    GGGGAGGAGCTCAATGAAACACTTGACTGGGTCTACGACATCCTCCTTCATCGCGCGTACCTCGATGGCACACGCT
    ATTATTTCGGCTCAGACACCTTCCTCTTCTTCCTTTCTCGACTTCTCTCCGAATCGCCATCCGTTTACGCCCGTTTCGC
    TCCGGTGTTCCAGGAGAGAGTCAAGGAGCGCATGGGGGCGACGGGAGATGCGATGTCCCTTGCGATGCGCATCA
    TCGCGGCCGCAACTGTCAAGATCCAAGACCGAGTCGACTGCGACGCTCTGCTGCAGACGCAGGAAGACGACGGT
    GGATTCCCGATAGGTTGGATGTACAAGTACGGGGCGACCGGGATGCTTCTGGGTAACAAGGGCTTGTCGACAGC
    TCTGGCAATCCAAGCTATCAAAGCGGTCGAATCTTTCCCTTGA
    - KLO09124.1 optimized cDNA
    SEQ ID NO: 49
    GGATCCAAGCTTAAGGAGGTAAAAAATGTCGATTCACGGTAGCAGCATGTCGTCTTATAGCAGCACGGTTCCATCT
    ATGACTAGCAGCCCGGCTTCCACGAGCACGCCGTCCAGCCCGGCCAGCAGCATCCACGAAATCGGCCCGGTCCCT
    GAGGCGCGTCGCAAGGGCCAATGCAATGCACTGATCTTCGACCTGGGTGATGTTCTGTTTACCTGGAGCGCAGAA
    ACCAAGACCACGATCAGCCCGAAGCTGCTGAAAAAGATTCTGAACAGCTTGACCTGGTTTGAGTATGAGAAAGGC
    AACATCGGTGAACAAGAAGCCTATGACGCCGTTGCGAAAGAGTTCGGTGTGCCGAGCTCTGAGGTTGGCGCTGC
    GTTTCAATGTGCGCGTGACTCCCTGCAAAGCAATCCGCGTTTGGTTAGCCTGATTCGTGAGCTGAAGTCCCAGTAC
    GACCTGAAAGTGTACGCTATGAGCAATATTAGCGCGCCAGACTGGGAAGTGCTGCGTACTAAAGCGACCCCGGAA
    GAGTGGGCAATGTTCGATCGTGTCTTTACTTCTGCGGCGGCGCGTGAGCGTAAGCCGAACTTGGGCTTTTACCGCC
    AAGTCGTGGAAGCAACCGGTGTCGATCCGGCGCGTAGCGTTTTCGTCGATGATAAACTGGACAATGTGATCAGCG
    CGCGCTCTGTCGGTCTGAACGCTATTATCTTCGACTCCTTCGAAAACGTCGCCCGTCAGCTGAAGAATTACGTCGCA
    GACCCGATTGGTCGCGCTGAGGCGTGGCTGCGCGACAACGCAAAGAAAATGCTGAGCATCACCGATGCGGGTGT
    TGTGGTTTACGAGAATTTTGGCCAGATGCTGATCCTGGAAGCTACCGGTGACCGTAGCCTGGTGGACTATGTGGA
    GTATCCGCGCCTCTTTAACTTCTTCCAGGGTAACGGCGTTTTTACGACCGAGAGCTTTCCATGCGATCTGGACAGCA
    CCAGCATCGGTCTGACTGTGACCAATCATGTGGACGAAAAGACTCGCCACAGCGTCATGGACGAAATGCTGACCT
    ACAAAAATGAAGATGGTATTATTGCGACGTACTTTGACGCGACGCGCCCGCGCATTGACCCTGTTGTCTGTGCCAA
    TGTTCTGACCTTCTTCTACAAAAACGGTCGTGGTGAAGAATTGAACGAAACCCTGGATTGGGTGTACGACATTCTG
    CTGCATCGCGCGTATCTGGACGGTACGCGTTATTATTTCGGCTCCGATACGTTCCTGTTTTTCCTGAGCCGTCTGCT
    GAGCGAGTCTCCGAGCGTTTACGCGCGTTTTGCCCCGGTGTTTCAAGAGCGCGTGAAAGAGCGTATGGGCGCGAC
    CGGTGATGCGATGAGCCTGGCCATGCGTATCATTGCAGCAGCAACCGTAAAGATCCAGGATCGTGTGGATTGCGA
    CGCACTGTTGCAGACCCAAGAAGATGATGGCGGTTTCCCGATTGGTTGGATGTACAAATATGGTGCGACCGGTAT
    GTTGCTGGGCAACAAAGGCCTGAGCACGGCCCTGGCGATCCAGGCAATTAAAGCCGTCGAGTCGTTCCCGTAAGG
    TACCATATATGAATTCATTAATCTCGAG
    OJI95797.1
    - 0JI95797.1 protein
    SEQ ID NO: 50
    MGSTKALVVDFGNVLCTWTPPRELSIPPKKLKQIMSSDIWLDYERGIYKSEDECYLAVATRFGVSPSDLSSVMKKARESL
    QPNTATLNHLSHLKKTQPGLRIYGLTNTPLPEQSSVRSIAQEWPIFDHIYISGILGMRKPDIGCYRLVLRKIGLPAESVVFID
    DSPENILAAQSLGVHSILFQSHDQLSRQLGNVLGDPIQRGHNFLLSNAKQMNSTTDKGVIIRDNFAQLLIIELTQNPDLV
    ALETWDRTWNFFIGPPQLTTESFPNDLDTTSIALSVLPVDKEVVWSVMDEMLTFTNADGIFMTYFDRSRPRVDPVVCT
    NVLNLFCMHGRESEVAATFDWVLDVLRNSAYLSGSRYYSSPDCFLYFLSRLSCVVRDGTRRRELKSLLKQQVSQRIGAD
    GDSVSLATRLLASNILGITNGRDRSRLLALQETDGGWPAGWVYKFGSSGVQIGNRGLSTALALKSIERQKGPVEAISSEP
    EAWWPSLRLDRLLNVWPFIDWKGYSPS
    - 0JI95797.1 cDNA
    SEQ ID NO: 51
    ATGGGTTCCACCAAGGCTCTTGTTGTTGACTTTGGGAATGTTTTGTGTACCTGGACACCACCCAGGGAGTTATCCAT
    CCCGCCCAAGAAGCTGAAACAAATCATGTCTTCTGACATTTGGCTCGACTATGAACGGGGTATCTATAAGTCGGAG
    GACGAGTGCTACTTGGCGGTTGCAACTCGCTTCGGCGTCTCTCCCAGCGACCTCTCCTCGGTGATGAAAAAGGCCC
    GCGAGAGCCTGCAACCAAACACCGCAACCCTGAATCATCTGTCTCATCTCAAAAAGACCCAGCCTGGCCTCAGGAT
    ATACGGTTTGACCAACACCCCTCTCCCAGAACAAAGCAGTGTACGATCCATCGCCCAGGAATGGCCTATCTTCGAC
    CATATCTACATATCAGGCATCCTCGGAATGCGCAAGCCGGACATTGGCTGCTACAGGCTGGTGCTGCGAAAGATT
    GGGCTTCCAGCGGAGTCCGTGGTCTTCATTGATGATTCACCCGAGAACATCCTGGCCGCGCAGTCACTGGGAGTA
    CACAGCATACTGTTCCAAAGCCACGACCAGCTCTCTCGTCAGCTTGGCAATGTGCTGGGTGATCCAATCCAGCGGG
    GCCATAACTTCCTACTCTCGAACGCAAAGCAAATGAATAGTACGACCGACAAGGGAGTTATTATCCGGGACAACTT
    TGCGCAACTGCTGATCATCGAGCTGACGCAGAACCCAGACCTTGTGGCGTTAGAAACATGGGACCGTACCTGGAA
    TTTTTTTATTGGACCTCCACAATTGACAACTGAAAGCTTTCCCAATGATCTTGACACTACCTCCATCGCTCTCTCGGT
    TCTTCCGGTTGACAAAGAAGTGGTATGGTCTGTGATGGACGAGATGCTAACGTTTACCAATGCGGATGGGATTTTT
    ATGACCTATTTCGACCGATCACGCCCTCGAGTTGATCCGGTAGTTTGCACCAATGTCCTGAATCTTTTCTGCATGCA
    TGGACGGGAAAGCGAAGTTGCAGCCACATTTGACTGGGTGCTGGACGTTCTTCGAAATTCGGCCTATTTATCAGG
    ATCCAGATACTATTCTTCGCCTGATTGCTTTCTATACTTTCTTTCACGGCTGAGCTGTGTGGTCCGAGACGGCACGC
    GACGCAGGGAGCTCAAGTCACTGTTGAAACAACAAGTGAGCCAGCGTATTGGCGCTGATGGTGATTCCGTCTCTC
    TCGCCACTAGGCTACTTGCATCGAACATTTTAGGAATCACAAATGGCCGTGATCGCTCCAGGCTTCTTGCTCTGCAG
    GAAACTGACGGTGGATGGCCTGCTGGGTGGGTTTATAAATTCGGAAGCTCGGGGGTACAGATTGGCAATCGGGG
    GCTCAGTACAGCCTTGGCGTTAAAATCAATTGAGCGTCAGAAGGGGCCTGTTGAGGCGATATCCAGTGAGCCAGA
    AGCGTGGTGGCCATCCCTCAGGCTTGACCGACTTCTCAACGTTTGGCCTTTCATCGACTGGAAGGGATATTCGCCG
    AGTTGA
    - 0JI95797.1 optimized cDNA
    SEQ ID NO: 52
    ATGGGTTCTACGAAAGCGTTGGTTGTTGATTTTGGTAATGTTCTGTGCACTTGGACGCCACCACGTGAATTGTCCA
    TCCCGCCGAAGAAACTGAAGCAAATCATGAGCAGCGACATTTGGCTGGACTATGAGCGTGGTATCTACAAATCGG
    AAGATGAGTGCTACCTGGCAGTTGCGACGCGCTTTGGTGTCAGCCCGTCCGACCTGAGCTCCGTTATGAAAAAAG
    CCCGTGAGAGCCTGCAGCCGAATACCGCAACGCTGAACCACTTGAGCCATCTGAAGAAAACCCAGCCTGGCCTTC
    GTATCTACGGCCTGACGAACACCCCGTTGCCGGAACAGAGCTCAGTCCGTAGCATTGCGCAGGAATGGCCGATTT
    TTGACCACATCTACATTAGCGGCATCTTGGGTATGCGCAAACCGGATATTGGTTGTTACCGTCTGGTTCTGCGTAA
    GATCGGTCTGCCAGCGGAGTCCGTCGTATTCATCGACGACAGCCCGGAGAACATTCTGGCAGCTCAATCGTTGGG
    TGTCCATAGCATCCTGTTCCAGTCCCACGATCAGCTGAGCCGTCAGCTGGGCAATGTGCTGGGTGATCCGATTCAG
    CGCGGTCACAACTTCCTCCTGTCCAACGCGAAGCAAATGAACAGCACCACCGATAAGGGTGTGATTATCCGCGAC
    AACTTCGCCCAGCTGCTGATTATTGAGCTGACCCAAAATCCGGATCTGGTTGCGCTGGAGACTTGGGACCGTACGT
    GGAATTTCTTTATTGGTCCGCCGCAACTGACCACCGAGAGCTTTCCGAACGACCTGGACACCACGAGCATTGCCCT
    GAGCGTGTTGCCGGTGGATAAAGAAGTCGTTTGGTCTGTGATGGATGAGATGCTGACCTTCACCAACGCAGACGG
    CATCTTCATGACCTATTTCGATCGTAGCCGTCCGCGTGTTGACCCGGTCGTTTGTACCAATGTCCTGAATCTGTTTTG
    CATGCATGGTCGCGAGAGCGAAGTGGCCGCGACGTTCGACTGGGTGCTGGACGTGCTGCGCAACAGCGCGTACC
    TGAGCGGTTCCCGTTATTACAGCAGCCCGGATTGTTTTCTGTATTTCCTGTCTCGTCTGAGCTGCGTCGTCCGTGAT
    GGCACGCGTCGTCGTGAACTGAAAAGCCTGCTGAAGCAACAAGTTTCTCAACGTATCGGCGCTGACGGTGATTCC
    GTCAGCCTGGCCACCCGTTTGCTGGCGAGCAACATCCTGGGCATTACTAACGGTCGTGACCGCAGCCGTCTGCTG
    GCATTGCAAGAAACCGATGGTGGCTGGCCTGCAGGCTGGGTCTATAAGTTTGGTAGCAGCGGCGTGCAAATTGG
    CAATCGCGGTCTGAGCACCGCGCTGGCTCTGAAGTCTATCGAGCGCCAGAAAGGTCCGGTGGAAGCAATCAGCA
    GCGAGCCGGAAGCGTGGTGGCCTAGCTTACGCTTGGACCGCTTGCTGAATGTTTGGCCATTTATCGACTGGAAGG
    GCTACTCCCCGAGCTAA
    Class I terpene synthase-like motif
    SEQ ID NO: 53
    DDxx(D/E), where x at position 3 is K, N, R, S, or Q and x at position 4 is
    L, I, G, P, or T
    Class I terpene synthase-like motif
    SEQ ID NO: 54
    DD(K/Q/R)(L/I/T)(D/E)NV
    Class I terpene synthase-like motif
    SEQ ID NO: 55
    DD(N/K/S/Q)(L/G/P)(D/E)N(V/I)
    Class II terpene synthase-like motif
    SEQ ID NO: 56
    DxD(T/S)T, where x at position 2 is V, M, F or L
    Class II terpene synthase-like motif
    SEQ ID NO: 57
    D(V/M/L/F)DTTS
    Class II terpene synthase-like motif
    SEQ ID NO: 58
    D(V/M/L)D(T/S)TS
    Conserved motif A
    SEQ ID NO: 59
    SxxWxxYExG, where x is any amino acid
    Conserved motif B
    SEQ ID NO: 60
    NFxQx(I/L)IxE, where x is any amino acid
    Conserved motif C
    SEQ ID NO: 61
    (D/E)(G/E)Ixx(T/V)YFDxxRxRxDPxVxxNVL
    Conserved motif D
    SEQ ID NO: 62
    QxxDGx(W/F)
    XP_006461126.1
    - XP_006461126.1 protein
    SEQ ID NO: 63
    MAPPQRPFTAIVFDIGDVLFQWSATTKTSISPKTLRSILNCPTWFDYERGRLAENACYAAISQEFNVNPDEVRDAFSQAR
    DSLQANHDFISLIRELKAQANGRLRVYAMSNISLPDWEVLRMKPADWDIFDHVFTSGAVGERKPNLAFYRHVIAATDL
    QPHQTIFVDDKLENVLSARSLGFTGIVFDEPSEVKRALRNLIGDPVQRGGEFLVRNAGKLGSITRTTAKHESIPLDENFAQ
    LLILEITGNRALVNLVEHPQTWNFFQGKGQLTTEEFPFDLDTTSLGLTILKRSREIADSVMDEMLEYVDPDGIIQTYFDHR
    RPRFDPVVCVNALSLFYAYGRGEQLRSTLTWVHEVLLNRAYLDGTRYYETAECFLYFMSRLLATSGDPDLHSLLKPLLKER
    VQERIGADGDSLALAMRILACDFVGIRDEVDLRTLLTLQCEDGGWEVGWMYKYGSSGISIGNRGLATALAIKAVDTMF
    QPQIRFSESPTDTLVENAIHKRRPSFSEKFLGKRPRSGSFRKPLQWILQGSKLRKSVEIGS
    - XP_006461126.1 cDNA
    SEQ ID NO: 64
    ATGGCTCCGCCTCAGCGACCCTTTACTGCGATTGTCTTTGACATCGGGGATGTTCTATTCCAATGGTCTGCAACCAC
    CAAAACCTCTATCTCACCAAAGACACTCCGCTCTATTCTCAACTGTCCGACATGGTTTGACTATGAACGTGGACGCC
    TGGCAGAAAACGCTTGTTATGCCGCTATCTCACAAGAATTCAACGTCAACCCAGACGAAGTTCGCGACGCTTTCAG
    CCAAGCGCGCGACTCTCTCCAAGCAAACCACGACTTCATCAGTCTCATCCGTGAGCTGAAGGCACAAGCAAATGGT
    CGTTTACGTGTGTACGCCATGTCGAACATATCTCTTCCTGATTGGGAAGTGCTGCGGATGAAACCTGCTGATTGGG
    ATATTTTCGACCACGTCTTCACATCCGGTGCGGTTGGGGAACGCAAGCCCAATCTCGCCTTTTATCGCCATGTTATC
    GCGGCCACCGATCTGCAGCCTCATCAGACAATATTTGTTGACGATAAGCTGGAGAATGTTCTCTCAGCACGTTCCC
    TCGGGTTCACAGGCATCGTGTTTGACGAGCCCTCCGAGGTCAAACGTGCGCTTCGTAACCTCATTGGGGATCCTGT
    TCAACGAGGAGGTGAATTCTTGGTTCGGAATGCCGGAAAGCTTGGCTCTATCACAAGGACTACTGCAAAGCACGA
    GTCAATCCCCCTCGACGAGAATTTTGCTCAGCTTCTTATTCTCGAGATAACGGGGAACAGGTGCGTTAGCTTCTTGT
    AGGGTCTTCTGTCGTAATACTAAATTTTTTCTGGTGTTTAGGGCTTTGGTCAACCTCGTTGAGCATCCTCAAACGTG
    GAATTTCTTCCAAGGTGCGCTGCTAAAATAAACATCCAGTTGCGTTTCGAAGCTCATTGTGGGCGTCCCGTCACAG
    GCAAGGGCCAGCTGACAACAGAAGAATTTCCATTCGATCTCGATACAACTTCTCTTGGTCTCACGATCCTCAAGCG
    AAGCAGGGAAATCGCCGATTCAGTCATGGATGAAATGCTGGAGTATGTCGATCCTGATGGTATCATTCAGGCAAG
    TTTCATTTATCGGCTTGAGAAAATAAAGACAAAAACGTTCTGATGGGGGGATGTTTCTAGACGTATTTCGATCATC
    GGAGACCACGTTTTGATCCAGTCGTGTGTGTCAATGCATTAAGCCTCTTCTATGCTTACGGCCGCGGGGAGCAACT
    GCGGTCGACTTTGACATGGGTACATGAAGTCCTTCTCAATCGAGCCTACTTGGATGGCACACGGTACTACGAAACA
    GCCGAATGCTTCCTCTATTTCATGAGCCGACTTCTCGCCACTTCAGGCGACCCTGACCTTCACTCCCTTCTTAAACCT
    CTTCTCAAAGAACGGGTGCAAGAACGCATTGGAGCTGATGGAGACTCTCTTGCACTCGCAATGCGTATTCTCGCCT
    GTGATTTCGTCGGAATCAGAGATGAAGTGGATTTACGCACACTTCTGACTTTGCAATGTGAAGATGGAGGTTGGG
    AAGTGGGTTGGATGTACAAGTATGGATCTTCCGGTATCAGTATCGGAAATCGTGGACTGGCCACCGCGCTCGCTA
    TCAAGGCCGTCGACACGATGTTTCAACCCCAAATTCGGTTCTCTGAATCACCCACAGATACTTTGGTTGAAAACGCT
    ATCCACAAACGCCGTCCCTCATTTTCCGAAAAATTCCTCGGCAAACGTCCTCGCAGCGGATCGTTCAGGAAACCTTT
    ACAGTGGATACTGCAAGGTTCCAAGCTTCGCAAATCTGTCGAAATAGGAAGCTAA
    - XP_006461126.1 optimized cDNA
    SEQ ID NO: 65
    ATGGCACCACCGCAACGTCCGTTCACTGCAATTGTTTTCGATATTGGCGATGTTTTGTTCCAATGGTCTGCGACCAC
    GAAAACCAGCATTAGCCCGAAAACCCTGCGCAGCATTCTGAATTGTCCGACCTGGTTTGATTATGAGCGCGGCCGT
    CTGGCGGAAAATGCGTGTTACGCTGCGATCAGCCAAGAATTTAACGTCAACCCGGACGAAGTTCGCGACGCCTTC
    AGCCAAGCGCGCGACAGCCTGCAGGCGAATCACGACTTCATCAGCCTGATTCGTGAGCTGAAAGCTCAGGCGAAC
    GGTCGTCTGCGTGTCTACGCCATGTCTAATATCAGCCTGCCGGATTGGGAAGTCCTGCGTATGAAGCCAGCCGATT
    GGGACATCTTTGACCATGTATTTACCAGCGGTGCGGTGGGTGAGCGCAAGCCGAACCTGGCCTTTTATCGTCACGT
    CATCGCGGCCACGGATCTGCAGCCGCACCAGACGATCTTCGTGGATGACAAACTGGAAAACGTGCTGTCTGCGCG
    CTCGCTGGGCTTCACGGGTATCGTGTTCGACGAGCCAAGCGAAGTCAAACGTGCGCTGCGTAATCTGATCGGCGA
    CCCGGTGCAGCGTGGTGGCGAGTTCCTGGTTCGTAATGCTGGCAAACTGGGTTCTATCACCCGTACGACCGCAAA
    ACATGAGAGCATCCCGCTGGATGAGAATTTTGCACAACTGTTGATTCTGGAAATTACTGGTAACCGCGCACTGGTC
    AATCTGGTTGAGCACCCGCAGACGTGGAACTTCTTCCAGGGTAAGGGCCAGCTGACGACCGAAGAATTTCCTTTT
    GACCTGGATACGACGAGCCTGGGTCTGACGATCCTGAAGCGTAGCCGCGAGATTGCCGACTCCGTCATGGACGAA
    ATGTTGGAATACGTGGACCCTGACGGCATCATTCAGACCTACTTCGATCATCGTCGCCCGCGCTTTGACCCGGTTG
    TTTGCGTTAATGCCCTGAGCCTGTTCTATGCATACGGCCGTGGTGAGCAACTGCGTTCCACCTTGACCTGGGTGCA
    CGAAGTTCTGTTGAACCGTGCGTATTTGGATGGTACGCGTTACTATGAAACGGCCGAGTGCTTTCTGTATTTCATG
    TCCCGTCTGCTGGCAACCAGCGGTGACCCGGATCTGCATTCCCTGCTGAAGCCGTTGCTGAAGGAACGCGTGCAA
    GAGCGCATCGGCGCTGACGGTGACAGCCTGGCGCTGGCGATGCGCATTTTGGCATGTGATTTTGTTGGCATCCGT
    GATGAAGTGGATCTGCGTACCCTGCTGACCTTACAGTGCGAGGATGGCGGTTGGGAAGTGGGCTGGATGTACAA
    ATACGGTAGCAGCGGTATTAGCATTGGTAACCGTGGTCTGGCAACCGCATTGGCGATCAAAGCTGTTGACACCAT
    GTTTCAACCGCAAATCCGTTTCAGCGAGAGCCCGACCGACACTCTGGTGGAGAACGCGATTCACAAGCGCCGCCC
    GAGCTTTTCAGAGAAATTTTTAGGTAAGCGTCCGCGTTCCGGTTCGTTCCGTAAACCGCTGCAATGGATTCTGCAG
    GGCAGCAAGCTGCGCAAGAGCGTCGAGATCGGTAGCTAA
    XP_007369631.1
    - XP_007369631.1 Optimized cDNA for S. cerevisiae expression
    SEQ ID NO: 66
    ATGGCTTCTATCCACAGAAGATACACTACTTTGATCTTGGACTTGGGTGACGTTTTGTTCAGATGGTCTCCAAAGAC
    TGAAACTGCTATCCCACCACAACAATTGAAGGACATCTTGTCTTCTGTTACTTGGTTCGAATACGAAAGAGGTAGA
    TTGTCTCAAGAAGCTTGTTACGAAAGATGTGCTGAAGAATTCAAGATCGAAGCTTCTGTTATCGCTGAAGCTTTCA
    AGCAAGCTAGAGGTTCTTTGAGACCAAACGAAGAATTCATCGCTTTGATCAGAGACTTGAGAAGAGAAATGCACG
    GTGACTTGACTGTTTTGGCTTTGTCTAACATCTCTTTGCCAGACTACGAATACATCATGTCTTTGTCTTCTGACTGGA
    CTACTGTTTTCGACAGAGTTTTCCCATCTGCTTTGGTTGGTGAAAGAAAGCCACACTTGGGTTGTTACAGAAAGGTT
    ATCTCTGAAATGAACTTGGAACCACAAACTACTGTTTTCGTTGACGACAAGTTGGACAACGTTGCTTCTGCTAGATC
    TTTGGGTATGCACGGTATCGTTTTCGACAACCAAGCTAACGTTTTCAGACAATTGAGAAACATCTTCGGTGACCCA
    ATCAGAAGAGGTCAAGAATACTTGAGAGGTCACGCTGGTAAGTTGGAATCTTCTACTGACAACGGTTTGATCTTCG
    AAGAAAACTTCACTCAATTGATCATCTACGAATTGACTCAAGACAGAACTTTGATCTCTTTGTCTGAATGTCCAAGA
    ACTTGGAACTTCTTCAGAGGTGAACCATTGTTCTCTGAAACTTTCCCAGACGACGTTGACACTACTTCTGTTGCTTT
    GACTGTTTTGCAACCAGACAGAGCTTTGGTTAACTCTGTTTTGGACGAAATGTTGGAATACGTTGACGCTGACGGT
    ATCATGCAAACTTACTTCGACAGATCTAGACCAAGAATGGACCCATTCGTTTGTGTTAACGTTTTGTCTTTGTTCTAC
    GAAAACGGTAGAGGTCACGAATTGCCAAGAACTTTGGACTGGGTTTACGAAGTTTTGTTGCACAGAGCTTACCAC
    GGTGGTTCTAGATACTACTTGTCTCCAGACTGTTTCTTGTTCTTCATGTCTAGATTGTTGAAGAGAGCTGACGACCC
    AGCTGTTCAAGCTAGATTGAGACCATTGTTCGTTGAAAGAGTTAACGAAAGAGTTGGTGCTGCTGGTGACTCTATG
    GACTTGGCTTTCAGAATCTTGGCTGCTGCTTCTGTTGGTGTTCAATGTCCAAGAGACTTGGAAAGATTGACTGCTG
    GTCAATGTGACGACGGTGGTTGGGACTTGTGTTGGTTCTACGTTTTCGGTTCTACTGGTGTTAAGGCTGGTAACAG
    AGGTTTGACTACTGCTTTGGCTGTTACTGCTATCCAAACTGCTATCGGTAGACCACCATCTCCATCTCCATCTGCTGC
    TTCTTCTTCTTTCAGACCATCTTCTCCATACAAGTTCTTGGGTATCTCTAGACCAGCTTCTCCAATCAGATTCGGTGA
    CTTGTTGAGACCATGGAGAAAGATGTCTAGATCTAACTTGAAGTCTCAATAA
    XP_006461126
    - XP_006461126 Optimized cDNA for S. cerevisiae expression
    SEQ ID NO: 67
    ATGGCTCCACCACAAAGACCATTCACTGCTATCGTTTTCGACATCGGTGACGTTTTGTTCCAATGGTCTGCTACTAC
    TAAGACTTCTATCTCTCCAAAGACTTTGAGATCTATCTTGAACTGTCCAACTTGGTTCGACTACGAAAGAGGTAGAT
    TGGCTGAAAACGCTTGTTACGCTGCTATCTCTCAAGAATTCAACGTTAACCCAGACGAAGTTAGAGACGCTTTCTCT
    CAAGCTAGAGACTCTTTGCAAGCTAACCACGACTTCATCTCTTTGATCAGAGAATTGAAGGCTCAAGCTAACGGTA
    GATTGAGAGTTTACGCTATGTCTAACATCTCTTTGCCAGACTGGGAAGTTTTGAGAATGAAGCCAGCTGACTGGGA
    CATCTTCGACCACGTTTTCACTTCTGGTGCTGTTGGTGAAAGAAAGCCAAACTTGGCTTTCTACAGACACGTTATCG
    CTGCTACTGACTTGCAACCACACCAAACTATCTTCGTTGACGACAAGTTGGAAAACGTTTTGTCTGCTAGATCTTTG
    GGTTTCACTGGTATCGTTTTCGACGAACCATCTGAAGTTAAGAGAGCTTTGAGAAACTTGATCGGTGACCCAGTTC
    AAAGAGGTGGTGAATTCTTGGTTAGAAACGCTGGTAAGTTGGGTTCTATCACTAGAACTACTGCTAAGCACGAAT
    CTATCCCATTGGACGAAAACTTCGCTCAATTGTTGATCTTGGAAATCACTGGTAACAGAGCTTTGGTTAACTTGGTT
    GAACACCCACAAACTTGGAACTTCTTCCAAGGTAAGGGTCAATTGACTACTGAAGAATTCCCATTCGACTTGGACA
    CTACTTCTTTGGGTTTGACTATCTTGAAGAGATCTAGAGAAATCGCTGACTCTGTTATGGACGAAATGTTGGAATA
    CGTTGACCCAGACGGTATCATCCAAACTTACTTCGACCACAGAAGACCAAGATTCGACCCAGTTGTTTGTGTTAAC
    GCTTTGTCTTTGTTCTACGCTTACGGTAGAGGTGAACAATTGAGATCTACTTTGACTTGGGTTCACGAAGTTTTGTT
    GAACAGAGCTTACTTGGACGGTACTAGATACTACGAAACTGCTGAATGTTTCTTGTACTTCATGTCTAGATTGTTGG
    CTACTTCTGGTGACCCAGACTTGCACTCTTTGTTGAAGCCATTGTTGAAGGAAAGAGTTCAAGAAAGAATCGGTGC
    TGACGGTGACTCTTTGGCTTTGGCTATGAGAATCTTGGCTTGTGACTTCGTTGGTATCAGAGACGAAGTTGACTTG
    AGAACTTTGTTGACTTTGCAATGTGAAGACGGTGGTTGGGAAGTTGGTTGGATGTACAAGTACGGTTCTTCTGGTA
    TCTCTATCGGTAACAGAGGTTTGGCTACTGCTTTGGCTATCAAGGCTGTTGACACTATGTTCCAACCACAAATCAGA
    TTCTCTGAATCTCCAACTGACACTTTGGTTGAAAACGCTATCCACAAGAGAAGACCATCTTTCTCTGAAAAGTTCTT
    GGGTAAGAGACCAAGATCTGGTTCTTTCAGAAAGCCATTGCAATGGATCTTGCAAGGTTCTAAGTTGAGAAAGTC
    TGTTGAAATCGGTTCTTAA
    LoTps1
    - LoTps1 Optimized cDNA for S. cerevisiae expression
    SEQ ID NO: 68
    ATGTACACTGCTTTGATCTTGGACTTGGGTGACGTTTTGTTCTCTTGGTCTTCTACTACTAACACTACTATCCCACCA
    AGACAATTGAAGGAAATCTTGTCTTCTCCAGCTTGGTTCGAATACGAAAGAGGTAGAATCACTCAAGCTGAATGTT
    ACGAAAGAGTTTCTGCTGAATTCTCTTTGGACGCTACTGCTGTTGCTGAAGCTTTCAGACAAGCTAGAGACTCTTTG
    AGACCAAACGACAAGTTCTTGACTTTGATCAGAGAATTGAGACAACAATCTCACGGTGAATTGACTGTTTTGGCTT
    TGTCTAACATCTCTTTGCCAGACTACGAATTCATCATGGCTTTGGACTCTAAGTGGACTTCTGTTTTCGACAGAGTTT
    TCCCATCTGCTTTGGTTGGTGAAAGAAAGCCACACTTGGGTGCTTTCAGACAAGTTTTGTCTGAAATGAACTTGGA
    CCCACACACTACTGTTTTCGTTGACGACAAGTTGGACAACGTTGTTTCTGCTAGATCTTTGGGTATGCACGGTGTTG
    TTTTCGACTCTCAAGACAACGTTTTCAGAATGTTGAGAAACATCTTCGGTGACCCAATCCACAGAGGTAGAGACTA
    CTTGAGACAACACGCTGGTAGATTGGAAACTTCTACTGACGCTGGTGTTGTTTTCGAAGAAAACTTCACTCAATTG
    ATCATCTACGAATTGACTAACGACAAGTCTTTGATCACTACTTCTAACTGTGCTAGAACTTGGAACTTCTTCAGAGG
    TAAGCCATTGTTCTCTGCTTCTTTCCCAGACGACATGGACACTACTTCTGTTGCTTTGACTGTTTTGAGATTGGACCA
    CGCTTTGGTTAACTCTGTTTTGGACGAAATGTTGAAGTACGTTGACGCTGACGGTATCATGCAAACTTACTTCGACC
    ACACTAGACCAAGAATGGACCCATTCGTTTGTGTTAACGTTTTGTCTTTGTTCCACGAACAAGGTAGAGGTCACGA
    ATTGCCAAACACTTTGGAATGGGTTCACGAAGTTTTGTTGCACAGAGCTTACATCGGTGGTTCTAGATACTACTTGT
    CTGCTGACTGTTTCTTGTTCTTCATGTCTAGATTGTTGCAAAGAATCACTGACCCATCTGTTTTGGGTAGATTCAGAC
    CATTGTTCATCGAAAGAGTTAGAGAAAGAGTTGGTGCTACTGGTGACTCTATCGACTTGGCTTTCAGAATCATCGC
    TGCTTCTACTGTTGGTATCCAATGTCCAAGAGACTTGGAATCTTTGTTGGCTGCTCAATGTGAAGACGGTGGTTGG
    GACTTGTGTTGGTTCTACCAATACGGTTCTACTGGTGTTAAGGCTGGTAACAGAGGTTTGACTACTGCTTTGGCTAT
    CAAGGCTATCGACTCTGCTATCGCTAGACCACCATCTCCAGCTTTGTCTGTTGCTTCTTCTTCTAAGTCTGAAATCCC
    AAAGCCAATCCAAAGATCTTTGAGACCATTGTCTCCAAGAAGATTCGGTGGTTTCTTGATGCCATGGAGAAGATCT
    CAAAGAAACGGTGTTGCTGTTTCTTCTTAA
    EMD37666.1
    - EMD37666.1 Optimized cDNA for S. cerevisiae expression
    SEQ ID NO: 69
    ATGTCTGCTGCTGCTCAATACACTACTTTGATCTTGGACTTGGGTGACGTTTTGTTCACTTGGTCTCCAAAGACTAA
    GACTTCTATCCCACCAAGAACTTTGAAGGAAATCTTGAACTCTGCTACTTGGTACGAATACGAAAGAGGTAGAATC
    TCTCAAGACGAATGTTACGAAAGAGTTGGTACTGAATTCGGTATCGCTCCATCTGAAATCGACAACGCTTTCAAGC
    AAGCTAGAGACTCTATGGAATCTAACGACGAATTGATCGCTTTGGTTAGAGAATTGAAGACTCAATTGGACGGTG
    AATTGTTGGTTTTCGCTTTGTCTAACATCTCTTTGCCAGACTACGAATACGTTTTGACTAAGCCAGCTGACTGGTCTA
    TCTTCGACAAGGTTTTCCCATCTGCTTTGGTTGGTGAAAGAAAGCCACACTTGGGTGTTTACAAGCACGTTATCGCT
    GAAACTGGTATCGACCCAAGAACTACTGTTTTCGTTGACGACAAGATCGACAACGTTTTGTCTGCTAGATCTGTTG
    GTATGCACGGTATCGTTTTCGAAAAGCAAGAAGACGTTATGAGAGCTTTGAGAAACATCTTCGGTGACCCAGTTA
    GAAGAGGTAGAGAATACTTGAGAAGAAACGCTATGAGATTGGAATCTGTTACTGACCACGGTGTTGCTTTCGGTG
    AAAACTTCACTCAATTGTTGATCTTGGAATTGACTAACGACCCATCTTTGGTTACTTTGCCAGACAGACCAAGAACT
    TGGAACTTCTTCAGAGGTAACGGTGGTAGACCATCTAAGCCATTGTTCTCTGAAGCTTTCCCAGACGACTTGGACA
    CTACTTCTTTGGCTTTGACTGTTTTGCAAAGAGACCCAGGTGTTATCTCTTCTGTTATGGACGAAATGTTGAACTAC
    AGAGACCCAGACGGTATCATGCAAACTTACTTCGACGACGGTAGACAAAGATTGGACCCATTCGTTAACGTTAAC
    GTTTTGACTTTCTTCTACACTAACGGTAGAGGTCACGAATTGGACCAATGTTTGACTTGGGTTAGAGAAGTTTTGTT
    GTACAGAGCTTACTTGGGTGGTTCTAGATACTACCCATCTGCTGACTGTTTCTTGTACTTCATCTCTAGATTGTTCGC
    TTGTACTAACGACCCAGTTTTGCACCACCAATTGAAGCCATTGTTCGTTGAAAGAGTTCAAGAACAAATCGGTGTT
    GAAGGTGACGCTTTGGAATTGGCTTTCAGATTGTTGGTTTGTGCTTCTTTGGACGTTCAAAACGCTATCGACATGA
    GAAGATTGTTGGAAATGCAATGTGAAGACGGTGGTTGGGAAGGTGGTAACTTGTACAGATTCGGTACTACTGGTT
    TGAAGGTTACTAACAGAGGTTTGACTACTGCTGCTGCTGTTCAAGCTATCGAAGCTTCTCAAAGAAGACCACCATC
    TCCATCTCCATCTGTTGAATCTACTAAGTCTCCAATCACTCCAGTTACTCCAATGTTGGAAGTTCCATCTTTGGGTTT
    GTCTATCTCTAGACCATCTTCTCCATTGTTGGGTTACTTCAGATTGCCATGGAAGAAGTCTGCTGAAGTTCACTAA
    XP_001217376.1
    - XP_001217376.1 Optimized cDNA for S. cerevisiae expression
    SEQ ID NO: 70
    ATGGCTATCACTAAGGGTCCAGTTAAGGCTTTGATCTTGGACTTCTCTAACGTTTTGTGTTCTTGGAAGCCACCATC
    TAACGTTGCTGTTCCACCACAAATCTTGAAGATGATCATGTCTTCTGACATCTGGCACGACTACGAATGTGGTAGAT
    ACTCTAGAGAAGACTGTTACGCTAGAGTTGCTGACAGATTCCACATCTCTGCTGCTGACATGGAAGACACTTTGAA
    GCAAGCTAGAAAGTCTTTGCAAGTTCACCACGAAACTTTGTTGTTCATCCAACAAGTTAAGAAGGACGCTGGTGGT
    GAATTGATGGTTTGTGGTATGACTAACACTCCAAGACCAGAACAAGACGTTATGCACTCTATCAACGCTGAATACC
    CAGTTTTCGACAGAATCTACATCTCTGGTTTGATGGGTATGAGAAAGCCATCTATCTGTTTCTACCAAAGAGTTATG
    GAAGAAATCGGTTTGTCTGGTGACGCTATCATGTTCATCGACGACAAGTTGGAAAACGTTATCGCTGCTCAATCTG
    TTGGTATCAGAGGTGTTTTGTTCCAATCTCAACAAGACTTGAGAAGAGTTGTTTTGAACTTCTTGGGTGACCCAGTT
    CACAGAGGTTTGCAATTCTTGGCTGCTAACGCTAAGAAGATGGACTCTGTTACTAACACTGGTGACACTATCCAAG
    ACAACTTCGCTCAATTGTTGATCTTGGAATTGGCTCAAGACAGAGAATTGGTTAAGTTGCAAGCTGGTAAGAGAAC
    TTGGAACTACTTCATCGGTCCACCAAAGTTGACTACTGCTACTTTCCCAGACGACATGGACACTACTTCTATGGCTT
    TGTCTGTTTTGCCAGTTGCTGAAGACGTTGTTTCTTCTGTTTTGGACGAAATGTTGAAGTTCGTTACTGACGACGGT
    ATCTTCATGACTTACTTCGACTCTTCTAGACCAAGAGTTGACCCAGTTGTTTGTATCAACGTTTTGGGTGTTTTCTGT
    AGACACAACAGAGAAAGAGACGTTTTGCCAACTTTCCACTGGATCAGAGACATCTTGATCAACAGAGCTTACTTGT
    CTGGTACTAGATACTACCCATCTCCAGACTTGTTCTTGTTCTTCTTGGCTAGATTGTGTTTGGCTGTTAGAAACCAAT
    CTTTGAGAGAACAATTGGTTTTGCCATTGGTTGACAGATTGAGAGAAAGAGTTGGTGCTCCAGGTGAAGCTGTTTC
    TTTGGCTGCTAGAATCTTGGCTTGTAGATCTTTCGGTATCGACTCTGCTAGAGACATGGACTCTTTGAGAGGTAAG
    CAATGTGAAGACGGTGGTTGGCCAGTTGAATGGGTTTACAGATTCGCTTCTTTCGGTTTGAACGTTGGTAACAGAG
    GTTTGGCTACTGCTTTCGCTGTTAGAGCTTTGGAATCTCCATACGGTGAATCTGCTGTTAAGGTTATGAGAAGAATC
    GTTTAA
    Primers
    - Primer for construction of fragment “a” (LEU2 yeast marker)
    SEQ ID NO: 71
    AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCATTCGACTACGTCGTAAG
    GCC
    - Primer for construction of fragment “a” (LEU2 yeast marker)
    SEQ ID NO: 72
    TCGTGGTCAAGGCGTGCAATTCTCAACACGAGAGTGATTCTTCGGCGTTGTTGCTGACCATCGACGGTCGAGGAG
    AACTT
    - Primer for construction of fragment “b” (AmpR E. coli marker)
    SEQ ID NO: 73
    TGGTCAGCAACAACGCCGAAGAATCACTCTCGTGTTGAGAATTGCACGCCTTGACCACGACACGTTAAGGGATTTT
    GGTCATGAG
    - Primer for construction of fragment “b” (AmpR E. coli marker)
    SEQ ID NO: 74
    AACGCGTACCCTAAGTACGGCACCACAGTGACTATGCAGTCCGCACTTTGCCAATGCCAAAAATGTGCGCGGAAC
    CCCTA
    - Primer for construction of fragment “c” (Yeast origin of replication)
    SEQ ID NO: 75
    TTGGCATTGGCAAAGTGCGGACTGCATAGTCACTGTGGTGCCGTACTTAGGGTACGCGTTCCTGAACGAAGCATC
    TGTGCTTCA
    - Primer for construction of fragment “c” (Yeast origin of replication)
    SEQ ID NO: 76
    CCGAGATGCCAAAGGATAGGTGCTATGTTGATGACTACGACACAGAACTGCGGGTGACATAATGATAGCATTGAA
    GGATGAGACT
    - Primer for construction of fragment “d” (E. coli origin of replication)
    SEQ ID NO: 77
    ATGTCACCCGCAGTTCTGTGTCGTAGTCATCAACATAGCACCTATCCTTTGGCATCTCGGTGAGCAAAAGGCCAGC
    AAAAGG
    - Primer for construction of fragment “d” (E. coli origin of replication)
    SEQ ID NO: 78
    CTCAGATGTACGGTGATCGCCACCATGTGACGGAAGCTATCCTGACAGTGTAGCAAGTGCTGAGCGTCAGACCCC
    GTAGAA

Claims (28)

1. A method for producing a drimane sesquiterpene comprising:
a. contacting an acyclic farnesyl diphosphate (FPP) precursor with a polypeptide comprising a Haloacid dehalogenase (HAD)-like hydrolase domain and having bifunctional terpene synthase activity to produce a drimane sesquiterpene, wherein the polypeptide comprises
i. a class I terpene synthase-like motif as set forth in SEQ ID NO: 53 (DDxx(D/E)); and
ii. a class II terpene synthase-like motif as set forth in SEQ ID NO: 56 (DxD(T/S)T); and
b. optionally isolating the drimane sesquiterpene or a mixture comprising the drimane sesquiterpene.
2. The method of claim 1, wherein the drimane sesquiterpene comprises albicanol and/or drimenol.
3. The method of claim 1, wherein the polypeptide having bifunctional terpene synthase activity comprises
a. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and
b. a sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
c. a sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58.
4. The method of claim 1, the method comprising transforming a host cell or non-human host organism with a nucleic acid encoding a polypeptide having bifunctional terpene synthase activity, wherein the polypeptide
a. comprises an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; or
b. comprises
i. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and
ii. a sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
iii. a sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58.
5. The method of claim 1, the method further comprising culturing a non-human host organism or a host cell capable of producing FPP and transformed to express a polypeptide comprising a Haloacid dehalogenase (HAD)-like hydrolase domain under conditions that allow for the production of the polypeptide, wherein the polypeptide
a. comprises an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; or
b. comprises
i. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63; and
ii. a sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
iii. a sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58.
6. The method of claim 3, wherein the polypeptide comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and SEQ ID NO: 62.
7. The method of claim 1, wherein the drimane sesquiterpene or the mixture comprising the drimane sesquiterpene is isolated.
8. The method as recited in claim 1, the method further comprising contacting the drimane sesquiterpene with at least one enzyme to produce a drimane sesquiterpene derivative.
9. The method as recited in claim 1, the method comprising converting the drimane sesquiterpene to a drimane sesquiterpene derivative using chemical synthesis or biochemical synthesis.
10. The method of claim 1, wherein the class I terpene synthase-like motif comprises SEQ ID NO: 54 (DD(K/Q/R)(L/I/T)(D/E)), the class II terpene synthase-like motif comprises SEQ ID NO: 57 (D(V/M/L)DTT), and the drimane sesquiterpene is albicanol.
11. The method of claim 1, wherein the polypeptide comprises
a. an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, or SEQ ID NO: 32,
b. a sequence of SEQ ID NO: 54 (DD(K/Q/R)(L/I/T)(D/E)), and
c. a sequence of SEQ ID NO: 57 (D(V/M/L/F)DTTS); and
wherein the drimane sesquiterpene is albicanol.
12. The method of claim 1, wherein the polypeptide comprises
a. an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 35, SEQ ID NO: 38, SEQ ID NO: 41, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, or SEQ ID NO: 63,
b. a sequence of SEQ ID NO: 55, and
c. a sequence of SEQ ID NO: 58; and
wherein the drimane sesquiterpene is drimenol.
13. An isolated polypeptide comprising a Haloacid dehalogenase (HAD)-like hydrolase domain and having bifunctional terpene synthase activity comprising an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5 or comprising
a. an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5;
b. a sequence as set forth in SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 55; and
c. a sequence as set forth in SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 48.
14. The isolated polypeptide of claim 13, wherein the polypeptide further comprises one or more conserved motif as set forth in SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, and SEQ ID NO: 62.
15. An isolated nucleic acid molecule
a. comprising a nucleotide sequence encoding the polypeptide of claim 13; or
b. comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68 or the reverse complement thereof;
c. comprising a nucleotide molecule that hybridizes under stringent conditions to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 68; or
d. comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70, or the reverse complement thereof
16. A vector comprising the nucleic acid molecule of claim 15.
17. The vector of claim 16, wherein the vector is a prokaryotic vector, viral vector or a eukaryotic vector.
18. The vector of claim 16, where the vector is an expression vector.
19. A host cell or a non-human host organism comprising the isolated nucleic acid of claim
15.
20. The method of claim 5, wherein the host cell is a prokaryotic cell.
21. The method of claim 20, wherein the prokaryotic cell is a bacterial cell.
22. The method of claim 21, wherein the bacterial cell is E. coli.
23. The method of claim 5, wherein the host cell is a eukaryotic cell.
24. The method of claim 23, wherein the eukaryotic cell is a yeast cell or a plant cell.
25. The method of claim 24, wherein the yeast cell is Saccharomyces cerevisiae.
26. A method of using the polypeptide of claim 13 for producing a drimane sesquiterpene or a mixture comprising a drimane sesquiterpene and one or more terpenes.
27. The method of claim 26, wherein the drimane sesquiterpene is albicanol.
US17/673,465 2017-06-02 2022-02-16 Method for producing albicanol and/or drimenol Active US11932894B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/673,465 US11932894B2 (en) 2017-06-02 2022-02-16 Method for producing albicanol and/or drimenol

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17174399 2017-06-02
EP17174399.0 2017-06-02
EP17174399 2017-06-02
PCT/EP2018/064344 WO2018220113A1 (en) 2017-06-02 2018-05-31 Method for producing albicanol and/or drimenol
US201916618737A 2019-12-02 2019-12-02
US17/673,465 US11932894B2 (en) 2017-06-02 2022-02-16 Method for producing albicanol and/or drimenol

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2018/064344 Division WO2018220113A1 (en) 2017-06-02 2018-05-31 Method for producing albicanol and/or drimenol
US16/618,737 Division US11293037B2 (en) 2017-06-02 2018-05-31 Method for producing albicanol and/or drimenol

Publications (3)

Publication Number Publication Date
US20220186265A1 US20220186265A1 (en) 2022-06-16
US20230148463A9 true US20230148463A9 (en) 2023-05-11
US11932894B2 US11932894B2 (en) 2024-03-19

Family

ID=59021376

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/618,737 Active 2038-11-07 US11293037B2 (en) 2017-06-02 2018-05-31 Method for producing albicanol and/or drimenol
US17/673,465 Active US11932894B2 (en) 2017-06-02 2022-02-16 Method for producing albicanol and/or drimenol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/618,737 Active 2038-11-07 US11293037B2 (en) 2017-06-02 2018-05-31 Method for producing albicanol and/or drimenol

Country Status (6)

Country Link
US (2) US11293037B2 (en)
EP (1) EP3635123A1 (en)
JP (1) JP7191860B2 (en)
CN (1) CN110691850A (en)
BR (1) BR112019025376A2 (en)
WO (1) WO2018220113A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345907B2 (en) * 2018-05-29 2022-05-31 Firmenich Sa Method for producing albicanol compounds
WO2021105236A2 (en) 2019-11-27 2021-06-03 Firmenich Sa Novel polypeptides for producing albicanol and/or drimenol compounds
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines
WO2023156429A1 (en) 2022-02-16 2023-08-24 Firmenich Sa Process for preparing octahydro-2(1h)-naphthalenone derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134523A2 (en) * 2005-06-17 2006-12-21 Firmenich Sa Novel sesquiterpene synthases and methods of their use
CN104053770A (en) * 2011-10-19 2014-09-17 凯金公司 Methods for producing cinnamolide and/or drimendiol
MX352318B (en) 2011-11-01 2017-11-21 Firmenich & Cie Cytochrome p450 and use thereof for the enzymatic oxidation of terpenes.
JP6882163B2 (en) 2014-05-01 2021-06-02 フイルメニツヒ ソシエテ アノニムFirmenich Sa Cohesive flavor system
WO2016094178A1 (en) * 2014-12-09 2016-06-16 Dsm Ip Assets B.V. Methods for producing abienol
US10849348B2 (en) 2015-09-21 2020-12-01 Firmenich Sa Sucrose monoesters microemulsions
WO2017077125A1 (en) * 2015-11-05 2017-05-11 Firmenich S.A Drimenol synthases iii

Also Published As

Publication number Publication date
WO2018220113A1 (en) 2018-12-06
CN110691850A (en) 2020-01-14
US20200140898A1 (en) 2020-05-07
US11293037B2 (en) 2022-04-05
US11932894B2 (en) 2024-03-19
EP3635123A1 (en) 2020-04-15
JP7191860B2 (en) 2022-12-19
JP2020523005A (en) 2020-08-06
US20220186265A1 (en) 2022-06-16
BR112019025376A2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
US11932894B2 (en) Method for producing albicanol and/or drimenol
EP3140409B1 (en) Drimenol synthase and method for producing drimenol
US20100311134A1 (en) Method for producing sclareol
US11773414B2 (en) Sesquiterpene synthases for production of drimenol and mixtures thereof
US20210010035A1 (en) Production of manool
EP3140410B1 (en) Drimenol synthases and method of producing drimenol
US10337031B2 (en) Production of fragrant compounds
US10385361B2 (en) Production of manool
US20200308612A1 (en) Vetiver

Legal Events

Date Code Title Description
AS Assignment

Owner name: FIRMENICH SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHALK, MICHEL;ANZIANI, PAULINE;GOERNER, CHRISTIAN;AND OTHERS;REEL/FRAME:059141/0729

Effective date: 20191128

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE